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ABSTRACT 
Of the plethora of parasitic diseases that afflict mankind, malaria remains the most 
significant with 100-300 million cases reported annually and 600,000 fatalities. Treatment 
and control measures have been hampered by the emergence of drug resistance to most 
antimalarial therapies. Early signs of drug resistance to the current frontline option, the 
artemisinins, make it imperative that novel drug candidates are discovered. One possible 
short-term solution is drug repositioning, via screening existing FDA-approved (Food and 
Drug Administration agency) drug libraries for antimalarial activity. Towards this goal, 
two, fast, simple, and reliable in vitro SYBR Green-based drug susceptibility assays were 
optimised. The first, the SYBR Green microplate method offered a medium throughput 
option that was used to screen two FDA-approved libraries (Z score = 0.68 +0.06), 
LOPAC and ENZO (~700 compounds). Approximately 60 hits, defined as > 50 % 
inhibition at 2.5 µM, were identified by the preliminary screen. The SYBR Green flow 
cytometer method, capable of providing direct parasitaemia estimates and stage-specific 
information, was used for second-phase characterisation of the hits. From these, anti-
amoebic compound emetine dihydrochloride hydrate was identified as a potent inhibitor of 
the multidrug resistant Plasmodium falciparum, strain K1, with an IC50 of 47 nM (95 % 
confidence interval 44.92-49.17). Further characterisation of the compound involved 
analysis of the parasite killing profile, to determine the parasite reduction ratio (PRR) and 
parasite clearance time (PCT) as well drug interaction analysis with existing antimalarials. 
Emetine was shown to have a similar killing profile to atovaquone inferring a similar 
mitochondrial mode of action, corroborated by fluorescence staining with the JC-1 
mitochondrial probe. Taken together, emetine’s pharmacokinetic matching and synergy 
with atovaquone provide an exciting drug combination for further investigation. The 
relatively high hit rate presented in the study, and in vitro workflow outlined for emetine, 
also showed drug repositioning to be a promising option for antimalarial drug discovery.    
 
 1 
 
CHAPTER 1 
INTRODUCTION 
1.1 Malaria: a historical perspective 
Despite decades of effort to eradicate or at least control malaria, it remains one of the most 
widespread and devastating diseases to afflict mankind. Its history extends to antiquity 
(Balint, 2001; Cox, 2002; Krungkrai et al., 2010). Indeed, it has been said our primate 
ancestors were recognisably malarious before they were recognisably human (Harrison, 
1978). Earliest evidence of the disease comes from Chinese scripts dating back to 2700 
BC. Other ancient references appear on Mesopotamia clay tablets (2000 BC) and Egyptian 
papyri (1570 BC) (Cox, 2010). Since then, the hallmark characteristics of malaria, namely: 
paroxysmal intermittent fevers, enlarged spleens and a tendency of epidemic occurrence, 
have been reported in every civilised society. Extending from the Hippocrates in ancient 
Greece (400 BC), to the Romans throughout their empire, and in the writings of Assyrian, 
Indian, Arabic, and European physicians (Carter and Mendis 2002; Cox, 2002).  In 
addition to ancient symptomatic descriptions, recent empirical evidence has shown the 
existence of Plasmodium falciparum malaria in Egyptian mummies from the Fayum 
depression in 800 BC (Lalremruata et al., 2013) and in amber preserved mosquitos (in the 
Dominican Republic) from the mid-Tertiary period 25-400 million years ago (Poinar, 
2005). Extending through Darwinian descent, malaria has therefore had a huge impact on 
human exploration, colonisation and development of the world as we know it today 
(Harrison, 1978). Even referred to as the ‘scientific control of nature’, many historical 
figures including, Alexander the great, Emperor Titus Ceaser, Oliver Cromwell, Otto II 
and Pope Gregory V are thought to have succumbed to the disease (Carter and Mendis 
2002, Harrison, 1978). More recently malaria, along with other diseases has had a huge 
impact on the world wars, where it is said that for every man lost in battle, another was lost 
to malaria. Commonly, the conditions of war encouraged the spread and resurgence of the 
disease (Cox, 2002; Harrison, 1978). 
The name malaria originated from the association of the disease with marshy areas and the 
misguided belief that it was caused by miasmas, ‘bad air’ in Italian ‘Mal’aria’, rising from 
the swamps. Scientific understanding of malaria and its association with the mosquito 
vector did not begin until the end of the 19
th
 century. The complex life cycle of the parasite 
involving an insect vector (females of Anopheline species) and an intermediate 
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vertebrate host, took almost 70 years to elucidate (Cox, 2010; Harrison, 1978). Four 
species of malaria infect man: P. falciparum, P. vivax, P. malariae, and P. ovale 
(Biamonte et al., 2013; Greenwood et al., 2008), the latter of which has now been divided 
into two sub-species P. ovale curtisi and P. ovale wallikeri (Sutherland et al., 2010).  More 
recently, it has been shown the P. knowlesi, which is known to cause malaria in long-tail 
macaques is also found consistently in man (Vythilingam et al., 2008).   
1.2 Life Cycle 
Following the bite of an infected anopheline mosquito, sporozoites are inoculated into the 
subcutaneous tissue of the invertebrate host. This motile form rapidly migrates to the blood 
stream where it circulates (~30mins) until it reaches and invades the hepatocytes.  Within 
the hepatocytes, pre-erythrocytic schizogony occurs whereby the parasites undergo asexual 
multiplication. Subsequently, 5-10 days after the initial infection thousands of merozoites 
are released into the blood circulation where they invade erythrocytes.  In P. vivax and P. 
ovale infections, some sporozoites differentiate into hypnozoites and remain dormant in 
the hepatocyte cells for months until they are re-activated, causing a relapse of the malaria 
infection. Once inside the erythrocytes, the parasite undergoes a further amplification step 
where it transforms from a ring, to a trophozoite and finally, as a result of DNA replication 
and schizogony, a multinucleated schizont. Upon schizont rupture, commonly 8-32 
merozoites are released from each red blood cell are are capable of invading yet more red 
blood cells (although odd numbers of daughter merozoites can also be produced). 
Repeated erythrocytic cycles, which occur every 48 hours in all human malaria species 
apart from P. malariae (72 hour cycle) and P. knowlesi (24 hour cycle), are responsible for 
the non-specific clinical symptoms of the disease (tertian and quartan fevers).  A small 
percentage (~1%) of merozoites transform into gametocytes (sexual form) and await 
ingestion by a mosquito during a subsequent blood meal. The asymptomatic gametocytes 
can persist for weeks and are responsible for malaria transmission (Biamonte et al., 2013; 
Delves et al., 2012; Flannery et al., 2013; Jensen and Mehlhorn, 2009; Rosenthal, 2008). 
In the mosquito, the sexual phase of the parasite life cycle is initiated by the fertilization of 
the male and female gametes to create a zygote. This brief diploid stage allows sexual 
recombination, and is a key source of genetic variation (Gregson and Plowe, 2005).  The 
zygote develops into a motile ookinete that migrates and through the gut wall and forms an 
oocyst. Further replication in the oocyst results in the release of thousands of sporozoites 
that migrate to the mosquito salivary gland. The mosquito stage is completed in 
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approximately 2 weeks (Delves et al., 2012; Jensen and Mehlhorn, 2009; Rosenthal, 
2008). The next blood meal along with the complimentary inoculation sporozites 
completes the parasite life cycle (Figure 1.1).   
 
 
 
1.3 Disease symptoms 
Of the four human malarias, P. falicparum is the most lethal and responsible for over 90% 
of malaria-related deaths (Hyde, 2007). This is the only species capable of causing severe 
disease, which is characterised by the parasites ability to sequester in various organs 
including the brain (Greenwood et al., 2008).  This occurs during an overwhelming 
erythrocytic stage infection and can lead to cerebral malaria (coma), vital organ 
dysfunction, acidosis, respiratory distress, and severe anemia. In children, hypoglycaemia, 
seizures and severe anemia are common manifestations (Krungkrai et al., 2010).  
1.4 Discovery of the malaria parasite and its complex life cycle 
Although the outline of the life cycle can be regurgitated almost effortlessly by a modern 
malariologist, the extensive body of work defining the complex relationships between 
man, mosquito and parasite should not be overlooked. Indeed the discovery of the parasite 
and the mode of malaria transmission remain some of the most important and interesting 
findings in the history of parasitology (Cox, 2002). The story began in 1880 when French 
army surgeon, Charles Louis Alphonse Laveran identified and detailed a protozoan 
Figure 1.1 Plasmodium life cycle showing the parasite development at the Liver, Erythrocyte 
and mosquitoes stages.  (Source: Biamonte et al., 2013) 
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parasite in the blood of a human malaria sufferer (Harrison, 1978). The initial unanimous 
resistance to the finding is not surprizing considering that this was the first report of a 
parasite inhabiting a human erythrocyte. Furthermore, the ‘miasma theory’ that had 
reigned for almost 2500 years was not completely out of favour (Cox, 2010). It was only a 
recent idea, with the advent of the germ theory and the development of microbiology as a 
discipline by Louis Pasteur and Robert Koch in 1878-1879, that specific living micro-
organisms could be causative agents of disease (Cox, 2010; Harrison, 1978). Investigations 
at the time were therefore intensified in the direction of finding the ‘bacteria’ responsible 
for malaria fever. Indeed, Edwin Klebs and Corrado Tommasi-Crudeli claimed as such, 
when they reported that a bacterium (Bacillus malariae), isolated from the Pontine 
marshland, was capable of causing febrile infections and enlarged spleens in rabbits (Cox, 
2010; Smith and Sanford 1985). Undeterred, Laveran continued to ‘follow the pigment’ 
and described various stages of the erythrocytic cycle, documenting quinine induced 
parasite clearance and the association of corpuscle (schizont) rupture and fever. His 
eventual visualization of the exflagellation process became harder to ignore and in 1890 
‘Laveran’s germ’ was finally accepted by the majority of the community. He was later 
awarded the Nobel Prize for Medicine in 1907 (Harrison, 1978). Further definition of the 
erthrocytic stage cycle and species characteristics was catalysed by technical advances in 
staining procedures leading to the use of Giemsa staining (methylene blue eosin stain, 
Dimitri Leonidovitch Romanowsky 1891) and the development of the oil immersion 
microscope (Carl Zeiss 1882-4), (Cox, 2010).   
Disease transmission, however, remained a mystery until Patrick Manson, after showing 
filarial worms were transmitted by mosquitos, suspected the same to be true for malaria. 
Postulated by the coincidently high prevalence of mosquitoes in the marshy associated 
with malaria, Manson recruited British army surgeon Ronald Ross to work on the project. 
Based in India, Ross’ initial observation of Laveran’s exflaggelation proved only that the 
mosquito midgut environment did not kill the parasite as the same could be observed in 
infected blood on a microscope slide.  However, on 20
th
 August 1897 (mosquito day), 
Ross discovered an oocyst on the wall of the mosquito midgut, and in doing so provided 
the first empirical evidence that the parasite could undergo further development in the 
mosquito (Harrison, 1978). In the meantime Canadian William MacCullum, had described 
a sexual recombination event in a related avian parasite Haemoproteus columbae. He 
proposed that the formation of a vermicule (ookinete) through the fusing of two distinct 
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bodies, one flagellated and motile, the other sessile and egg-like was also likely to occur in 
malaria (Cox, 2010). Both Ross and Manson were more concerned with what happened 
post oocyst formation and expected to find, in the mosquito, a hardened free living form of 
the parasite ready to be discharged into the external environment (Harrison, 1978). 
Circumstance favoured Ross, and, forced to work on an avian (pigeon) model of malaria, 
in 1898 he discovered the presence malaria parasites (Plasmodium relictum) in the salivary 
gland of a culicine mosquito (Cox, 2010). He later showed that uninfected birds could be 
experimentally infected by malarious mosquitoes. Hot on his heels, the Italians, Giovanni 
Battista, Grassi, Amico Bignami and Giuseppe Bastianelli proved Ross’ inclinations that 
the same cycle occurred in the human system and that mosquitos of the genus Anopheles 
were specifically responsible for human malaria transmission (Cox, 2002; Harrison, 1978). 
Fortunately, Ross’ painstaking hard work and persistence did not go unnoticed and 
deservedly he claimed the Nobel Prize for the discovery of Malaria transmission in 1902 
(Harrison, 1978). In fact, the life cycle of Plasmodium was incompletely understood for 
almost another 50 years, until Henry Shortt and Cyril Garnham (1947) showed that the 10 
day lag phase following mosquito inoculation, was due to the hepatic stage prior to the 
erythrocytic cycle. Their collaboration with an American, Wojciech Krotoski, in 1982 
solved the final conundrum, P.vivax was capable of producing dormant liver stages that 
could recrudesce several months or even years later (Cox, 2002; Cox, 2010; Harrison, 
1978; Schlitzer, 2007). 
1.5 History of malaria prevention and treatment 
1.5.1 Mosquito Control 
In the early-mid 20th century efforts to control the disease were aimed at eliminating the 
Anopheline vector. Breeding sites situated close to residential areas were drained of 
swamplands and standing water sources. Puddles and pot holes were layered with oil to 
prevent egg laying and larval develpoment. Overall, some improvements were made. A 
major breakthrough was the discovery of the insecticidal properties of 
dichlorodiphenyltrichloroethane (DDT) in 1939. The military were first to apply DDT for 
public health purposes in Southern Italy 1944, as opposed to its development as an 
agricultural pesticide. DDT then went on to play an important role during the latter years 
of the Second World War in preventing malaria (Sadasivaiah et al., 2007).  
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1.5.2 Quinine and its synthetic derivatives 
For many years quinine was the only chemotherapeutic agent available for directly 
targeting the malaria parasite during human infection. Quinine, the bark extract of the 
Peruvian Cinchona tree species, was first discovered in the 17
th
 century by the Jesuit 
priests, who learned of its potential from indigenous practices.  Word soon spread 
throughout Europe and other areas of the world regarding the medicinal properties of the 
‘Jesuit bark’ for the treatment of agues. It wasn’t until 1820 that quinine was isolated from 
the bark along with other alkaloids such as quinidine, quinamine, cinchonine and 
cinchonidine. The quinine content of cinchona trees varied not only between species but 
also within the same plantation, leading to inconsistent reports of therapeutic efficacy. 
Numerous expeditions sought to obtain the seeds from the best plants to maximise yield. 
Charles ledger and his native servant Manuel Mamani discovered a species with 
particularly high quinine content (11-13%), Cinchona legderiana, and successfully 
exported seeds to Britain. For this betrayal and ultimately the loss of South America’s 
monopoly on quinine production Mamani was severely beaten and later died as a result of 
his injuries. The British, failing to realise the potential of this find, sold the seeds to the 
Dutch in 1865, leading to a Dutch monopoly (97%) on the production of quinine in the 
1800s (Kitchen et al., 2006).  
The limited supply and resultant high cost of quinine during World War I prompted the 
search for cheaper, synthetic alternatives in the early 1900’s (Jensen and Mehlhorn, 2009). 
This led to the development of the quinoline classes: the 4-aminoquinolines the 8-
aminoquinolines and the amino alcohols. Quinine itself was known to have toxic 
liabilities, such that sustained use could result in tinnitus, hypoglycaemia, abdominal pain, 
visual impairments, vertigo, hepatic injury, asthma, and psychosis (Achan et al., 2011).  
Investigations into tissue staining identified the first synthetic antimalarial, methylene blue 
(by Paul Ehrlich 1891).  Further work led to the development of pamaquine (plasmochin 
1926/27) and later primaquine, creating the 8-aminoquinoline class; of which, tefenoquine 
is a more recently identified member. However, toxicity associated with glucose 6-
phosphate dehydrogenase deficiency, methaemoglobinaemia, and severe gastrointestinal 
disturbances precluded the use of the early derivatives (Peters, 1999). Renewed American 
interest in primaquine (during the Korean War), was a result of its particular effectiveness 
against liver-stage parasites and its potential to tackle relapsing P. vivax infections. In 1932 
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another dye, 9-amino acridine, atabrine, was also shown to be a potent antimalarial. 
Unfortunately, like methylene blue, atabrine discoloured skin and eyes and rumours that it 
caused impotence resulted in compliance issues (Kitchen et al., 2006). The most 
significant breakthrough came when Andersag and co-workers modified atabrine by 
replacing its acridine ring with a quinoline ring creating the 4-aminoquinoline resochin 
(later to be renamed chloroquine) in 1934. However, concerns about its toxicity in humans 
meant that the drug didn’t become available for malaria treatment until 1946 (Coatney, 
1963; Krafts et al., 2012; Schlitzer, 2007).   
1.5.3 The Malaria Eradication Programme 
Due to its therapeutic success, both as a prophylactic and curative drug, chloroquine was 
soon included in the malaria eradication programme (1955) alongside DDT, to elicit a two-
pronged attack against the parasite and mosquito (Dondorp et al., 2010; Jensen and 
Mehlhorn, 2009). The unprecedented reduction in morbidity and mortality that ensued 
resulted in elimination of the disease from Europe in 1975, and its redefinition to tropical 
and subtropical regions (Figure 1.2). Unfortunately, the success of DDT and chloroquine 
was short-lived. The intensified efforts were not financially sustainable in underdeveloped 
countries. The disease remained, as it is today, inexorably linked to poverty and the 
prospect for eradication of African malaria was as unattainable as ever.  
Environmental concerns arose about the use of DDT instigated by the publication of 
Rachel Carson’s ‘Silent Spring’ in 1962, highlighting the harmful effects of bio-
accumulation in both wildlife and human health. The use of DDT was further hampered by 
the onset of insecticide resistance. Consequently, although DDT was never banned, its 
usefulness was restricted.  The situation was worsened by evidence of chloroquine 
resistance (Figure 1.3), initially at the Thailand-Cambodia border (1957), then 
independently in South America (1959) and finally in East Africa (1974) where it 
dispersed rapidly to the west of the continent. Duly, the eradication campaign was 
abandoned in 1972 (Greenwood et al., 2008).   
The next 50 years saw an incessant downfall of chloroquine, from the most widely used 
drug to the most ineffective (Dondorp et al., 2010; Payne, 1987; Randrianarivelojosia et 
al., 2009; Valecha et al., 2009). This instigated investigations into the mechanism of action 
and causes of resistance to chloroquine.  
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Figure 1.2 The global distribution of Malaria 
since pre-intervention (a) and current (2013) 
malaria distribution data (b). (a) An imaging 
system was used to compile data from 
distribution maps generated between 1900 and 
2002, specifically at the dates indicated. Data 
from 1992 was also included but it was too 
similar to the 1994 data to be shown on the 
map (Source: Hay et al., 2004). (b) The map 
shows up-to-date information from the most 
recent WHO report of malaria distribution. 
Colour codes indicate Country malaria 
classification (Source: WHO, 2013). 
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The drug was shown to kill the parasite indirectly by accumulating in the food vacuole, 
where it interfered with haeme sequestration. Haem is a toxic bi-product of haemoglobin 
digestion, a major source of amino acids for the parasites. It is usually detoxified via 
conversion, through bio-crystallization, to haemozoin (malaria pigment) (Djimde et al., 
2001; Hyde, 2007).  In resistant P. falciparum parasites, alterations in a transporter protein, 
chloroquine resistance transporter (PfCRT), located on the membrane of the digestive 
vacuole ensures that the build-up of chloroquine within the vacuole is progressively 
diminished, together with the killing properties of the drug (Djimde et al., 2001; Hyde, 
2007). The resistance phenotype is attributable to multiple mutations on the pfcrt gene 
(encoding PfCRT) (White, 2004). A single mutation in the pfcrt gene, where threonine 
(T76) is substituted for lysine at position 76, has been shown to be responsible for 
resistance (Djimde et al., 2001). The complexity of the trait arises from the finding that 
this mutation can only occur on the back of several other pfcrt mutations, which 
themselves do not cause resistance (Dondorp et al., 2010; Plowe, 2009).  Additional copy 
number polymorphisms in the P. falciparum multi-drug resistance gene, pfmdr 1, have 
also been associated with varying levels of chloroquine resistance. However, this also 
seems dependent on the presence of the pfcrt mutations (Djimde et al., 2001).  
The failure of DDT and chloroquine triggered a resurgence and fresh outbreaks of the 
disease.  A period of despondency ensued, resulting in a unanimous acceptance that the 
Figure 1.3 Antimalarial drug timeline. Numbers to the left of coloured bars indicate when the drug was 
first in use and the first sign of resistance appeared (also represented by the dark shaded regions of the 
bars). Coloured ovals dictate the geographical regions of resistance development. The dashed lined in the 
Amodiaquine bar indicates a break in it’s used due to toxicity concerns. (Source: Ekland and Fiddock, 2008) 
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burden of malaria would remain indefinitely. Plans for eradication were abandoned and 
discussions turned to renewed efforts to treat and control the disease (Carter and Mendis, 
2002). 
1.5.4 The impact of the antifolate drugs  
Fortunately, the rampant resurgence of the disease was stalled by the discovery of another 
class of antimalarial drugs, the antifolates. Originally developed for the treatment of 
tumours, the success of the antifolates meant that they were soon applied to other systems 
of rapidly dividing cells, such as bacteria and parasites. Proguanil was the first antifolate 
shown to be effective against Plasmodium, in 1945 during the Second World War (Nzila, 
2006). Structurally similar to proguanil, pyrimethamine and cycloguanil were shown to 
target the dihydrofolate reductase (DHFR) enzyme in the folate pathway. This enzyme is 
present in both the parasite and the human host. Fortuitously, anti-DHFR drugs have a 
much higher affinity for the parasite enzyme than the human orthologue.  The antifolate 
class was further expanded once it was discovered that sulfa drugs block de novo folate 
synthesis. The parasite can synthesise folate de novo, thus it transpired that sulfadrugs 
were also effective at targeting the folate pathway in malaria (Nzila, 2006). Sulphonamide 
drugs and sulphones: namely, sulfadoxine, sulfalene, sulfone, and dapsone inhibit 
dihydropteroate synthetase (DHPS) activity in the folate pathway. Unique to the parasite, 
this enzyme is essential for biosynthesis of coenzymes in the folate metabolic pathway. 
Although proguanil and pyrimethamine have been used in monotherapy, the sulfadrugs 
(apart from dapsone) had poor efficacy an unacceptable toxicity. Success came when the 
class I antifolates (DHPS inhibitors) and class II antifolates (DHFR inhibitors) were 
combined. Although not considered combination therapy, as both drugs act on the folate 
pathway, the combination was found to have synergistic activity and was more effective 
than either drug used alone (Gregson and Plowe, 2005). Together the class I and class II 
antifolates effectively block the folate pathway and the production of important reduced 
folate cofactors. The folate cofactors are essential for the syntheisis and metabolism of 
certain amino acids, therefore, a consequence of antifolate treament is the inhibition of 
DNA synthesis (Hyde, 2005; Hyde, 2007).  During the erythrocytic cycle, the parasite 
undergoes a huge amplification step for which DNA synthesis is a pre-requisite. The 
parasite’s high demand for nucleotides at this stage, and its preference for endogenous 
folate, make the folate pathway an excellent drug target and the basis for the success of the 
antifolates as anitmalarials. The most extensively used combination is fansidar (SP), a 
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fixed-dose drug combination comprised of sulfadoxine and pyrimethamine approved by 
the FDA in 1983 (Gesase et al., 2009; Kitchen, Vaughn and Skillman, 2006; Ridley, 
2002).  Fansidar was largely employed to target chloroquine-resistant parasite populations 
in the late 1980s and for some years it effectively replaced chloroquine as a first line 
treatment for P. falciparum malaria (Miller and Su, 2011). Unfortunately, resistance to 
fansidar, and consequently resistance to other antifolates ensued (Figure 1.3), and 
developed fairly rapidly in response to drug pressure (Koram et al., 2005; Ratcliff et al., 
2007; White, 2004). Single mutations in either of the dhps and dhfr genes were enough to 
provide some degree of protection against the drug and led to localised reduction in drug 
susceptibility (Plowe, 2009).  The current situation of widespread highly resistant parasite 
populations is a consequence of a stepwise acquisition of mutations, each bestowing a 
further reduction in susceptibility to the drug (Gregson and Plowe, 2005; White, 2004).  
Treatment failure is characterised by a double mutation on the dhps gene and a triple 
mutation one the dhfr gene. An additional forth mutation has also emerged on the dhfr 
gene in Asia which denotes a high level of resistance to SP as well as the chlorproguanil-
dapsone combination (Gesase et al., 2009; Plowe, 2009).   It is suspected that, although 
low level resistance can develop locally, high level resistance arose from only two 
ancestral origins; once in South America and once in South East Asia, the latter of which 
eventually disseminated to Africa (Figure 1.3). It is noteworthy that the pattern of 
sulfadoxine/ pyrimethamine resistance is akin to the spread of chloroquine resistance 
(Plowe, 2009). 
1.2.5 The amino alcohols and artemsinins 
 Malaria related impacts during the Vietnamese war (1954-1975) led to the intensification 
of efforts into antimalarial drug discovery by both the Americans and North Vietnamese 
(Milner and Su, 2001). The 15 year drug discovery programme (1963-1976), initiated at 
the Walter Read Army Institute of Research (WRA), culminated in the discovery of two 
aryl amino alcohols, mefloquine and halofantrine, as novel antimalarials. The compounds 
were shown to be effective against chloroquine-resistant strains and were advanced quite 
rapidly for public use. Mefloquine and halofantrine were granted FDA approval by 1989 
and 1992 respectively (Croft, 2007). Unfortunately, their lifetime was limited as resistance 
developed rapidly (Figure 1.3), particularly, when the drugs were used alone (Ridley, 
2002). This was not entirely surprising considering their relatedness to the quinolines. 
Additional limitations associated with both mefloquine and halofantrine included 
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toleration issues, with increasing reports of neuropsychiatric disturbances and 
cardiotoxicity (Croft, 2007; Na-Bangchang and Karbwang, 2009; Ridley, 2002). The high 
cost of the compounds also prohibited their widespread use in sub-Saharan Africa (Ridley, 
2002).   
The North Vietnamese took a different direction and sought help from their wealthy 
Chinese neighbours, who set up an intensive top-secret project, Project 523. The aim of the 
project was to trawl ancient scriptures of traditional Chinese medicine with the hope of 
finding an efficacious herbal remedy for the disease. After testing more than 2000 plant 
compounds, Artemesia annua (qinghao) was found (Dondorp et al., 2010; Miller and Su, 
2011).  Following improved extraction procedures and elucidation of its sesquiterpene 
lactone structure, more potent, water-soluble (artesunate and artelinate) and oil soluble 
(artemether and arteether) derivatives were synthesised (Meshnick et al., 1996; Ridley, 
2002). Widespread drug resistance to the existing antimalarials and the ensuing resurgence 
in malaria mortality led to the artemisinin derivatives being fast-tracked for medicinal use. 
Fortunately, the neurotoxicity problems seen in animal studies did not manifest clinically, 
and to this day the drugs remain safe, well tolerated, and highly effective in most areas of 
the world (Meshnick et al., 1996; Rosenthal, 2008). Employed since the 1990s the 
artemisinins have saved countless lives and fought back in what was otherwise a losing 
battle (Figure 1.3). With no new alternatives available to replace the artemisinins, in the 
way SP replaced chloroquine, inital reports of early signs of artemisinin resistance 
appearing at the Thailand-Cambodia border set alarm bells ringing. There was once a 
perception that the artemisinins were less prone to resistance development due to their 
short-half life, rapid parasite clearance times and the resultant short selective window for 
resistance development. However, at this historical epicentre for the emergence of 
multidrug resistance, ideal conditions of uniquely high drug pressure, propagated by the 
use of sub-lethal doses, poor compliance with treatment regimes and low malaria 
transmission have allowed resistant populations of chloroquine (1957), 
sulfadoxine/pyrimethamine (1982) and more recently mefloquine (1990s) parasites to 
originate and establish (Alker et al., 2007; Dondorp et al., 2009; Krungkrai et al., 2010; 
Plowe, 2008).  After over 30 years of artemisnin monotherapy evidence of resistance came 
from slower parasite clearance, persistence for more than 7 days alongside adequate drug 
concentrations and re-emergence of parasites after 28 days of treatment (Krungkrai et al., 
2010; Noedl, 2008; WHO, 2010). A specific region of the kelch gene (K13) is now also 
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used as a genetic marker to identify artemisinin-resistant parasites (Tun et al., 2015). The 
growing number of cases reported in the field was accompanied by the ability to generate 
resistance in laboratory strains in vitro (Krungkrai et al., 2010). As a consequence, efforts 
to contain the spread of artemisinin resistance were intensified. Strategies involved the 
detection of all artemisinin resistant cases, the adoption artemisinin-based combination 
therapy regimes, the reduction of drug pressure in affected areas and the education of 
communities about the risk of using counterfeit drugs (Ioset and Kaur, 2009). Increased 
used of personal protective equipment (impregnated bednets) and mosquito control was 
also widely advocated (WHO, 2010). Since the early reports in 2005/2006, other, less 
severe cases (the proportion of patient’s still parasitaemic on day 3 of treatment) at the 
Myanmar-Thailand, China–Myanmar borders and in one province of Vietnam have also 
been reported (Dondorp et al., 2009; Ioset and Kaur, 2009). More worryingly however, a 
recent survey using the K13 marker has identified artemisinin resistant P. falciparum 
parasites in Myanmar, just 25 km from the Indian border (Tun et al., 2015).  Referred to as 
the gateway to the global spread of drug resistance, these recent reports at the Indian 
border provide further evidence that trajectory of artemisinin resistance is following that of 
the previous antimalarials. As the artemisinins are currently the main component of 
antimalarial treatment programmes throughout the world, prevention of the imminent 
spread of resistance to high transmission areas is, evidently, vital (Bhattarai et al., 2007; 
Miller and Su, 2011; Obonyo and Juma, 2012, WHO, 2010).  
1.6 Malaria today 
The Malaria World report estimated that in 2012 there were 207 million cases (uncertainty 
range: 135–287 million) and 627,000 deaths (uncertainty range:  473,000–789,000). Most 
cases (80%) and deaths (90%) occurred in Africa and the tragedy is multiplied by the fact 
that a majority of these preventable deaths occur in children (77%) under the age of 5 
(Wells, 2011; WHO, 2013). Areas that achieved eradication in the 1970s and 1980s 
maintain this status, but the disease persists in the poorest areas of the world that span the 
equator (See Figure 1.2 a and b) where the situation fluctuates between worse and better 
(Cox, 2002). 
1.6.1 The status of vaccine development 
The tools that we have available today, chemotherapy and insecticides, are the same as 
those deployed over 60 years ago during the eradication era. Resistance to both is an 
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ongoing challenge (Na-Bangchang and Karbwang, 2009; White, 2004). Despite the fact 
that it has been over 40 years since sterile immunity was generated in humans, in response 
to A bite from infectious irradiated mosquitoes, there is still no effective vaccine available 
(Heppner, 2013). The manufacture and administration of an attenuated whole parasite 
vaccine has proved too challenging. Subunit vaccines have failed to achieve comparable 
efficacy.  The most promising candidate to date is the pre-erythrocytic stage vaccine 
candidate RTS/S/AS01. This vaccine targets the sporozoite stage and is based on a region 
of the circumsporozoite protein, fused to the surface antigen of the hepatitis B virus and 
combined with a potent adjuvant. RTS/S/AS01 has now entered clinical trials with 
predicted licensure in 2015 (Guerin et al., 2002, Seidlein and Bejon 2013). Despite reports 
of only 50% efficacy, the malaria community is hopeful that the candidate could help save 
countless lives. Other subunit vaccines target blood-stage meroziotes, or gametocytes for 
transmission blocking purposes (Seidlein and Bejon 2013). Unfortunately there has been 
poor immunogenicity in the blood-stage candidates, possibly owing to the fact that the 
vaccine would have to induce a stronger immune reaction than the merozoite itself during 
a normal course of infection (Hill, 2011). The main disadvantage of the ‘altruistic’ 
transmission blocking vaccines are that prevention at the community level manifests in no 
immediate or direct benefit for the sufferer (Guerin et al., 2002). It is unlikely that any 
candidate targeting a single antigen will provide complete protection, and a multistage, 
multicomponent vaccine would be the most feasible option for success (Guerin et al., 
2002; Heppner, 2013; Seidlein and Bejon 2013). The added complexity of such a 
candidate obviously poses more challenges and is unlikely to materialise in the near future 
(Hill, 2011). 
1.6.2 Current mosquito control measures 
In terms of mosquito control, indoor residual spraying (IRS) remains an important 
component of control programmes. The most commonly used insecticide class for IRS is 
the pyrethroids. There are a few other options available, but they are more expensive. The 
use of insecticide treated bednets (ITN) and the more recently developed long-lasting 
insecticide treated bednets (LLITN), with a 3 year lifespan, have had a marked impact on 
malaria prevention in recent years. A combination of these vector control interventions is 
recommended. One problem is that all available mosquito nets are treated with 
pyrethroids. Unfortunately, there is already resistance to pyrethriods in the in the field, 
therefore, careful monitoring and insecticide rotation for IRS are imperative to curtail 
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widespread resistance development until other effective insecticide classes are developed 
(WHO, 2013).   
1.6.3 Current chemotherapy recommendations 
The history of malaria drug discovery has demonstrated that the parasite has been 
effortlessly capable of developing resistance against all purified single compound 
antimalarials used to date (Figure 1.3). For this reason, there has been a definitive 
abandonment of monotherapy. The idea is, that alongside the synergistic or additive 
activity conferred by a combination, there will be mutual protection against resistance 
bestowed to each of the partner drugs.  The current recommendation by the World Health 
Organisation for uncomplicated malaria is artemisinin-based combination therapy (ACT) 
(Grandesso et al., 2006; Valecha et al., 2009). One such combination is lumefantrine-
artemether (For other examples see Table 1.1). The combination has been shown to be 
synergistic (Schlitzer, 2007). Lumefantrine is a more recent member of the amino-alcohol 
class. It is structurally similar to halofantrine, less potent, but comparatively well tolerated 
due to the absence of cardiac side effects (Katrak et al., 2009; Schlitzer, 2007). Other non-
artemsinin-based combinations are also available (Table 1.1) and deployed regionally 
where necessary (Yeka et al., 2005). For the treatment of severe malaria quinine or one of 
the artemisinin derivatives, artemether or artesunate, are recommended (WHO, 2013). For 
the high risk groups: namely, pregnant women and children < 5 yrs, intermittent 
preventive treatment (IPTp and IPTi for pregnancy and infants, respectively) with the 
sufadoxine-pyremethamine (SP) combination is recommended. The treatment is given at 
the same time as the diphtheria-tetanus-pertussis vaccination. Surprisingly, SP remains 
effective as a prophylactic, despite a high level of resistance in the field (Craft, 2008). 
Seasonal malaria chemoprevention (SMC) with amodiaquine, plus SP is recommended for 
children aged 3-59 months (Andrews et al., 2014; WHO, 2013). Amodiaquine is a 4-
aminoquinoline that is closely related to chloroquine but it is effective against chloroquine 
resistant strains, apart from those that display very high levels of resistance. However, 
toxicity is a restrictive factor of the drug with reports of agranulocytosis, myelotoxity, 
hepatotoxicty and immune toxicity. Its use is therefore reliant on whether the benefits out-
weigh the cost (Na-Bangchang and Karbwang, 2009; Obua et al., 2006; Ridley, 2002). 
Malarone, the atovaquone-proguanil combination is primarily used as a prophylactic for 
travellers from developed countries, due to its high cost. This restriction on use is thought 
to be the reason for a lack of widespread resistance development to the combination. 
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Although atovaquone is distinct from the existing antimalarial classes, resistance can 
develop readily to the compound when used in monotherapy (Ridley, 2002). For P. vivax 
chloroquine is still effective in most areas (Andrews, 2014; WHO, 2013). 
 
 
Antibiotics such as doxycycline and clindamycin (Table 1.1) have also been used in 
combination therapy in recent years (Andrews et al., 2014). Antibiotic activity against the 
malaria parasite was initially unexpected due the specificity of antibiotics against 
prokaryotic structures. However, the eukaryotic malaria parasite possesses two organelles 
that have their own DNA and bacteria-like machinery; namely, the mitochondria and the 
apicoplast, on which the drugs are most likely to act. Most usually causing a delayed death 
phenotype, where antimalarial activity is not detected until the second erythrocytic cycle 
following drug exposure (Schlitzer, 2007). Although the use of antibiotics has increased 
the number of combinatory options and diversified the available chemotypes, most current 
treatments rely on either an artemisinin derivative or compounds related to existing, failing 
chemotherapies. 
Furthermore, recent concerns about the pharmacokinetic mismatch of current 
combinations have been expressed, particularly for high transmission settings (Kremsner 
and Krishna, 2004; Nandakumar et al., 2006; Ramharter et al., 2003). Disagreements as to 
Artemisinin-based combinations Safety PK match Evidence of field 
resistance 
 Artemether-lumefantrine +/- - some/no 
 Artesunate + mefloquine + - some/some 
 Artesunate + SP +/- - some/yes 
 Artesunate + amodiaquine +/- - some/yes 
 Artesunate + pyronaridine +/- - some/no 
 Dihydroartemisinin + piperaquine +/- - some/no 
 Artesunate + Chloroprogunil-dapsone +/- - some/unknown/unknown 
Non-Artemisinin combinations    
 Sulfadoxine-Pyrimethamine (SP) +/- +/- yes/yes 
 Chloroquine + SP +/- - yes/yes 
 Amodiaquine + SP +/- - yes/yes 
 Quinine + SP +/- - some/yes 
 Mefloquine + SP +/- - some/ yes 
 Quinine + tetracycline  - +/+ some/no 
 Quinine + Clindamycin + + some/no 
 Atovaquone-proguanil + +/- some/some 
 Chloroprogunil-dapsone - ++ unknown/unknown 
Table 1.1 Artemisinin and non-artemsinin containing drug combinations for malaria treatment. 
Abbreviations are as follows -= poor, +/-= unclear, += acceptable, ++= desirable. Drugs with – in the title are 
approved whilst drugs with + are not. Red text indicates self-determined assessment based on citations read.  
(After:  Kremsner and Krishna, 2004; Na-Bangchang and Karbwang, 2009). 
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whether the killing profile of each drug in the combination should be similar or dissimilar, 
in order to exert the greatest effect, have arisen. It was previously thought that fast-acting 
compounds should be combined with slow-acting compounds to limit the chances of 
recrudescent infections. However, while a fast-acting rapidly excreted compound, such as 
an artemisinin derivative, is protected by its partner drug, the longer plasma half-life 
partner is left exposed. Sub-lethal concentrations of the partner compound towards the end 
of the treatment regime may therefore increase the risk of selecting drug resistant mutants 
(Na-Bangchang and Karbwang, 2009; Dondorp et al., 2010; Koram et al., 2005; Walsh et 
al., 2007).  
While eradication should ultimately be a long term goal, the foreseeable future should 
focus on protecting existing treatments against impending failure (Greenwood et al., 
2008). The longevity of second-generation compounds is questionable, and a formidable 
concern, due to widespread resistance against the parent molecules (Na-Bangchang and 
Karbwang, 2009). The desperate need for novel antimalarial drug classes can therefore not 
be overemphasised. Unfortunately, antimalarial drug discovery has always been and 
remains, to this day, a challenging endeavour. 
1.7 Drug discovery 
Active drug discovery in general is not much older than a century, and the history of 
antimalarial drug discovery cannot be detached from contextual developments of 
medicinal science. Traditionally, disease treatments relied on the serendipitous discovery 
of natural product remedies, such as digitalis (foxglove) for the treatment of congestive 
heart failure, ipecacuanha (cephaelis plant bark or root) for the treatment of dysentery, 
aspirin (willow tree bark) for the treatment of fever and quinine (cinchona bark) for the 
treatment of malaria (Ng, 2009).  The earlier use of dried and ground preparations, was 
followed by the isolation and purification of active components during the early 19
th
 
century. Indeed, quinine was extracted in 1820. In an attempt to synthesise quinine in 
1856, William Henry Perkin created ‘mauve’ the first synthetic textile dye. From then 
onwards synthetic dyes had a profound impact on drug discovery (Schlitzer, 2007). With 
the advent of the germ theory (1870) and numerous observations that fungal contamination 
had an antagonistic effect on bacteria, a haphazard observation that eventually lead to the 
discovery of penicillin by Alexander Fleming (1928), there was already an idea that such 
interactions could be exploited pharmacologically (Rubin, 2007). A major breakthrough, 
coined as the beginning of a revolution in drug discovery, was when Paul Ehrlich (1890) 
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stained the malaria parasite with methylene blue. Inadvertently this demonstrated the 
selectivity of chemical dyes for biological tissues, prompting the development of the drug 
receptor concept. Thereafter, medicinal chemistry was born out of the realization of a 
connection between drug structure and biological activity (Drews et al., 2000). 
There was no greater impact on human health than antimicrobial therapy. History dictates 
that even penicillin was an indirect consequence of investigations into the antibacterial 
properties of synthetic dyes. Gerhard Domagk (1927) tested numerous dyes against a novel 
in vivo mouse model of Streptococcus pyogenes infection. Prontosil, a sulfonomide 
derivative (sulphonamide active component discovered as a dye in 1909) synthesised by 
Fritz Mietzsch and Josef Klarer, was shown to be the most efficacious (1935). Most 
importantly, Domagk had induced a change of opinion: that the administration of a 
substance systemically could cure a bacterial infection (Rubin, 2007). Interestingly, during 
its interval of popularity (1937) prontosil was also tested against P. falicparum with 100 % 
cure rates (Gregson and Plowe, 2005). At the time, the use of the sulfa drugs was limited 
by their ineffectiveness against tuberculosis and pneumonia and the potential for resistance 
development. It wasn’t until the 1950/1960s that interest in the compounds was re-ignited 
for an antimalarial indication. The eventual systemic challenge of bacterial infections with 
purified penicillin (Chain and Florey, 1938) led to the phenomenal success of a broad 
spectrum, specific, potent antibiotic with low toxicity that is still in use today (Rubin, 
2007). 
1.7.1 The golden era of drug discovery 
Other breakthroughs followed, and the mid part of the 20
th
 century (1928-1962) was 
considered the golden era of drug discovery. Medicinal chemistry advanced and treatments 
became available for numerous indications including, malaria, tuberculosis, hypotension, 
diabetes, psychosis, analgesia, and septicaemia (Burger, 1983).  The drug discovery 
pipeline involved in vivo animal models to demonstrate biological activity, followed by the 
purification and synthesis of compounds. Subsequent lead optimisation involved structural 
modifications to enhance efficacy through derivatization (Pina, et al., 2010). For malaria, 
animal models consisted of P. relictum in canaries (1926-1935), later P. gallinaceum in 
either chicks, ducklings or turkeys (1935-1948) and finally the rodent P. berghei model, 
that was first isolated from the thicket rat (central Africa, 1948) and remains widely used 
today (Burger, 1983). Eventually, in vitro culture methods replaced the preliminary in vivo 
investigations. Trager and Jensen made this transition possible for malaria in 1976, by 
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successfully culturing P. falciparum parasites, isolated from Aotus trivirgatus monkey, in 
human blood (Trager and Jensen, 1976). Accompanied with the genomics revolution 
(1980’s), these advances instigated a more rational design approach to drug discovery 
(Kotz, 2012). Optimism ensued from the idea that a greater understanding of disease 
aetiology, molecular biology and cellular processes would lead to the identification of 
essential defined targets, and in due course an influx of novel chemotherapies (Chatterjee 
and Yeung, 2012; Jana and Paliwal 2007; Wells, 2010). For malaria this prospect was 
promoted by the sequencing of the P. falciparum genome (Gardner et al., 2002) and the 
discovery that 60 % of the parasite proteins have no orthologues in humans (Guiguemde et 
al., 2012).  
1.7.2 Target-based drug discovery 
The framework for a target-based drug design strategy is to identify a metabolically 
essential target, most commonly from genomic analysis. Ideally, the target should be 
specific to the disease causing organism to help mitigate adverse effects (Chatterjee and 
Yeung, 2012). Once the target has been genetically validated, through knock-out studies, 
an in vitro chemical assay is developed to permit high-throughput screening (Chatterjee 
and Yeung, 2012; Frearson et al., 2007).  At this point either druggable small molecules, 
obeying the rule of 5, or smaller fragments that conform to the rule of 3 are screened 
against the target (Blaazer et al., 2014). Subsequently, hit compounds undergo structural 
optimisation to enhance the potency, selectivity and pharmacokinetic properties (Gilbert, 
2013). X ray crystallography and computational 3D modelling can also be used to inform 
structural alterations (Jana and Paliwal, 2007; Gilbert, 2013). Selectivity can be 
determined by subsequent screening of hit compounds against related human targets and in 
cellular assays. Toxicology and resistance potential is also evaluated (Gilbert, 2013; 
Chatterjee and Yeung, 2012). A novel target is not considered fully validated until a drug 
acting on that target is shown to be effective in the clinic (Gilbert, 2013; Wells, 2010). 
Since this approach has been adopted for malaria, numerous putative targets have emerged 
in the literature (See Table 1.2) (Fidock et al., 2004; Jana and Paliwal, 2007). These 
include as the cysteine protesases, protein farnesyl transferases, dihydrofolate reducatase 
and phospholipid biosynthesis, to name a few (Gelb, 2007; Fidock et al., 2004; Nwaka et 
al., 2004; Winstanley, 2000).  
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Target Location Pathway/ mechanism Target molecule                             Examples of therapies 
   Existing therapies New compounds 
Cytosol Folate Metabolism Dihydrofolate reductase Pyrimethamine, Proguanil Chlorproguanil 
  Dihydropteroate synthase Sulfadoxine, dapsone  
 Pyrimidine metabolism Thymidylate synthase  5-Fluoroorotate 
 Purine metabolism HGPRT  Immucillin-H 
 Glycolysis Lactate dehydrogenase  Gossypol derivatives 
  Peptidedeformylase  Actinonin 
 Protein Synthesis Heat shock protein 90  Geldanamycin 
 Glutathione metabolism Glutathione reductase  Enzyme inhibitors 
 Redox system Thioredoxin reductase  5,8-Dihydrooxy-1,4-napthoquinone 
  Gamma-GCS  Buthionine sulfoximine 
 Signal transduction Protein kinases  Oxindole derivatives 
 Shikimate  EPSPS  Glyphosate 
 CDK Pfmrk  Oxindole derivatives, thiophene sulfonamide 
 Unknown Ca2+ - ATPase Artemisinins  
Parasite membrane Phospholipid synthesis Choline transporter  G25 
 Membrane transport Unique channels Quinolines Dinucleoside dimers 
  Hexose transporter  Hexose derivatives 
Food vacuole Haem polymerization Haemozoin Chloroquine New quinolines 
 Haemoglobin hydrolysis Plasmepsins  Protease inhibitors,  pepstatin  
  Falcipains  Protease inhibitors,  leupeptin 
 Free radical generation Unknown Artemisinin New peroxides 
Mitochondrion Electron transport Cytochrome c oxidoreductase Atovaquone  
Apicoplast  Protein synthesis Apicoplast ribosome Tetracyclines, Clindamycin  
 DNA synthesis DNA gyrase Quinolines  
 Transcription RNA polymerase Rifampin  
 Type II fatty acid biosynthesis FabH  Thiolactomycin 
  FabI/PfENR  Triclosan 
 Isoprenoid synthesis DOXP reductoisomerase  Fosmidomycin 
 Protein farnesylation Farnesyl transferase  Peptidomimetics 
Extracellular Erythrocyte invasion Subtilisin serine proteases  Protease inhibitors 
Table 1.2 The existing and novel drug targets in Plasmodium falciparum. Abbreviations: EPSPS, 5-enolpyruvl shikimate 3-phospate synthase; CDK, Cyclin dependent protein 
kinases; DOXP, 1-deoxy-D-xylulose-5-5phosphate; GSC, glutamylcysteine synthetase; HGRT, hypoxanthine-quanine-zanthine phosphoribosyltransferase; PfENR, Plasmodium 
falciparum enoyl-ACP reductase. (After: Fiddock, 2004; Jana and Paliwal, 2007; Rosenthal, 2003). 
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Unfortunately, the heralded breakthrough has been disappointing, as clinical validation of 
novel targets has proven more difficult than expected (Wells, 2010).  Although potent hits 
are readily identified and can be genetically validated, translational problems often arise at 
the whole parasite or animal model level. Referred to as in vitro/ in vivo disconnect, this 
has been the fate of numerous compound series produced against prospective novel targets 
in recent years (Chatterjee and Yeung, 2012; Gilbert, 2013). Indeed, enzyme inhibition 
failed to correlate with whole-parasite activity for the targets: lactate dehydrogenase (LDH), 
thioredoxin reductase (TrxR) and the fatty acid biosynthesis enzyme (FabI), despite 
extensive lead optimisation. Eventually, LDH and TrxR were deemed not druggable and 
FabI was shown to be dispensable during the intraerythrocytic cycle (Guiguemde et al., 
2013).  A number of reasons have been put forward for the issue, mostly concerned with 
the lack of cellular context by which the hit compounds are identified. This results in 
unpredictable problems with cellular penetration, compound efflux, sequestration in lipid 
compartments, non-specific binding, alterations in protonation state of the molecule (in the 
enzyme active site) or undesirable kinetic properties (Gilbert, 2013). Despite our 
understanding of parasite biology, target identification is constrained by our existing 
knowledge base. Hindsight has led to the realisation that the parasite commonly uses novel 
modes of metabolism, cell division and trafficking, signalling and communication 
pathways. This means that the biological spectrum affecting a particular target is often 
poorly understood (Reaume, 2011). This incomplete knowledge results in unexpected 
adverse events and the poor attrition rates most frequently achieved (Jana and Paliwal, 
2007). 
1.7.2.1 Validated antimalarial drug targets 
Despite almost 30 years of target-based drug discovery, the antimalarial development 
pipeline has struggled to deviate from three validated targets. These targets are based on 
the action of pre-existing antimalarials that were not developed in accordance with the 
modern fully rational, target-based drug discovery framework (Na-Bangchang and 
Karbwang, 2009). They include (1) the haemozoin pathway (chloroquine) the folate 
pathway, (anti-folates Dihydrofolate reductase and dihydropteroate synthase inhibitors) 
and the cytochrome bcl complex of the mitochrondria, reportedly the principle target of 
atovaquone (Chatterjee and Yeung, 2012; Gilbert, 2013). In all cases, the antimalarial 
activity of the drug was discovered prior the identification of the target and mode of 
action.  Even the activity of antifolates, often considered an exemplar class of targeted 
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antimalarials, was recognised in the form of Prontosil long before their development 
specifically for the indication (Rubin, 2007). 
Furthermore, the majority of new antimalarials undergoing clinical development are 
actually resurrected from previous discovery programs. The second or third generation 
compounds are re-designed to be less toxic and retain efficacy where resistance to parent 
compounds is established (Gelb, 2007). One prospective example is Isoquine, a second-
generation aminoquinoline, that is active against chloroquine and amindoquinoline 
resistant parasite strains (Nwaka et al., 2004). However, the limited pool of refined targets 
and the pre-existing resistance capabilities of the parasite calls into question the longevity 
of such second generation compounds (Canfield et al., 1995; Wells, 2010). 
1.7.2.2 Problems with target-based drug discovery 
The reduction in output of novel first class medicines is not restricted to malaria, a decline 
has been seen across the disease spectrum (Ashburn and Thor, 2004; Boguski et al., 2009; 
Reaume, 2011). Since the 1990’s the capital spent on research and development has 
increased, while the number of chemical entities reaching regulatory approval has 
decreased (Boguski et al., 2009; Fidock et al., 2004). This has called into question over-
reliance on the target-based strategy and genetic approach to drug discovery (Kotz, 2012). 
A recent review indicated that in total there are 1065 drugs targeting 324 targets, 266 of 
these are human targets and the remainder constitute those targeting pathogens (Gilbert, 
2013). In reality, selective compounds are rare due to conserved homology (Chatterjee and 
Yeung, 2012).  
Focus on the target-based strategy has not been the only issue for malaria drug discovery. 
A persistent problem is that, although the malaria drug market is one of the largest in the 
world, with half a billion people needing treatment per annum, the majority of patients that 
require treatment cannot afford to pay for it (Craft, 2008). Unsurprisingly, the discovery 
and development of a drug product with a negligible profit margin is an unattractive 
investment for pharmaceutical companies (Craft, 2008; Muthyala, 2011; Winstanley, 
2000). The profit from prophylactic drugs for travellers from developed countries can in 
no way compensate for the capital needed for treatment of the underdeveloped world 
(Craft, 2008). Fortunately, in recent years this ‘not-for-profit’ area has been subsidised by 
the formation of non-profit public, private and philanthropic partnerships, such as the 
Medicine for Malaria venture (1999) and the Bill and Melinda Gates foundation, 
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substantially increasing efforts into malaria drug discovery (Fidock et al., 2004). As a 
result, the involvement of academia in drug discovery has become increasingly important 
(Kotz, 2012; Oprea et al., 2011).  
Ultimately, these academic and industrial partnerships have been formed on the back of a 
unanimous realization that the number of programs focussing on novel antimalarials, and 
the predominantly target-based approach that was being adopted, will be insufficient to 
sustain the antimalarial drug pipeline (Gelb, 2007; Gilbert, 2013; Wells 2010).  The 
considerably long development time of de novo drug discovery is further hampered by the 
high failure rate of candidates, with compounds at the lead optimisation stage having only 
a 7% chance of becoming a drug. Moreover, once is use, there is a possibility the novel 
drug may only have a short window of effectiveness, as demonstrated by the antifolates. 
Accompanied by inevitable spread of artemisinin resistance, these factors, predict an 
imminent, potentially catastrophic void in the malaria drug market. Thus making it 
imperative that faster development processes are sought and adopted (Craft, 2008; Gelb, 
2007).  
1.7.3 Phenotypic drug screening 
Towards the above mentiond aim, the drug discovery industry has turned to more 
traditional approaches in order to surmount the innovation gap caused by the dependence 
on target-based approaches (Boguski et al., 2009; Reaume, 2011). Historically, 
antimalarial drug discovery has benefited from phenotypic screening and the whole-
organism based approach (Chatterjee and Yeung; 2012). This top-down development 
process involves testing against the whole parasite followed by compound purification 
according to potency. Drug targets and mechanisms of action are defined retrospectively 
(Gilbert, 2013).  Regardless of the vast amount of information known about the 
Plasmodium life cycle, the most important and by far most efficacious antimalarial classes, 
the quinolines and the artemisinins, were discovered serendipitously from ancient herbal 
fever cures in this manner (Chatterjee and Yeung, 2012). Remarkably, the oldest 
antimalarial agent, quinine, remains effective despite nearly 400 years of use (Achan et al., 
2011). This is particularly striking when compared with the targeted anti-folate class of 
drugs that succeeded in retaining efficacy for relatively short 5 year period (Craft, 2008). 
While the action of the quinolines has since been elucidated, the target or most likely 
targets of the artemisinins, the most promising new class of antimalarials, are still in 
dispute. Indeed, evidence has been put forward implicating the involvement of 
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haemoglobin and haem (Klonis et al., 2011; Zhang and Gerhard, 2009), free radicals 
generated by the reduction of the endoperoxide bridge (Meshnick, 2002), reactive oxygen 
species generated by the activation on the mitochondrial electron transport chain (Mercer 
et al., 2011) and the involvement of the calcium pump PfATP6 (ortholog of endoplasmic 
reticulum pump SERCA) (Valderramos et al., 2010).  It appears that the complex nature of 
the parasite infection cannot be defeated by simple single-targeted compounds. The 
superiority of plant-based compounds is perhaps due do the complexity of their 
promiscuous binding and the benefits incurred by multiple off-target effects that are 
altogether lacking in their synthetically refined counterparts. Such issues of resistance 
development towards existing antimalarials has prompted the obligatory adoption of 
combination therapy for malaria in recent years. This, in turn has inadvertently doubled the 
quota for a continued supply of affordable new antimalarials (Craft, 2008). The modern 
perspective of phenotypic screening aims to address these issues by acknowledging the 
advances made in medicinal chemistry over the past century. Referred to as ‘drug 
repositioning’ or ‘repurposing’ (Figure 1.4), this novel strategy uses phenotypic screening 
to identify novel indications for existing or abandoned pharmacotherapies (Boguski et al., 
2009; Medina-Franco et al., 2013).  
1.7.4 Drug repositioning 
There have been numerous success stories of drug repositioning for other diseases. For 
instance, Sildenfil (Viagra) was originally developed to treat cardiovascular diseases but is 
now widely used for erectile dysfunction (Fink et al., 2002). Thalidomide was formally 
developed to treat morning sickness but was withdrawn due to adverse severe birth defects 
in children. The drug was later found to be uniquely effective for the treatment of 
Erythema nodosum leprosum and has more recently been patented for the treatment of a 
type of cancer (multiple myeloma) (Walker et al., 2007). Buproprion (Wellbutrin) and 
Duloxetine (Cymbalta) were both originally developed to treat depression but are now 
repurposed as a smoking cessation aid and for stress urinary incontinence respectively 
(Boguski et al., 2009). Clearly such fortunate medical triumphs highlight an opportunity 
that should not be missed by the malaria community. 
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Figure 1.4 Target-based and drug repositioning development timelines. De novo drug discovery, which in the last 30 years has focussed on a target-based strategy, can 
take 10-17 years with only a < 10 % probability of success. The drug repositioning timeline is shorter (3-12). Frequently repositioned candidates have already been 
evaluated at several phases of the pipeline for their previous indication. ADMET, absorption, distribution, metabolism, excretion and toxicity information may already be 
available for the candidate and the drug may already be approved for human use by the EMEA or FDA. For parasitic disease when knowledge of the target is not 
essential, target identification can run in parallel to lead optimisation, clinical development and regulatory approval. (After: Ashburn and Thor, 2004; Frearson et al., 
2007 Wells, 2010) 
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In the last 5 years, the literature has been inundated with reports of drug repositioning for a 
range of different human and infectious diseases (Ekins et al., 2011; Nzila, 2011; Oprea et 
al., 2011). An approach that once relied only on serendipitous instances has been 
transformed into a more systematic method of drug discovery (Medina-Franco et al., 
2013).  In effect, the strategy encompasses the benefits of the previous drug discovery 
methods; phenotypically, by using high throughput in vitro whole-cell screening and 
pharmacologically by exploiting diverse chemical libraries, the product of nearly 100 years 
of medicinal chemistry. 
1.7.5 Phenotypic screening for malaria 
Phenotypic screening for malaria has been made possible by recent developments of more 
high-throughput, whole-parasite screening techniques against the erythrocyte stages. These 
include the hypoxantine incorporation assay, ELISA and SYBR Green-based methods. 
More recently high-throughput liver stage assays have also been developed (Derbyshire et 
al., 2012). Demonstration of whole-cell activity means that the aforementioned issues 
often faced by targeted antimalarials, such as permeability and cellular efflux, have already 
been addressed. Selectivity and toxicity can be determined by screening against 
mammalian cell lines (Wells, 2011). One problem is that without prior knowledge about 
the target, structural alterations to improve compound activity are less informed (Gilbert, 
2013).  However, advances have been made in target identification using chemical 
proteomics, which could later be used to improve treatments by the creation of rationally 
designed second generation molecules (Gilbert, 2013; Kotz, 2012). Nevertheless, history 
has demonstrated that the most successful antimalarials are most likely to be those that 
display promiscuous binding and have multiple targets, which are much more difficult to 
elucidate and may have poor or narrow structural activity relationships (Chatterjee and 
Yeung, 2012; Melinda-Franco et al., 2013). The over-emphasis on the importance of 
knowing the drug target prior to use has dominated opinion in the drug discovery arena in 
recent years. However, in practice this is not always possible. In many cases knowledge of 
the target is not always a requirement for regulatory approval (Kotz, 2010; Melinda-Franco 
et al., 2013). For diseases like malaria, in particular, the need for the rapid deployment of 
an effective affordable antimalarial outweighs the idealism and benefits of knowing the 
target. 
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1.7.6 Drug repositioning for malaria 
Drug repositioning has been made possible in recent years by the commercial and 
scholarly availability of chemically diverse compound repositories, produced by the 
pharmaceutical industry. The pharmacological advantages of screening such high quality 
libraries are that they permit quick access to innovative chemical entities that may act via 
novel and potentially, multiple targets in the malaria parasite. The value of identifying 
distinct, multiple-targeted antimalarials that would inherently help circumvent resistance is 
indisputable. Although devoid of target information, scaffolds of compounds that display 
varied degrees of activity can be used to inform structural optimisation and improve 
physiochemical properties. Early in vitro pharmacokinetic profiling and selection of 
compounds with favourable intrinsic properties will also enhance the chance of success 
(Chatterjee and Yeung, 2012). Generally, and of utmost importance for the discovery of 
antimalarial drugs, the pace of the drug repositioning development route is much more 
efficient (Figure 1.4), particularly if the selected compound libraries have already been 
approved by the Food and Drug Administration agency or the European Medicines 
Agency (Chatterjee and Yeung, 2012; Wells, 2010) 
For diseases like malaria, where time and cost are significant factors, drug repositioning is 
an attractive, alternate approach to drug discovery (Figure 1.4). Not only will it offer an 
interim solution, while novel target-based drugs are developed, it may also help identify 
suitable candidates for combinatory regimes with existing antimalarials. Ultimately, this 
could help bridge the gap between the eventual failure of current antimalarials and future 
drug developments.  
1.8 Future directions 
The adoption of a balance between target-based drug discovery and drug repositioning will 
most likely be the best strategy (Gilbert, 2013). Existing target-based studies should be 
ongoing with the hope that the benefits of the last 30 years of scientific enquiry should 
materialise in the not too distant future.  Novel drug repositioning approaches should 
simultaneously aim to identify drug targets, but such investigation should run in parallel 
and not prohibit development and regulatory approval of much needed drugs (Kotz, 2012). 
Drug repositioning is often viewed as less scientific, when compared with the rational 
design target-based approach, due to its reliance on serendipity. However, the underlying 
hypothesis is that drugs are innately promiscuous, and access to unexplored chemical 
Chapter 1: Introduction 
28 
 
space for a particular disease indication should permit the discovery of novel targets 
(Reaume, 2011). This is exemplified by a common finding that the moiety required for 
activity in the previous indication is often dispensable for the repositioned activity, 
seemingly the result of off-target effects (Gelb, 2007). Following this rationale, the 
hypothesis of the current study is that antimalarial hit compounds will be identified from a 
preliminary screening of two FDA approved drug libraries.  
Subsequently, hit compounds should undergo more detailed characterisation in the 
academic setting so that early no-go and prioritization decisions can be made sooner 
(Chatterjee and Yeung, 2012). Indeed, for parasitic diseases, including malaria, 
preliminary screens of compound libraries, containing bioactive compounds with known 
safety profiles, have already begun (Baniecki, et al., 2007; Chong et al., 2006; Jones et al., 
2010; Lucumi et al., 2010, Major and Smith, 2011). Despite the huge volume of hits 
identified, few have been taken beyond the hit identification stage, devaluing the approach 
as a fast-track strategy (Baniecki, et al., 2007). The relatively refined compound screen (~ 
700 compounds) proposed here will permit a self-contained workflow of hit identification, 
prioritization and characterisation. Finally, the study will serve to further validate drug 
repositioning as an effective paradigm for antimalarial drug discovery. 
1.9 The objectives of the PhD 
1. To identify compounds that display potent in vitro antimalarial activity against the 
multidrug resistant P. falciparum K1 strain from medium-throughput phenotypic 
screens of two FDA approved drug libraries. 
2. To further characterise the action of selected hit compounds by defining their IC50 
level of inhibition and killing profile.  
3. Investigate the interaction of hit compounds with existing antimalarials, 
particularly artemisinin to determine suitability and potential for artemisinin-based 
combination therapy.  
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
2.1 In vitro culture of Plasmodium falciparum 
All procedures were carried out in the pathogen laboratory (University of Salford) sterile 
hood (ESCO class II Biological safety cabinet), using aseptic techniques and pre-sterilised 
equipment. Virkon (Antec International, UK) was used to disinfect waste material before 
autoclaving and disposal. All routine culture methods are consistent with those employed 
by Read and Hyde (1993). 
2.1.1 Preparation of complete mediim 
RPMI 1640 1x (+) L-Glutamine (+) 25 mM HEPES (4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid) (Gibco, Life Technologies, UK) was used as the basis of the culture 
medium.  Four additives; 2.5 g Albumin bovine serum fraction V (Sigma, UK), 2.5 ml 1 
mg/ml hypoxanthine (Sigma, UK) in phosphate buffered saline (PBS) (Fisher Chemical, 
UK), 2.5 ml 40% glucose (Dextrose Anhydrous, Fisher Scientific, UK) in sterile water and 
0.5 ml 50 mg/ml gentamycin (Sigma, UK) in PBS were transferred to a 50 ml falcon tube 
along with approximately 20 ml RPMI 1640 from a newly opened bottle. The contents of 
the falcon tube were allowed to dissolve and were subsequently passed through a 0.22 µm 
filter directly into the 500 ml bottle of RPMI 1640 medium using a 20 ml syringe. 
Following gentle mixing, the complete medium was stored at 2-8
o
C. 
2.1.2 Washing Medium 
A 500 ml bottle of pre-sterilised RPMI 1640 1x (+) L-Glutamine (+) 25mM Hepes (Gibco, 
Life Technologies, UK ) without additives was used as washing medium throughout the 
study and stored at 2-8
o
C for up to 2 weeks. 
2.1.3 Preparation of human blood for culture of Plasmodium falciparum 
To remove leukocytes, O+ whole blood (obtained from the human blood bank) was 
washed immediately before use. An equal volume of whole blood was added to two 50 ml 
falcon tubes and centrifuged for 5 mins and 3,400 rpm. Following centrifugation, blood 
plasma and the pale layer (the buffy coat-containing white blood cells) that forms on top of 
the red blood cells was removed. Blood was then re-suspended in an equal volume of 
washing medium and following centrifugation (as described previously) the supernatant,
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 along with the buffy coat, was discarded. The washing process was repeated 3x to ensure 
that all leukocytes were removed from the blood.  For the latter of the three washes, 
complete medium not washing medium was used. Finally, full blood (100% haematocrit) 
was re-suspended in an equal volume of complete medium to give a final haematocrit of 
50% and stored at 2-8
o
C until further use. 
2.1.4. In vitro Plasmodium falciparum culture 
To begin a new culture, 10 ml of complete medium and 0.5 ml of washed blood was added 
to a 50 ml culture flask and warmed to 37
o
C prior to the addition of the parasites. 
Approximately 0.5 ml of parasitised blood (retrieved from liquid nitrogen, refer to section 
2.1.7) was then added to the warmed culture medium to give a final haematocrit of 5 %. 
Following inoculation, the parasite culture was gassed with a 5 % CO2, 5 % O2 and 90 % 
N2 gas mixture (BOC Limited, UK) and placed in the incubator (Leec culture safe touch 
190 CO2, Leec Limited, Uk) at 37
o
C.  
2.1.5 Routine maintenance of a Plasmodium falciparum culture 
Parasites were routinely cultured at a final volume of either 10 ml or 30 ml in 25 cm
3
 or 75 
cm
3
 flasks respectively. For experimental set up, smaller flasks (12.5 cm
3
) with a final 
culture volume of 5 ml were used.  For each of the varying flasks volumes, the culture was 
maintained at approximately 5 % final haematocrit (for every 10 ml of complete medium 1 
ml of 50 % haematocrit blood was added). The medium was changed at either 48 or 72 
hour intervals. In brief, spent medium was removed and discarded without dislodging the 
parasitised blood layer that formed at the bottom of the flask.  Subsequent to the estimation 
of parasitaemia (see section 2.1.6), the continuous culture was diluted to 0.5-1 % 
parasitaemia with washed blood (50 % haematocrit). New complete medium was added to 
give a final haematocrit of 5 %.  Both washed blood and complete medium had been 
warmed prior to the dilution and re-suspension procedure. The culture was then gassed and 
placed in the incubator under conditions described previously. 
2.1.6 Estimation of parasitaemia  
One drop of concentrated parasitised blood (from the bottom of a culture flask) was 
transferred to the outer margin of a microscope slide. The blood was thinly smeared across 
the slide using a second slide and a single swift smooth action to obtain a monolayer of 
cells. The slide was then air dried at room temperature and fixed by rinsing in 100% 
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methanol. After an additional air drying step, the slide was immersed in Giemsa stain at 
room temperature for ~20 minutes. The Giemsa staining solution was prepared by diluting 
Gurr’s Giemsa stain solution (BDH/VWR international limited, UK) 1:10 with Giemsa 
buffer.  To prepare the buffer solution one tablet pH 6.4 (BDH laboratory supplies, 
England) was added to 1 litre of freshly distilled water. Following staining, the slides were 
rinsed with a gentle stream of tap water, dabbed dry and viewed under oil immersion (x 
100) using a Leica DM 500 compound microscope.  Parasitaemia was estimated by 
counting the total number of red blood cells per field of view (approx 100-200) and noting 
those containing parasites. Multiple infections were counted as one (as only one parasite is 
expected to reach full development). For each slide, at least 3 fields of view were counted 
from which the average percentage of infected cells was calculated. 
2.1.7 Preservation in liquid nitrogen 
A predominantly ring stage culture at approximately 15-20 % parasitaemia was selected 
for preservation in liquid nitrogen. In brief, the culture was centrifuged at 3,400 rpm for 5 
min, the supernatant removed and the culture reconstituted to a 50 % haematocrit by 
adding an equal volume of warmed complete medium. Aliquots (0.5 ml) of the suspension 
were transferred into 2 ml cryotubes and 0.5 ml 20 % dimethyl sulphoxide (sterile filtered 
DMSO, Sigma, UK) in Ringer’s solution (9 g NaCl, 0.42 g KCl and 0.25 g CaCl2/ Litre) 
was added. The tubes were immediately snap-frozen in liquid nitrogen for preservation and 
storage.  
2.1.8 Retrieval from liquid nitrogen 
Following an initial thawing period at 37
o
C the contents of the cryotube were transferred 
to a microcentrifuge tube and centrifuged at 14,000 rpm for ~1 min using the minispin 
(eppendorf, UK) centrifuge.  Once the supernatant had been discarded the parasitised 
blood was gently re-suspended in 1 ml of 10% sorbitol (Fisher Scientific, UK) solution (in 
PBS) with continuous mixing. This was then centrifuged and the process repeated twice 
more with subsequent re-suspensions in 5 % sorbitol (in PBS) and finally, complete 
medium. Following the latter washing step in complete medium, the culture was re-
suspended in complete medium and inoculated into a culture flask containing 0.5 ml of 
newly washed blood (50 % haematocrit) and 10 ml of complete medium (see 2.14).  
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2.1.9 Sorbitol synchronisation 
During continuous culture P. falciparum parasites rapidly loose synchronisation. If 
synchronisation was required prior to experimental set-up, sorbitol synchronisation was 
used to obtain a predominantly ring stage parasite culture. Sorbitol (5 % w/v) was prepared 
in distilled water and filtered through a 0.22 µm filter.  The sorbitol solution was then 
added directly to pelleted parasite culture (9 ml to 1 ml of culture pellet) and incubated for 
5 mins at room temperature. Following this, the culture was centrifuged at 3,400 rpm for 5 
mins and the supernatant was discarded.  The parasite pellet was then subjected to three 
washing steps in complete medium, before re-suspension in complete medium at 50 % 
haematocrit. The synchronised parasite culture was used to set up a new culture as 
described previously (section 2.1.4). 
2.2 Drug susceptibility assays 
Initial optimisation experiments for SYBR Green-based assays are described in chapter 3. 
The final versions of the assays are described here. 
2.2.1 Preparation of existing antimalarial primary stock solutions 
The four selected existing antimalarials used in the current study were obtained from 
Sigma Aldrich, UK. Primary stock solutions were prepared in accordance with 
manufacturer instructions. In brief, atovaquone (MW = 366.84) was dissolved at 5 mg/ml 
(13.63 nM) in DMSO. For dihydroartemisinin (MW = 284.35) 1.4 mg of the powder stock 
was dissolved in 1 ml of DMSO to obtain a primary stock concentration of 5 mM. 
Proguanil was dissolved at 1 mg/ml in acetonitrile: water (60/40). All primary stock 
solutions were passed through a 0.22 µm porosity filter, aliquoted and stored at -20
o
C until 
further use. Chloroquine (MW = 515.86) was prepared freshly on the day of use. An initial 
stock solution was prepared at 5 mM (10.32 mg/ 4ml) and sterile filtered. For experimental 
set up, the primary stock solutions were further diluted with complete medium to give 
working solutions. Various amounts of the working solution were then transferred as 
required to achieve final test concentrations.  
2.2.2 SYBR Green microtitre plate assay for Plasmodium falciparum 
For the SG-MicroPlate assay a black bottom 96 well plate was used (Nunc, Denmark). 
Dependent upon the nature of the experiment treated infected blood, untreated infected 
blood (positive control) and uninfected blood (negative control) samples were suspended 
in complete medium, RPMI or PBS at a final volume of 100 µl and a haematocrit of either 
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5 or 10 %. One hundred microliters of SYBR Green 1 (nucleic acid gel stain 10,000 x, 
Sigma, UK) staining solution (5 x SG in wash medium or PBS) was added to each well. 
This gave a final well volume of 200 µl and a SG concentration of 2.5 x. Final 
haematocrits were therefore also adjusted to 2.5 % and 5 % respectively. Following a 1 
hour incubation period at room temperature, fluorescence intensity was measured from the 
top using a GENius plate reader (Tecan) set at 485 nm excitation and 535 nm emission 
wavelengths. 
2.2.3 SYBR Green flow cytometry method for Plasmodium falciparum 
Following the drug treatment procedures, 50 µl of 5 % haematocrit culture was transferred 
from the infected-blood control, the non-infected-blood control and each treatment flask, 
into separate eppendorf tubes (for plate experiments maintained at 2.5 % haematocrit the 
transfer volume was adjusted to 100 µl). After a single washing step (in PBS, 
centrifugation: 90 seconds at 14, 0000 rpm) each pellet was re-suspended in 1 ml 5 x 
SYBR Green 1 solution (in PBS) and incubated in the dark for 20 minutes at room 
temperature.  Subsequently, the samples were centrifuged for 90 seconds at 14,000 rpm, 
the supernatant was removed and discarded and samples were re-suspended in 250 µl of 
0.37 % formaldehyde solution in PBS (formaldehyde solution for molecular biology 36.5 
%, Sigma, UK). After the addition of the fixative the samples were placed in the fridge at 4 
o
C for 10-15 minutes. Following fixation, the samples were washed 3 x in PBS and finally 
re-suspended in 1 ml of PBS. Fifty thousand events were recorded for each sample using 
the FITC channel of the BD FACsVerse flow cytometer system.  
2.2.4 Calculation of IC50 and IC90 values 
For all dose response data sets, values were transferred from respective software 
programmes into Microsoft excel. The infected blood controls were set at 100% and 
percentage parasitaemia for drug treated samples was calculated relative to the infected 
control. For IC50 and IC90 calculations, data was further processed using Gaphpad prism 
5.0. Data was normalised so that the largest value in the data set corresponded to 100% 
and the smallest value corresponded 0%. Log-transformed drug concentrations were then 
plotted against the dose response and the IC50 and IC90 values were determined using 
nonlinear regression (Graphpad prism 5.0). The log(inhibitor) vs. Normalised response-
Variable slope option was selected for IC50 calculation whilst the log(agonist) vs. 
Response-find ECanything with the F values set at 10 was used for the IC90 calculations.
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CHAPTER 3 
OPTIMISATION OF FLUORESCENCE-BASED DRUG SUSCEPTIBILITY ASSAYS 
3.1 INTRODUCTION 
A pre-requisite for the screening of FDA-approved drug libraries containing hundreds of 
compounds, is the establishment and optimisation of medium-high throughput screening 
methods for the malaria parasite. Over the years, many drug screening assays have become 
available. Most focus on the erythrocyte stages of the parasite life cycle. These include; the 
WHO microtest, the radioisotopic test, enzyme-linked immunosorbent assays (ELISA) and 
more recently, the fluorometric assays that utilise DNA-binding fluorescent dyes (Basco, 
2007; Co et al., 2010).  Details of each method will be discussed in the chronological order 
of discovery and suitability for use in the current study will be determined. 
3.1.1The WHO microtest 
The traditional microscopy test, to determine the sensitivity of Plasmodium falciparum to 
antimalarial drugs, was first announced in 1978 (Rieckmann et al., 1978). After further 
development by Wernsdorfor et al. (1980), the test gained support from the World Health 
Organisation (WHO).  As a result, the WHO standard microtest kit was produced, and the 
procedure named accordingly (Payne and Wernsdorfer, 1989). The test uses microscopic 
evaluation to enumerate schizont maturation following growth in the presence of an 
antimalarial (Bacon et al., 2007; Noedl, 2002). In brief, a Giemsa stained blood film is 
examined and 200 parasites are counted. Parasites with three or more nuclei are considered 
to have matured and are, therefore, not sensitive to the test drug. For drugs that Affect 
nuclear division, such as pyrimethamine, three or more nuclei may develop even when the 
drug is effective. For this reason, the threshold is raised; schizonts with eight nuclei or 
more are considered mature. For adequate comparisons, the figure in the control sample 
must reach at least 10 % (WHO, 2001). The figures from the control and treated samples 
can then be used to determine the drug concentration that inhibits 50 % of parasite growth 
(IC50).  This is a standard measurement used across disciplines to indicate the effectiveness 
of a particular compound.  Still in use today, for both in vivo and in vitro experiments, the 
WHO microtest is a reliable, sensitive, and inexpensive epidemiological tool. It can, 
however, be subjective and is highly labour intensive (Bacon et al., 2007; Noedl et al., 
2002; Rason et al., 2008).  Considering the large number of drugs to be tested, this method 
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would be too time-consuming. A more high-throughput method will therefore be 
necessary. 
3.1.2 Radioactive isotope incorporation 
The isotopic technique quantifies parasite uptake of various radioactive substrates as a 
measure of parasite growth (Smilkstein et al., 2004). Commonly used substrates include 
(3H)-hypoxanthine (Desjardin et al., 1979) and (3H)-ethanolamine (Elabbadi et al., 1992).  
The former substrate is incorporated into nucleic acids whilst the latter is a precursor of 
phospholipids (Desjardin et al., 1979; Elabbadi et al., 1992). The principle behind the 
technique is that the parasite cannot produce these substrates itself and must, therefore, 
obtain them from its environment. A second condition is that the parasite must not be able 
to acquire a non-labelled form of the substrate from additional sources, such as the blood 
or medium. For this reason, the hypoxanthine method is slightly flawed as hypoxanthine is 
a common component of P. falciparum culture medium. This problem has been overcome 
by purine starvation prior to pulsing with the radioactive-label (Smilkstein et al., 2004). 
The ethanolamine method, on the other hand, is devoid of this problem; the erythrocytes 
do not undergo phospholipid biosynthesis and the fatty acids and polar heads required are 
entirely absent from the growth medium (Elabbadi et al., 1992). For both substrates, the 
multistep procedure involves an initial 24 hr incubation period in the presence of the test 
drug. After incubation, the samples are pulsed with the radioactive-label and returned to 
the incubator for an additional 24 h. At 48 h, the plates are removed from the incubator, 
freeze-thawed, and each sample is harvested onto fibre-glass paper.  The paper is then 
dried and mixed with scintillation fluid. To determine IC50 values, incorporation of the 
radioactive-label is measured by a liquid scintillation counter (Cerutti Junoir et al., 1999; 
Noedl et al., 2002; Rason et al., 2008; Smilkstein et al., 2004). The isotopic method is the 
most widely used technique for assessing P. falciparum drug sensitivity. Indeed, Bacon et 
al. (2007) refer to it as the ‘gold standard’. Like the WHO micro test, the isotopic method 
is extremely reliable. Its major shortfall is that it requires the handling of radioactive-
isotopes. Not only are they expensive to buy, but, the equipment needed to process and 
dispose of them is also incredibly costly (Bacon et al., 2007; Noedl et al., 2002; Rason et 
al., 2008; Smilkstein et al., 2004).  Although the isotopic technique is a more high-
throughput method than the WHO microtest, it has a reduced sensitivity. To obtain 
adequate readings parasitaemia must reach 0.2-0.5%. This is a more serious problem for in 
vivo and ex vivo rather than in vitro culture systems, where starting parasitaemias can be 
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controlled (Noedl et al., 2002).   In view of the aforementioned problems, the handling of 
radioactive waste being the most limiting, the isotopic technique would not be suitable for 
use in our lab.                                                                                                         
3.1.3 ELISA-based assays 
The two enzyme-linked immunosorbent assays (ELISA) for malaria drug screening 
purposes were originally adapted from enzymatic assays (Co et al., 2010).  The more 
recent methods utilize two monoclonal antibodies against P. falciparum. The two most 
commonly used targets are histidine rich protein two (HRPII) and P. falciparum lactate 
dehydrogenase (pLDH) (Bacon et al., 2007). As its name suggest HRPII is a histidine and 
alanine rich protein that is associated with parasite development (Noedl et al., 2002). 
Localised to both the parasite, and the infected erythrocyte cytoplasm it is also found in 
pockets on the infected erythrocyte membrane and has been recovered from culture 
supernatants as a secreted water-soluble protein (Co et al., 2010). The other target, pLDH, 
is an enzyme that catalyses the conversion of pyruvate to lactate, in the glycolytic 
pathway, and is essential for energy production and parasite growth. Conveniently, the 
parasite enzyme is distinct from the human form of LDH and can be used as indicator of 
parasite growth (Kaddouri et al., 2006; Makler et al., 1998; Co et al., 2010). 
The ELISA is now a widely used method for malaria drug susceptibility testing (Bacon et 
al., 2007). The assay works by measuring changes in the levels of either target (pLDH or 
HRPII) as an indicator of parasite growth. Various groups have adapted different ELISA 
protocols using the different targets. For example, Druilhe et al (2001) developed the 
double enzyme-linked LDH immune-detection assay (DELI) using pLDH, Noedl et al. 
(2002) on the other hand developed the HRPII ELISA using HPRII. Although 
modifications have been made to improve assay performance for malaria drug screening 
purposes, all of the assays available follow the basic capture-ELISA procedure. Initially, 
the plates are coated with the primary antibody, specific for either HRPII or pLDH, and 
incubated overnight at 4
o
C. Following the incubation period, the plates are washed, leaving 
only the immobilised antibodies in the wells. Haemolysed infected blood can then be 
added to the pre-coated wells and incubated for 1hour at room temperature. This allows 
any antigen, for example HRPII, within the sample to bind to the antigen specific antibody. 
Subsequent to washing, the antibody-enzyme conjugate is added. Any unbound conjugate 
is then washed away and a colourless substrate is added to the wells. In the presence of the 
enzyme, which at this point is attached to the antibody-antigen-antibody sandwich, the 
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colourless substrate is converted into a coloured product.  The absorbance can then either 
be read immediately, or at a later time point following the addition of a stop solution to 
prevent any further reactions. The intensity of this colour change, measured by a microtiter 
plate reader, corresponds to the level of parasite multiplication.  
The ELISA-based methods offer high throughput, sensitive, non-subjective screening tests 
(Noedl et al., 2002; Rason et al., 2008). In addition, the more recently optimised DELI and 
HPRII methods have been shown to correlate well with the traditional, WHO microtest 
and radioactive-isotope, methods (Grimberg, 2011). However, the multistep procedure is 
time consuming, stage-specific and requires a minimum incubation time before detectable 
effects can be observed, while only providing indirect information about the response of 
the parasite to a test drug (Bacon et al., 2007; Grimberg 2011; Noedl et al., 2002). 
Furthermore, the commercial test kits available for both the pLDH and the HPRII ELISAs 
are expensive (Noedl et al., 2005; Rason et al., 2008).  The individual assay components 
can be purchased separately for HRPII ELISA, but not for pLDH-based assays (Bacon et 
al., 2007). The downfall is that the in-house procedure needs to be standardised which can 
be time-consuming and labour intensive (Noel et al., 2005).  
3.1.4 SYBR Green-based microtitre plate assay 
The use of SYBR Green in screening takes advantage of the fact that the parasite’s host 
cells (human erythrocytes) are devoid of DNA. For this reason, the majority of 
fluorescence observed in a sample can be attributed to parasite DNA. SYBR Green is one 
of the most sensitive DNA stains available. It is a cyanine dye that binds to double 
stranded parasite DNA and once intercalated becomes highly fluorescent (Vossen et al., 
2010). For the purpose of drug screening, a lower fluorescence intensity reading, in 
comparison with the control sample, reflects a lower amount of DNA present, which in 
turn infers a decrease in parasite growth. The main advantages of the SYBR Green assay 
are that it is relatively simple, quick and inexpensive to perform (Rason et al., 2008). 
Indeed, the one-step procedure involves the addition of dilute SYBR Green to the sample 
followed by a 1 hour incubation period in the dark at room temperature. The sample can 
then be read immediately (Smilkstein et al., 2004). Apart from a fluorescent plate reader, 
no specialised equipment is required for the assay. In some studies the lysis of the 
erythrocytes prior to or during the staining procedure is included as an additional step to 
reduce background fluorescence (Johnson et al., 2006; Moneriz et al., 2009. One problem 
is that the SYBR Green dye can indiscriminately bind to non-parasite DNA as well as 
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parasite DNA. The presence of any remnant white blood cells in the sample may therefore 
interfere with the results, or cause a high background. The dye is also capable of binding to 
single stranded DNA and RNA but at a much lower affinity than double stranded DNA, 
again contributing to background interference (Smilkstein et al., 2004).  However, the 
results obtained by the relatively novel SG approach are comparable to those obtained via 
the more traditional methods (Rason et al., 2008). Vossen et al. (2010) on the other hand 
suggests that for drug susceptibility assays a relatively high starting parasitaemia is 
required, indicating that the assay may be more suitable for in vitro culture systems, rather 
than as a field application, where such parameters can be controlled.  
3.1.5 SYBR Green-based Flow cytometric method 
 Like the plate reader assays that use a fluorescent DNA stain, the flow cytometric method 
exploits the fact that circulating red blood cells predominantly lack DNA (Grimberg 2011). 
There are a multitude of fluorescent nucleic acid dyes available for use with a flow 
cytometer, each of which has varying specificities for DNA and/or RNA (Table 3.1) 
(Bianco, Battye and Brown, 1986; Hare and Bahler, 1986; Jackson et al., 1977; Makler, 
Lee and Recktenwald, 1987; Shapiro and Mandy, 2007; Van Vianen et al., 1993).  In 
addition to the DNA stains, fluorescent antibodies against malaria blood cell surface 
antigens can be used to gain a clearer image of antigen expression during the parasite life 
course. Stains specific to human blood cells can also be employed to exclude unwanted 
cells from the analysis. This toolbox of dyes can be used individually or in conjunction 
with other dyes that have different wavelengths to gain more information about parasite 
response to drug exposure. Indeed, Malleret et al. (2011) used a tri-coloured method with 
which they were able to determine parasitaemia according to DNA content, using either 
Hoechst 33342 or SYBR Green as a DNA stain. In addition, they calculated the frequency 
of leukocytes, normocytes and recticulocytes by using an anti-CD45 antibody and 
dihydroethidium which stains both DNA and RNA (Malleret et al., 2011). Others suggest 
that this exclusion process, adopted to avoid the confounding effects of recticuloctyes and 
white blood cells, is not necessary, particularly when using an in vitro culture method. The 
RNA present in recticulocytes (1.5% of human blood) degrades within a few days of in 
vitro culture and any remnant white blood cells, left behind after the blood washing 
procedure can be easily identified on the flow cytometer output and thus eliminated due to 
the differential size of human DNA relative to the parasite genome (Grimberg, 2011).  
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Dye Class Specificity Wavelength Cell permeability 
Hoechst 
33258 
Miscellaneous DNA ex345 em478 permeant 
Hoechst 
33342 
Miscellaneous DNA ex355 em465 permeant 
GFP  Varies ex481 em507 permeant 
SYTO-9 Cyanine stain DNA/RNA ex485/486 
em598/501 
permeant 
SYBR Green Miscellaneous DNA ex488 em522 impermeant 
SYTO 16 Cyanine stain DNA/RNA ex488/494 
em518/525 
permeant 
YOYO-1 Cyanine stain Nucleic acids, 
high affinity for 
DNA 
ex491 em509  impermeant 
Acridine 
orange 
Miscellaneous DNA/RNA ex503 em530 impermeant 
SYTOX Green Cyanine stain Nucleic acids ex504 em523 impermeant 
Thiazole 
orange 
Cyanine stain Primarily RNA ex509 em533 permeant 
Ethidium 
bromide 
Intercalating 
stain 
Nucleic acids ex510 em595 permeant 
Propidium 
iodide 
Intercalating 
stain 
Nucleic acids ex535 em617 impermeant 
Hydroethidine Intercalating 
stain 
DNA (live 
parasites only) 
ex365/535 
em435/610 
permeant 
SYTO-61 Cyanine stain Nucleic acids ex628 em645 permeant 
Table 3.1 A range of fluorescent dyes used to study malaria by flow cytometry. (After Grimberg, 2011) 
 
The fluorescence-based options are an attractive alternative to the more traditional 
methods used for drug susceptibility testing. They appear to be devoid of many of the 
tedious technical complications that plague the microscopic, isotopic and ELISA-based 
methods. The current study will aim to contribute to the growing body of evidence that the 
SYBR Green-based microtitre plate and flow cytometry methods are indeed reliable.  
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3.2 METHODS 
3.2.1 Optimisation of the SYBR Green Microtitre plate assay (SG-MicroPlate) 
An experiment was set up to determine the correlation between fluorescence intensity and 
parasite density. In brief, spent medium was removed from a continuous culture of P. 
falciparum, strain K1, and the parasitaemia was determined by blood smear. The 
parasitised blood (50 % haematocrit) was then diluted with RPMI to a range of starting 
haematocrits (2.5 %, 5 %, 10 %, and >10 %) before being transferred in duplicate (200 µl 
per well) to column 1 of a 96 well plate. A non-infected blood sample (5 % haematocrit) 
was also added to column 1, in duplicate, and served as a negative control. Two-fold serial 
dilutions were then performed using 100 µl of RPMI (columns 1-12) leaving a final 
volume of 100 µl per well. Additional controls included wells containing 100 µl of  either 
wash medium or complete medium. The SG-MicroPlate staining procedure was carried out 
as described elsewhere (Chapter 2 section 2.2.2). 
3.2.2 Optimisation of the SYBR Green Flow Cytometry assay (SG-FCM) 
In order to establish whether the SG-FCM method described by Karl et al., (2009) was 
reproducible, an unsynchronised parasite culture (~2 % parasitaemia) was stained in 
accordance with the methods described in chapter 2 (section 2.2.3). Comparisons were 
made, in parallel, between flow cytometric data and confocal microscopy of Giemsa 
stained blood smears, slides were stained with both Giemsa and SYBR Green and with 
SYBR Green only (See Appendix I for slide staining procedures).  
3.2.3 Comparison of the Giemsa microscopic test, SG-MicroPlate and SG-FCM 
The reliability of the SG-MicroPlate and SG-FCM methods were evaluated in comparison 
to the Giemsa microscopic test, by determining the 50 % inhibitory values of 
dihydorartemisinin against the K1 strain of P. falciparum.  Synchronised ring stage 
cultures were diluted with fresh culture media to approximately 1 % parasitaemia (5 % 
hematocrit) and divided into 12.5 ml culture flasks (5 ml final culture volume). Doubling 
concentrations (1.25 nM, 2.5 nM, 5 nM, 10 nM, 20 nM and 40 nM) were added to the 
flasks in duplicate. A drug-negative control was included and the cultures were incubated 
at 37 
o
C.  The first 7 of 14 flasks were exposed to the various DHA concentrations for 48 h 
whilst the replica flasks were exposed for a 72 hr time period. The two time points were 
selected to allow the analysis of the effects of DHA on parasite maturation and 
multiplication respectively. Subsequent to drug exposure, the three assays were completed 
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in parallel using the optimised staining procedures (Chapter sections 2.1.6, 2.2.2 and 
2.2.3). In brief, 4 ml of spent, complete medium was removed and Giemsa blood smears 
were prepared for each sample. The haematocrit was then restored (to 5%) with 4 ml of 
warmed washing media. Triplicate samples were taken for SG-MicroPlate (100 µl) and 
SG-FCM (50 µl) analysis. Three experimental repeats were completed. The percentage 
fluorescence (SG-MicroPlate) or percentage parasitaemia (SG-FCM and Giemsa 
Microtest) comparative to the infected control samples were used to compile data, from the 
separate experiments. IC50 values were determined using regression analysis (As described 
in Chapter 2 section 2.2.4) and compared via one-way ANOVA (Graphpad prism 5.0). 
3.2.4 Optimisation of 96 well plate culture of P. falciparum 
Strain K1 parasites were diluted to ~1% parasitaemia, treated with a series of chloroquine 
(200 nM, 250 nM, 300 nM) and dihydoartemisinin (2.5 nM, 5 nM and 10 nM) 
concentrations. Triplicate samples (200 µl) were transferred to a 96 well plate at 2.5 % or 5 
% haematocrit. Flask cultures were maintained at 5% haematocrit and grown in parallel. 
Following 48 h of incubation Giemsa stained blood smears were prepared for each sample 
(see Chapter 2, Methods 2.16 for details). For SG-MicroPlate analysis the previously 
optimised method was employed. In brief, 100 µl of medium was removed from each well 
prior to the addition of the SG-staining solution to reduce background fluorescence. One 
hundred microliters of the parallel flask culture treatments were also transferred to the 
plate. The final volume of each well was therefore 100 µl, before the addition of 100 µl of 
SG (in RPMI 1640).  (Note this means that the haematocrit from the flask cultures was 
diluted 1:1 in the plate from 5 % to 2.5 % haematocrit). The original 200 µl final volume 
of the plate cultures was restored with the addition of SG staining solution, and thus the 
same haematocrit was maintained. Staining and analysis procedures were consistent with 
(Chapter 2, Methods 2.2.2).   
3.2.5 Optimisation of a medium-throughput SG-MicroPlate assay  
The following experiment was conducted in order to establish whether the previously 
optimised SG-MicroPlate protocol should be modified to include additional washings 
steps, following parasite growth in a 96 well plate format.  A continuous culture of P. 
falciparum was diluted to ~ 3 % parasitaemia. Three conditions were set up, with both 
infected and non-infected blood, as follows: (1) 5 % haematocrit blood suspended in 
complete media and serially diluted with complete media (CM/CM P and CM/CM B for 
parasitised and uninfected blood respectively). Note: this was consistent with previous 
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experiments as there remains 100 µl of complete media in each well prior to the addition 
of SG. (2) 5 % haematocrit blood suspended in complete media and serially diluted with 
RPMI (CM/RPMI P and CM/RPMI B). (3) Parasitised and uninfected blood washed in 
RPMI and re-suspended in RPMI at 5 % haematocrit before being serially diluted with 
RPMI (RPMI/RPMI P and RPMI/RPMI B). Initially, 200 µl of each sample (in duplicate) 
was transferred to the first column of a black-bottom 96 well plate and serially diluted 
(1:1) with either complete media or RPMI as indicated above. One hundred microlitres of 
each mixture was discarded from the last well (leaving 100 µl per well).  The SG-
MicroPlate method was employed (Chapter 2, section 2.2.2) 
3.2.6 Time-course analysis of DHA treatment using SG-FCM 
In order to investigate the parasites response to DHA treatment in more detail and further 
validate the reliability of the SG-FCM, for stage-specific detection, a time-course analysis 
of DHA exposure during erythrocytic cycle progression of K1 parasites was completed, 
alongside Giemsa imaging. The experiments were initiated at the late ring/early 
trophozoite stage. The first study compared untreated control samples with DHA 
treatment, for a short time-course at regular intervals (4, 8, 24, 28, 32, 48 hours). The 
second study expanded the time-course to 24, 48 and 72 hour intervals. Parasites were 
treated with the previously determined IC50 concentration of DHA and analysed at each 
time point using the SG-FCM method (Chapter 2, section 2.2.3). 
3.2.7 Stage-specific effects of DHA using SG-FCM 
Following the validation the SG-FCM technique, this assay was used solely to determine 
whether stage specific effects of DHA could be analysed. During previous experiments 
drugs were added when parasites were predominately at the ring stage. This meant that at 
the 48 and 72 hour time points the parasites had entered a subsequent cycle and were 
analysed at the ring and trophozoite stage respectively. This routine effectively missed any 
effects on the schizont stage.  As the cytometer is capable of discriminating between 
mononuclear (ring and trophozoite) and multinuclear (schizont) parasites, the aim of this 
experiment was to analyze the parasites at the schizont stage and establish whether DHA 
had an effect on schizont formation.  To ensure parasites were treated with DHA for the 
duration of an erythrocyte cycle, a range of DHA concentrations (0.63 nM, 1.25 nM and 
2.5 nM) were added, and analysed at schizont stage (45 hr incubation).  Parasitaemia was 
estimated as described previously (Chapter 2, section 2.16). 
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3.2.8 IC50 determination of existing antimalarials against K1 parasites 
Following preliminary screens (data not shown), refined dose ranges were selected for 
atovaquone, chloroquine, dihydroartemisinin and proguanil to permit accurate IC50 
calculation against the P. falciparum strain K1. The dose range selected for each 
antimalarial is shown in Table 3.2. 
 
 
Trophozoite stage parasites (0.5- 1%) were treated for 48 hours and parasitaemia was 
determined using the SG-FCM. Data were analysed in accordance with Chapter 2, sections 
2.2.3 and 2.2.4. IC50 estimates were compared with those reported in the literature. 
 
Atovaquone (nM) Chloroquine (nM) Dihydroartemisinin (nM) Proguanil (µM) 
0.64 100 1.25 3.77 
1.28 150 2.5 7.54 
2.56 200 5 15.08 
5.11 250 10 30.15 
10.22 300 20 60.31 
20.45 350 40 120.61 
40.89 ---- ---- 241.22 
Table 3.2 Drug concentration ranges selected to obtain dose response curves for atovaquone, 
chloroquine, dihydroartemisinin and proguanil against P. falciparum strain K1. 
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3.3 RESULTS 
3.3.1 Optimisation of the SG-MicroPlate assay for malaria 
The fluorescence intensity of SYBR Green 1 nucleic acid dye was measured, for a range of 
parasite density dilutions, using the SG-MicroPlate assay. The results showed that as 
parasite density became more diluted, fluorescence intensity decreased.  The results also 
indicated that complete medium, not washing medium or non-infected blood, had an 
inherently high level of fluorescence (Figure 3.1). 
 
 
 
 
3.3.2 Optimisation of the SYBR Green Flow Cytometry assay (SG-FCM) 
A comparison of infected and non-infected blood samples showed that the SYBR Green 1-
based flow cytometry assay can detect parasite DNA within the parasitised red blood cells 
(Figure 3.2). As demonstrated previously by Karl et al., (2009), the unsynchronised culture 
presented two populations of varying fluorescence intensity on the cytometer output 
showing good labelling and differentiation of mononuclear and multinuclear parasites 
(Figure 3.2 b). The BDFACSverse software can be used to accurately determine 
parasitaemia by recording the percentage of infected cells relative to the total number of 
events recorded (red blood cells) (Figure 3.2 c).  
Figure 3.1 the effect of parasite density dilution on fluorescence intensity of SYBR Green 1. Parasitised 
blood (approx 3%) was diluted with RPMI (wash media) to either a 10 % or 5 % starting haematocrit. The 
infected samples were further (1:1) diluted 12 x alongside a non-infected blood control sample (5 % 
starting haematocrit) and subjected to the SG-MicroPlate assay. Complete media and RPMI served as 
controls. Error bars represent the standard error of two replica experiments 
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Figures 3.2 Comparison of infected and uninfected blood samples using SG-FCM. Scatterplots based on 
forward scatter (FSC-A) and fluorescein isothiocyanate (FITC-A) (490/520) are examples of an uninfected 
blood sample (a) and an unsynchronised parasite culture (b). The gating strategy, adapted from Karl et al., 
(2009), was employed to distinguish between mononuclear (rings and trophozoites) and multinuclear 
(schizonts) parasite stages. The % grandparent represents the % of mononuclear and multinuclear cells 
relative to the totol number of events recorded. The % paraent reflects the % of gated, uniform red blood 
cells displaying mononuclear and multinuclear fluorescence.  The BDFACSVerse software program was 
used to determine the percentage of parasitised cells (c).  
b 
 
f 
 
g 
 
Figure 3.3 Confocal microscopy of the 
malaria parasite. Staining of parasite 
DNA was confirmed by fluorescence 
confocal microscopy. A dual staining 
assay for giemsa (a) and SYBR Green 
(b) was completed alongside an 
alternative SYBR Green staining 
method (c) as described in Appendix I. 
Two SYBR Green staining procedures 
were adopted in an attempt to reduce 
background fluorescence. 
10 µm 
a 
b c 
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Fluorescence confocal microscopy images confirmed that SYBR Green 1 stained parasite 
DNA inside the erythrocytic cells (Figure 3.3). All samples were prepared from the same 
culture of P. falciparum strain K1 parasites. The dual giemsa and SYBR Green staining 
procedure (Appendix I a and b) permitted concurrent images (Figure 3.3 a and b) but 
showed a high level of background fluorescence and staining artefacts. The SYBR Green 
staining method (Appendix I c) used for Figure 3.3 c reduced background fluorescence and 
revealed parasitaemia estimates consistent with the giemsa staining (figure 3.3 a). 
3.3.3 Comparison of the Giemsa microscopic test SG-MicroPlate and SG-FCM 
SYBR Green flow cytometric (SG-FCM), micro titre plate (SG-MicroPlate) and traditional 
Giemsa microscopic (Giemsa) assays were compared by parallel analysis of the 
dihydroartemisinin dose-response for synchronised, ring stage, K1, P. falciparum cultures 
(Figure 3.4). IC50 values for cultures sampled at 48 and 72 hr post drug exposure were 
determined (Table 3.3) and compared, using a one-way ANOVA (Graphpad prism). There 
were no significant differences between the three assays and although the IC50 values 
appear to be consistently higher at 72 hours than at the 48 hour time point for all 3 assays 
(Figure 3.4), this difference was also shown not to be statistically significant. Exemplar 
Giemsa images and flow cytometer output can be found in Appendices II and III. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time points Giemsa IC50 (nM)  SG-MicroPlate IC50 (nM)   SG-FCM IC50 (nM) 
48 h  1.976 (1.60-2.45)  1.54 (1.12-2.11)  1.81 (1.30-2.53)  
72 h  2.264 (1.85-2.78) 2.781 (2.26-3.42) 2.785 (1.87-4.14)  
Figure 3.4 Dose response curves for dihydroartemisinin against the K1 strain. A set of three parallel assays: 
namely, Giemsa microscopic test (Giemsa), SYBR Green microtitre plate assay (SG-MicroPlate) and the SYBR 
Green flow cytometer assay (SG-FCM). Data is from three independent cultures exposed to DHA for 48 or 72 h. 
 
Table 3.3 In vitro IC50 (nM) sensitivity of the K1 strain to dihydroartemisinin at 48 and 72 h. Three assays 
were used to determine parasitaemia (i) Giemsa Microscopic test (ii) SYBR Green MicroPlate assay and (iii) the 
SYBR Green flow cytometer assay. Numbers in brackets are indicative of 95 % confidence intervals. 
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3.3.4 Optimisation of medium-throughput SG-MicroPlate assay for malaria 
The Giemsa results of the initial comparison between plate growth and flask growth 
indicate that an equivalent growth rate can be achieved in a 96 well plate format, compared 
to the flask culture (Figure 3.5 a). A clear dose-response for chloroquine and 
dihydroartemisin was also observed. These findings, however, are not mirrored in the SG-
MircoPlate assay results that were completed in parallel (Figure 3.5 b). It appears that in 
the latter assay, only media composition and the amount of haematocrit have an effect on 
the absolute fluorescence reading obtained, and not parasite growth. The non-infected 
blood control also displayed a relatively high level of fluorescence. 
 
 
 
 
Figure 3.5 Comparison of parasite growth in a 96 well plate and 12.5 cm
3
 flasks following exposure to a 3 
point dose series of chloroquine and dihydroartemisinin. Parasites were grown 96 well plate format at 
either 2.5 % or 5 % haematocrit or in a flask at 5% haematocrit. Viability was analysed using the Giemsa 
microscopic test (a) and the SG-MicroPlate method (b). For SG-MicroPlate analysis the flask culture was 
analysed at 2.5 % haematocrit (although grown at 5 %). 
 
b 
a 
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In order to overcome background fluorescence problems associated with the complete 
media, infected and non-infected blood was suspended and serially diluted in either 
complete media or RMPI (Figure 3.6).  In the CM/CM conditions (suspended in complete 
media, diluted with complete media) there was a relatively high level of fluorescence 
irrespective of whether the blood was infected or non-infected.  In the CM/RPMI condition 
(suspended in complete media, diluted with RPMI) a density dependent effect was 
observed. However, although the infected blood displayed higher fluorescence in this 
condition than the non-infected counterpart, a density-dependent effect was still apparent 
in the non-infected blood condition. In the RPMI/RPMI condition (suspended in RPMI, 
diluted with RPMI) the parasite density dilution effect observed in the infected blood was 
not seen in the non-infected blood.  
 
 
 
 
 
3.3.5 SG-FCM for detailed in vitro investigations of parasite killing 
3.3.5.1 Time-course analysis of DHA treatment
Figure 3.6 The effects of complete media on the SG-Microplate method. The serial dilution of infected 
blood (p), starting at 3 % parasitaemia, and uninfected blood (b) was analysed using the SYBR Green 
MicroPlate assay.  Comparisons were made between blood suspended and diluted in either complete 
media /complete media (CM/CM), complete media/RPMI 1640 (CM/RPMI) or RPMI 1640/RPMI 1640 
(RPMI/RPMI) respectively. 
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  15µm 
Late Troph  Schizont/Ring Late Ring/ Early Troph 
24 h 
4 h 
48 h 
0 h 
8 h 32 h 
28 h Figure 3.7 Short time-course analysis 
(48 h) for DHA treatment of K1 
parasites.   DHA treated samples (2.5 
nM) were analysed alongside controls 
using SG-FCM at 4 hourly intervals.  Fifty 
thousand events were recorded for each 
sample. Giemsa images of the control 
samples were used to confirm the 
parasite stage at each time point.  
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Figure 3.8 Extended time-course analysis of P. falciparum strain K1 exposure to DHA. Control and DHA IC
50
 treated samples were analysed at 24h 
intervals for a 72 hour time-course. The percentage of mononuclear and multinuclear cells were recorded using SG-FCM. Error bars represent 
standard error of the mean (SEM) for duplicate samples. Giemsa imaging was used to confirm the parasite stage at each analysis point. 
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Time-course analysis data showed that drug induced alterations in parasitaemia could not 
be detected until parasites had entered a subsequent erythrocytic cycle (Figures 3.7 and 
3.8). Indeed, no differences were detected during the short time-course until the schizont to 
ring transition was completed at 48 h (Figure 3.7). These findings were mirrored by the 
extended time-course at 48 h. Notably, there was a comparable rise in parasitaemia in both 
control and treated samples by the 72 hr time point while DHA-induced growth inhibition 
remained relatively constant (Figure 3.8). The results also appear to show a delay in 
parasite progression into multinuclear forms, particularly seen at the 32 hour reading 
(Figure 3.8). 
3.3.5.2 Stage-specific effects of DHA 
The SG-FCM assay was used to assess stage-specific effects of DHA and also effects on 
schizont development. The results show that the SG-FCM method has the potential to 
analyse stage specific effects during the course of drug treatment. The results also 
indicated that higher concentrations of dihydroartemisinin had a more pronounced effect 
on the disruption of schizont formation (Figure 3.9). 
 
 
 
 
 
3.3.5.3 Determination of baseline IC50 values for existing antimalarials 
The dose-response curves generated (GraphPad Prism 5.0) using nonlinear regression 
analysis are shown in Figure 3.10. The IC50 values obtained for atovaquone, chloroquine, 
dihydroartemsinin and proguanil are displayed alongside those reported in the literature 
(Table 3.4). All values presented in the current study are within the range of those 
Figure 3.9 The effects of dihydroartemisinin on schizont development. A range of DHA concentrations 
were added at the schizont stage and the culture was incubated for 45 h under the conditions described 
previously. At the 45 hr time point the SYBR Green 1-based flow cytometer method was used analyse the 
effects of DHA. Data are based on a single replica. 
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determined elsewhere, although, they are consistently at the lower end of the scale (Table 
3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimalarial IC50 against P. falciparum K1 Reference 
 Current study Literature reports  
Dihydroartemsinin 2.62 nM 3.15 + 1  
1.67 + 0.43 
Zongo et al., 2011  
Fivelman et al., 2004 
Chloroquine 228 nM 255.86 + 65.58 
266.58  + 15.06 
Vivas et al., 2007 
Fivelman et al., 2007 
Atovaquone 1.52 nM 2.32 + 1.35  
2.41+ 0.51 
Vivas et al., 2007  
Fivelman et al., 2004 
Proguanil 15.79 µM 34.27 ± 2.894 Fivelman et al., 2004 
Table 3.4 Comparison of the IC50 values determined in the current study for existing antimalarials with 
values reported elsewhere in the literature. 
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Figures 3.10 Dose response curves for dihydroartemisinin (a), chloroquine (b) atovaquone and proguanil. 
Trophozoite stage parasites were treated for 48 hours with pre-selected dose ranges. The normalised dose 
response for each compound was plotted over loq transformed drug concentrations. IC
50
 values were 
determined using nonlinear regression analysis (Graphpad prism 5.0). Error bars represent the standard 
error of the mean (SEM) for triplicate data. 
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3.4 DISCUSSION 
3.4.1 Fluorescence-based drug susceptibility assays for malaria 
The versatile fluorescent DNA stain-based technique is ideally suited for use in malaria 
studies (Grimberg, 2011). The FCM method tackles many of the aforementioned problems 
posed by pre-existing assays; it is objective, rapid, simple and labour-saving (Grimberg, 
2011; Saito-Ito et al., 2001). The procedure can be completed in a single step, this being 
the addition of the fluorescent dye. Washing and fixation are optional, dependent on the 
dye being used, and the operating procedures of the machine (Karl et al., 2009; Malleret et 
al., 2011; Grimberg, 2011). Despite numerous advantages, the use and popularity of the 
technique has been limited by the cost of the flow cytometry equipment, more so in the 
developing world, and by concerns about insufficient sensitivity.  The latter, is possibly 
because the fluorescence intensity of some stains is not high enough to overcome auto-
fluorescence, particularly in fixed samples (fixed red blood cells auto-fluoresce) (Saito-Ito 
et al., 2001). For this reason, selection of a highly fluorescent dye, such as SYBR Green 1 
is of paramount importance. Indeed, the robust data generated from both the SG-
MicroPlate and SG-FCM assays preformed here indicate that SYBR Green 1 is capable of 
overcoming background fluorescence, even in fixed samples. Two methods of staining and 
analysis with SYBR Green were optimised in the current study for different purposes. The 
SG-MicroPlate assay, for use as a medium-throughput preliminary screen, and the SG 
Flow cytometry-based method, for more accurate second-phase definition of selected hit 
compounds.  
3.4.2 Validation of SYBR Green staining procedures 
Initially optimisation of SG-based methods focussed on the validation of the staining 
procedures described by Karl et al. (2009).  Parasitised blood was used to show that a 
density dilution effect could be detected using the SG-MicroPlate staining and analysis 
methods. Although the complete media displayed a high level of inherent fluorescence, the 
preliminary work indicated that the removal of 100 µl of complete media, leaving 100 µl 
per well (subsequently diluted 1:1 with the SG-staining solution), reduced background 
effects and permitted reproducible sensitivity.  An unsynchronised culture was used to 
show that adoption of the SG-FCM method can provide accurate parasitaemia estimates 
and stage-specific information. Confocal microscopy was also used to visualize and 
confirm the staining of parasites within red blood cells. The second-phase of staining 
validation used the dihydroartemsinin dose response to compare the SG-based methods 
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with each other and with the traditional Giemsa microscopic test. Consistent with the 
finding presented here, Karl and colleagues (2009) showed that the SG-FCM method 
compared well with the 4 other in vitro assays; namely, the hypoxanthine incorporation 
assay, the pLDH ELISA, the SG-MicroPlate assay and the WHO microscopic test (Karl et 
al., 2009). The particularly high concordance with microscopy, demonstrated here and in 
previous studies, is noteworthy as it is the only other method to count parasites directly 
(Bei et al., 2010; Malleret et al., 2011). Like the microtest, the FCM method is capable of 
resolving single, double or triple infections (Bei et al., 2010). In fact some argue that it 
may even be more accurate, as early ring stage parasites can often be overlooked by 
microscopy (Saito-Ito et al., 2001). In the current study, the compiled data for the Giemsa 
microscopic test shows minimal variation between experiments. However, the inherent 
subjectivity of the assay means that variation between different individuals and observer 
error for inexperienced users is likely. Such potential issues are absent from the more 
objective SG-based methods. Unlike the Giemsa microtest the FCM, however, is incapable 
of distinguishing between triple infections and early trophozoites (Bei et al., 2011). 
Fortunately, for drug susceptibility screens, these factors are not problematic as the assay 
is mainly concerned with parasite multiplication or maturation via 48 hr or 72 hr assays 
respectively.  Parasite multiplication is defined as the parasite’s ability to grow and 
undergo nuclear division during schizont formation. Maturation, on the other hand 
corresponds to successful completion of the erythrocyte cycle in the presence of the test 
drug and also successful invasion of new red blood cells to begin the subsequent 
erythrocytic cycle (Grimberg, 2011). Overall, the dose response data and IC50 values 
obtained for SG-based methods were in agreement with each other and with those obtained 
from the Giemsa microtest. There was a slight shift in the values obtained between the 48 
and 72 hour time points but this was not shown to be statistically significant. 
3.4.3 SG-MicroPlate optimisation 
Once the staining procedure had been validated, using flask cultures of P. falciparum, it 
was necessary to optimise growth and drug treatment in a 96 well plate format to achieve 
medium-throughput efficiency for the SG-MicroPlate assay. In order to overcome issues 
with poor parasite growth in the 96 well plates, gas exchange was improved through the 
use of gas permeable films and replacement of old gassing chambers. Different 
haematocrits were also selected to determine the optimal plate growth conditions. The 
Giemsa results indicated that parasite growth was sufficient at both the 5 % and 2.5 % 
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haematocrits and clear dose response to both antimalarials used in the study were 
observed.  At the lower haematocrit, however, plate growth was either equal to or greater 
than flask growth at the standard 5 % haematocrit. Furthermore, there appeared to be no 
benefit bestowed by a 5 % haematocrit condition in the plate, even though the starting 
number of parasites would have been double. Taken together the results suggested that 2.5 
% haematocrit may be optimal in the plate system. This is consistent with the literature, 
lower haematocrits are commonly used for plate growth experiments to permit a better 
surface area to blood volume ratio. This allows more efficient gas exchange and nutrient 
acquisition between parasites and the above culture media (Karl et al., 2009; Vossen et al., 
2010). A further issue was that there was a discrepancy between SG-MicroPlate and 
Giemsa results as a comparable dose response pattern was not observed with the SG-
MicroPlate readings. Despite previous in-house optimisation of the SYBR Green 
MicroPlate assay, other experiments have shown inconsistencies between the SG-
MicroPlate and both the Giemsa and Flow cytometer assays (data not shown). The SG-
Microplate data only showed absolute fluorescence differences between the variable 
haematocrits (Plate 2.5 % and Plate 5 %) and  varying amounts of complete media (Plate 
2.5 % and Flask 2.5 %). The earlier experimental method (Figure 3.1) that showed a 
parasite density dilution effect, represented by the CM/CM condition, also displayed a 
high level of background fluorescence for both infected and non-infected blood in the 
latter study, that overcome any SG staining that represented bound parasite DNA. One 
possibility was that the albumin from bovine serum (Sigma) used in the latter experiments 
contributed to higher background fluorescence than the AlbuMAX (lipid rich albumin 
from bovine serum, Gibco) used in the initial optimisation work.  The trend observed in 
the CM/RPMI condition most likely represented a serial dilution of complete media with 
RPMI. However, the clear difference in the level of absolute fluorescence between the 
infected and non-infected blood indicated notable detection of parasite DNA. The 
RPMI/RPMI condition showed that when all of the complete media had been removed, the 
dilution of non-infected blood had no effect on fluorescence intensity. Therefore, the 
modest density dilution effect observed in infected blood series (RPMI/RMPI P) 
accurately represented parasite DNA. It was also possible that in the original SG-
MicroPlate protocol the DNA from dead or dying parasites, outside the erythrocytes, may 
be recorded as live. Washing would also help reduce this confounding factor, improving 
the accuracy of the SG-MicroPlate assay and concordance with Giemsa staining and SG-
FCM. Taken together, the data highlighted the importance of the inclusion of washing 
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steps in the SG-MicroPlate protocol in order to achieve true parasite density readings. 
Indeed, variable volumes of complete media could drastically alter the results this is 
particularly important for growth inhibition studies where parasitaemia may be low.  
3.4.4 SG-FCM for detailed in vitro investigations of parasite killing 
Unlike any other currently available objective method, the unique advantage of the SG-
FCM technique is that it offers the opportunity to gain more information about intra-
erythrocytic parasite growth and development and toaccurately monitor stage-specific 
effects in response to drug treatment (Izumiyama et al., 2009; Grimberg, 2011.) Indeed, 
the corroboration of the SG-FCM data and Giemsa images during time-course analyses 
provided further confirmation that the method can be used to accurately monitor 
mononuclear and multinuclear parasite transitions. The results of the current time-course 
and stage-specific investigations were in agreement, showing delayed progression to 
schizont formation under DHA drug pressure. The stage-specific data clearly demonstrated 
that this disruption in schizont formation is dose dependent. This is in line with previous 
findings that suggest artemisinins arrest parasite development at the ring stage (Klonis et 
al., 2011). However, although differences in stage-specific detection can be reported here, 
stage-specific inhibition cannot be inferred, as the drug was present throughout the 
erythrocytic cycle and transition through parasite stages. To obtain true stage specific-data 
using the SG-FCM method any future work should direct drug exposure against a single 
parasite stage. This could be achieved by altering the treatment regime to a short 6 hr 
window of drug exposure, followed by washing, removal of the drug and subsequent re-
incubation to permit completion of the 48 hr erythrocytic cycle.  Wein et al (2010) suggest 
that a 72 hour treatment period is needed to obtain reliable data using the SG-based 
methods. Conversely, the data from both the time-course analysis and IC50 determination 
of four existing antimalarials: namely, atovaquone, dihydroartemisin, chloroquine and 
proguanil, suggests that so long as the 48 hr treatment period spans the transition into the 
subsequent erythrocytic cycle, accurate drug inhibition and IC50 data can be generated. 
Data presented here, irrespective of whether parasites were grown under flask or plate 
conditions (all analysed using SG-FCM) shows that 48 hr exposure initiated at trophozoite 
stage yields the expected dose response for the four existing antimalarials selected. The 
IC50 values obtained were all within the range of the values reported elsewhere in the 
literature. The advantages of this treatment protocol are that it allows all stages of the 
parasite to be exposed to the drug, permits entry into a subsequent erythrocytic cycle and 
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ensures that early ring stages are not overlooked as all parasites should have entered the 
trophozoite stage at the time of the analysis.  The data presented, therefore, indicates that 
parasite maturation rather than treatment period is important for analyzing the efficacy of 
antimalarials with different modes of action. Indeed focusing on multiplication only may 
overlook drugs with novel modes of action, for example targeting other organelles such as 
those involved in invasion. It is evident that a number of findings presented here highlight 
the importance of timing in the basic drug susceptibility assays. Firstly, the comparison 
study of the Giemsa microscopic test, the SG-MicroPlate and the SG-FCM assays revealed 
a slight shift in IC50 values between the 48 h and 72 h time points. Secondly, during the 
extended time-course analysis there was an increase in parasitaemia from the 48 hr to the 
72 h reading. This suggests that some parasites may have become unsynchronized and had 
not entered the subsequent erthrocytic cycle at 48 hours, but had successfully invaded new 
erythrocytes by the 72 h time point. Thirdly, without alterations in the treatment and 
analysis protocol, the dose-dependent effects of DHA on schizont formation would have 
been missed.  
3.4.5 Conclusion 
In conclusion the above findings indicate that various factors such as: the parasite stage at 
which the drug is added, the drug treatment period, and the stage at which samples are 
taken for analysis could all affect the results and the detail of the information obtained 
from individual experiments.  Evidently, consistency should be maintained between 
replicate experiments and the above mentioned variables considered when comparisons are 
drawn across different studies. The results of the current study empirically confirm that the 
SG-based methods are not only reliable but also offer fast, simple, quantitative, parasite 
detection devoid of human error and bias. Additionally, the more accurate SG-FCM option 
also offers the opportunity to obtain stage-specific information. The low cost of the reagent 
and the availability of the both the fluorescent plate reader and flow cytometer made the 
technique ideal for use in our laboratory. The proposed workflow was, therefore, to adopt 
both SG-based methods. The modified SG-MicroPlate assay would be employed, in 
accordance with the improved protocol to overcome Albumin-related fluorescence, for the 
preliminary screening of FDA approved compound repositories. The SG-FCM would be 
used, subsequently, for more detailed second-phase characterisation of antimalarial hits. 
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CHAPTER 4 
SCREENING FDA APPROVED DRUG LIBRARIES FOR ANTIMALARIAL ACTIVITY 
4.1 INTRODUCTION 
Since the late 2000’s, the prospect of drug repositioning for malaria has received 
increasing attention (Guiguemde et al., 2012).  One of the earlier studies by Weisman et al. 
(2006), served as proof-of-concept that novel chemical scaffolds, capable of inhibiting the 
malaria parasite, could be identified from existing compound libraries. Using the YOYO-1 
microplate method, the whole-parasite study screened 2,160 compounds and uncovered 36 
novel inhibitors of P. falciparum (strains 3D7 and W2). Of these, 19 were approved 
therapeutics. The antimalarial hit list was further refined based on the drug delivery route 
and the closeness of the effective dose (EC50) against P. falciparum, to the current safe 
therapeutic window in humans. From these, 5 compounds: namely, propafenone, 
thioridazine, chlorprothixene, perhexiline and azlocillin were proposed as feasible 
candidates for further development (Weisman et al., 2006).  
Concurrently, another group, Chong et al. (2006) screened the Johns Hopkins Clinical 
Compound Library using the (
3
H)-hypoxanthine
1,2 
incorporation assay. They selected 
1,937 FDA approved drugs plus 750 approved for use outside America or undergoing 
Phase 2 clinical trials. Of these, 189 compounds displayed >50% inhibition at a 
concentration of 10 µM against P. falciparum strains 3D7, Dd2 or ItG. Further refinement 
came from the elimination of compounds that were cytotoxic drugs, topical therapies, 
known antimalarials and compounds previously shown to have antimalarial activity 
(Chong et al., 2006). From the most potent of remaining compounds that offered potential 
starting points for lead optimisation, the group deemed the anti-histamine astemizole, as 
the most promising candidate. This compound is structurally related to the 4-
aminoquinolines and likely to act via the inhibition of heme crystallization, therefore, not 
representing a completely novel antimalarial class (Chong et al 2006; Lotharius et al., 
2014). However, the effectiveness of the compound against drug resistant strains in vitro, 
and against 2 mouse models in the 4-d suppression test in vivo raised optimism. 
Unfortunately, side effects were a concern as the compound had been withdrawn from its 
previous use due to adverse cardiovascular side effects linked specifically to QTc 
prolongation.  The group emphasised that the drug was widely used before its withdrawal, 
which was largely due to the availability of safer alternatives. They also supposed that its
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 use for malaria would be relatively acute and intermittent when compared with the 
continuous everyday use as an anti-histamine (Chong et al., 2006). A recent article by 
Lotharius et al., (2014) suggests that the compound is no longer under consideration for 
repositioning in malaria, while reporting data regarding its cardiotoxicity and withdrawal 
from use in 1999. In fact, the discovery of its antimalarial properties was not until 2006 
(Chong et al., 2006) and the relevant safety data for doses applicable to malaria have not 
yet been published.  Furthermore, recent studies have reported submicromolar potency 
(<10 µM) of the compound against P. berghei liver stages (Derbyshire et al., 2012) and the 
effectiveness of a chloroquine-astemizole hybrid molecule against CQ resistant strains 
both in vitro and in vivo (Musonda et al., 2009), indicating that the molecule is not yet 
completely out of favour.  
A larger screen, by Baniecki and colleagues (2007), investigated 79,000 small molecules 
for antimalarial activity using the fluorescent dye 4’,6-diamidino-2-phenylindole (DAPI) 
plate reader method as a reporter of parasite growth. They identified 181 hits, defined as 
inhibiting 90 % of parasite growth, against either single or multiple parasite strains (Dd2, 
HB3 and 3D7) at a concentration of 6 µM (Baniecki et al., 2007). 
The Lucumi group (2010) reported a high-throughput screening initiative on three 
compound libraries, namely the Library of Pharmaceutically Active Compounds 
(LOPAC), the library from the National Institute of Neurological Disorders and Stroke 
(NINDS) and the Library of uncharacterised compounds (Chembridge). A 384-well 
luciferase screen on 12,320 compounds, at 5.5 µM concentrations, yielded a total of 163 
compounds exhibiting a reduction in parasitaemia > 85 % in the drug sensitive 3D7 strain 
of P. falciparum.  Through structural clustering, the group was able to identify 12 novel 
scaffolds. A 1,4-naphthoquinone moiety, similar to atovaquone, was deemed the most 
interesting chemotype because of its novel mechanism. They also propose the histamine 
antagonist, zolotadine, as an attractive lead (Lucumi et al., 2010). 
The success of these initial screens prompted a wide-scale drug discovery initiative 
involving three academic and corporate institutions: namely, The St Jude’s children 
research hospital (Guiguemde et al., 2010) GlaxoSmithKline (Gamo et al., 2010) and 
Novartis (Plouffe et al., 2008).   
The St Jude Children’s Hospital screened at total of 309,474 compounds against the P. 
falciparum strain 3D7 at fixed drug dose of 7µM, using various fluorescent-based DNA 
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stains to evaluate parasite growth (namely, YOYO-1, SYBR Green 1 and DAPI). This 
gave 1,300 hits with >80 % activity. The hit compounds were subjected to dose-response 
screens against multi-drug resistant strains, as well as counter screening against 
mammalian cell lines HepG2 and BJ, to determine toxicity. Cut offs were set at < 2µM 
effective dose (EC50) (against 3D7 or K1) and a > 10 fold increase was considered a safe 
therapeutic window against the mammalian cell lines. A structurally diverse set of 
compounds was selected from the hits for further interrogation. Of the 172 validated hits, 
58 displayed similar potencies (< 3-fold shift in EC50) when analysed with a panel of seven 
P. falciparum strains with different chemo sensitivities. Reverse chemical genetic profiling 
showed that 80 % represented novel modes of action with regard to three well 
characterised antimalarial targets: Pyrimidine biosynthesis (specifically inhibition of the P. 
falciparum dihyrooroate dehydrogense enzyme, PfDHOD), inhibition haem detoxification, 
which is usually converted to inert crystallised haemozoin by the parasite, using the in 
vitro haemozoin formation assay, and haemoglobin degradation through the analysis of  P. 
falciparum falcipain-2 (PfFP-2) inhibition, an enzyme which is reported to have a critical 
role (Guiguemde et al., 2010; Guiguemde et al., 2012).   
Gamo and colleagues (2010) at GSK screened a chemical library, the Tres Cantos 
Animalarial Compound Set (TCAMs) of nearly 2,000,000 compounds against P. 
falciparum strains 3D7 and Dd2. They identified 13,533 and 8,000 compounds capable of 
inhibiting parasite growth by 80 % and 50 % at 2 µM, in the susceptible and multi-drug 
resistant strains respectively. Out of the verified hits only 15 % were considered cytotoxic 
by 50 % inhibition of the HepG2 cell line at 10 µM. Encouragingly, the majority of the 
compounds are new to the malaria research community (82 %) and the data has been 
released into the public domain to promote further investigation and lead compound 
identification (Gamo et al., 2010; Guiguemde et al., 2012). 
Novartis have been involved in various screening and lead optimisation programmes with 
numerous academic collaborators. One of their initial large scale screens identified ~6,000 
possible drug discovery leads from a collection of 1.7 million compounds in the Genomics 
Institute of the Novartis Research Foundation (GNF) chemical library. The library was 
reported to have drug-like characteristics and high conformity to Lipinski’s rule of 5. 
SYBR Green 1 staining was used to define hit compounds that displayed 50 % inhibition 
at a concentration of < 1.25 µM against P.falciparum strain 3D7. Plouffe et al., (2008) 
then employed in silico activity profiling to reveal potential mechanism of action of hit 
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compounds by adopting a guilt-by-association approach. Information was gathered from 
previous evaluations of the compounds across 131 cellular enzymatic assays. This helped 
inform cross-reactivity/toxicity information and the prediction of pathways and targets. 
Pooling of data, and discovering patterns amongst immense biological data sets, may be an 
effective tool in modern drug discovery. The expanded chemical space occupied by the 
6,000 novel inhibitors offered the opportunity to discover a new-generation of 
antimalarials (Plouffe et al., 2008). Since the initial investigations, various compound 
series have undergone lead optimisation, namely: the Benzamides (Wu et al., 2009), 1H-
imidazol-2-yl-pyrimidine-4,6-diamines (Deng et al., 2010) and the Imidazolopiperzines 
(Wu et al., 2011). The latter of which, in the form of the optimised derivative GNF 156, 
has recently completed phase 1 clinical trials (Guiguemde et al., 2012). 
One of the most successful reports to date of repositioning efforts for malaria came from a 
Novartis screen of 12,000 natural product compounds. These included pure, natural 
products and synthetic compounds with natural product features. The preliminary screen 
yielded 275 hits active at submicromolar concentrations. Of these, 17 were taken forward, 
based on the criteria that they were active against multiple drug resistant strains and were 
not cytotoxic (> 50% inhibition at 10 µM in cell lines of neural, renal hepatic, and 
monocytic origin). Based on its desirable pharmacokinetic and physical properties, a 
synthetic compound related to the spiroazepineindole class surfaced as a promising 
candidate for lead optimisation. Synthesis and evaluation of 200 compound derivatives led 
to the selection of the optimised spiroindolone (spirotetrahydro beta-carboline) compound 
NITD609, that was shown to have an IC50 ~1nM against P. falciparum (Rottmann et al., 
2010; Yeung et al., 2010). Most importantly, compound NITD609 (renamed KAE609) 
was shown to act via a new mechanism of action based on the inhibition of PfATP4 
(Rottmann et al., 2010; White et al., 2014). KAE609 has now completed phase 1 and 
phase 2 clinical trials with a positive outcome (Guiguemde et al., 2012; White et al., 
2014). 
Although the successful outcome of the larger screening initiatives has resulted in two 
compounds entering clinical trials within 5 years post discovery (Guiguemde et al., 2012), 
it is likely that more potentially medically valuable hits are awaiting lead optimisation. 
Indeed, it has been reported that since 2006 approximately six million compounds have 
been phenotypically screened in this manner (Spangenberg et al., 2013), providing more 
hits (~ 20,000) than can reasonably be investigated (Meister et al., 2011).  For this reason a 
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revolutionary approach to drug discovery has made early screening data available in the 
public domain to encourage industrial and academic collaborations, and the development 
of a faster more efficient drug discovery paradigm (Burrows et al., 2012; Spangenberg et 
al., 2013). 
In order to harness the usefulness of the screening information and overcome the 
practicalities of obtaining physical compound samples Medicines for Malaria Venture 
(MMV- not for profit public and private partnership) has refined the list of 19,876 
compounds from the initial St Judes, Novartis, and GSK screens, to a set of just 400 
compounds, now referred to as “The Malaria Box”. (Burrows et al., 2012; Spangenberg et 
al., 2013). The first filtering step was to include only commercially available compounds 
which reduced the collection from 20,000 to 5,000. The remaining compounds were 
thought to be good representatives of the chemical space occupied by the whole set. Next, 
they were subdivided into those that obey Lipinski’s rule of 5 and those that did not: 
namely: drug-like and probe-like groups respectively. Structural clustering was then used 
for each group so that representatives of each cluster were included in the final compound 
set. The aim was to maximise diversity while maintaining some cluster pairs that varied in 
antimalarial potency in order to help inform structure-activity investigations (Spangenberg 
et al., 2013). The Malaria Box is now freely available, upon request, for a more rigorous 
definition and characterisation of antimalarial efficacy and activity against other diseases, 
on the condition that any data obtained is released into the public domain (Biamonte et al., 
2013; Burrows et al., 2012). 
Despite expectation for the Malaria Box to provide chemotherapies suitable for malaria 
eradication, and the collection is in no doubt an invaluable tool for malaria drug discovery, 
it is only a small fraction of the armamentarium of compounds available in a multitude of 
untested drug libraries that should not be overlooked. Indeed, the key to a “miracle cure” 
may even been embedded within those compounds that have be filtered out of contention. 
Accordingly, the objectives of the current study were to complete a preliminary single-
dose phenotypic screen on the Screen-Well™ FDA approved drug library from ENZO, 
which to our knowledge has not yet been evaluated for antimalarial activity. The set of 640 
chemically and pharmacologically diverse compounds, boast a rich source of bioactivities 
and the highest degree of drug-likeness available. The preliminary screen against the 
multi-drug resistant strain K1 had a rigorously low cut off point of 2.5 µM, less than half 
of most previous reports, in an attempt to retain a refined, reliably potent short list. An 
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additional aim was to selectively corroborate some of the data published by the Lucumi 
group (2010) by completing secondary phase screening on the most potent antimalarial 
candidates identified (against 3D7) from the Library of pharmaceutically active 
compounds (LOPAC). Against a backdrop of emerging artemisinin resistance and a fast-
depleting armamentarium of affordable antimalarial therapeutic options, it is critical that 
candidates from such preliminary screening initiatives are further investigated objectively 
and systematically to evaluate their therapeutic potential. Further characterisation of leads, 
to identify stand-alone antimalarial options and potential synergistic candidates for 
combination therapy with artemisinins or other existing antimalarials, is of utmost 
importance. 
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4.2 METHODS 
4.2.1 Preliminary screening of the ENZO library for antimalarial activity  
The ENZO library, which contains 640 chemically and pharmacologically diverse 
compounds, was kindly donated by Dr. Farid Khan (Protein technologies Ltd, Manchester 
Science Park, UK). The compounds were stored at -20 
o
C in a 96 well plate format, at a 
stock concentration of 400 µM (in DMSO). A relatively rigorous preliminary screen 
concentration of 2.5 µM was selected for all compounds. This meant that 1.25 µl of each 
compound (in DMSO) was transferred directly into 200 µl of parasite culture, ensuring 
that DMSO concentrations did not exceed 0.625 %. Each treatment was set up in duplicate 
and controls consisted of non-treated, parasitised blood, dihydroartemisinin treated 
samples (2.5 µM), and DMSO only treated cultures at 0.625 %. Plate cultures were 
initiated at 2.5 % haematocrit containing 0.5 - 1 % trophozoite stage parasites and 
incubated for 48 hours at 37 
o
C under a 5 % CO2 5 % O2 and 90 % N2 gas mixture as 
described previously. Following the treatment period 100 µl of PBS was added to each 
well (300µl final well volume), samples were mixed thoroughly and centrifuged at 1000 
rpm for 3 minutes. A 200 µl aliquot of the supernatant was then removed from each well 
using a multichannel pipette to ensure that the parasitised blood was not dislodged from 
the bottom of the plate. The washing procedure was subsequently completed twice more 
with 200 µl PBS.  Once the final washing step had been completed, and 200 µl of the 
supernatant discarded, the SG-MicroPlate staining and analysis procedure was performed 
as described elsewhere (section 2.2.2). A non-infected blood control sample (2.5 % 
haematocrit) was also included and background fluorescence was deducted from 
parasitised blood samples accordingly.  
4.2.2 Preliminary screening of LOPAC compounds for antimalarial activity 
Five compounds, previously reported by Lucumi et al. (2010) to be potent against 
Plasmodium falciparum strain 3D7 (IC50 < 5 nM), were taken forward for preliminary 
screening against the multidrug resistant K1 strain.  The compounds:  Emetine 
dihydrochloride hydrate, SKF 95282 dimaleate, S (-)-UH-301 hydrochloride, Vinblastine 
and Vincristine (Figure 4.1), were selected from the Library of pharmaceutically active 
compounds (LOPAC).  The LOPAC libraries were stored at -20 
o
C in a 96 well plate 
format at a concentration of 1 mM. Working stocks were prepared by diluting 1:10 with 
DMSO, and test concentrations prepared by further dilution with RPMI 1640. Parasites 
were treated with the respective IC50 of each compound (Lucumi et al., 2010) and 10x the 
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IC50 to account for the resistance phenotype of the K1 strain (5 ml flask format as 
described previously). In addition to corroborating the previous work published by the 
Lucumi and co-workers (2010) by analysing the potency of the selected compounds 
against K1, the LOPAC compounds were administered in combination with 
dihydroartemisinin (DHA). For the preliminary combination assays LOPAC compounds at 
IC50 were used with dihydroartemisinin 0.63 nM or 1.25 nM. The LOPAC 10 x IC50 
treatments were co-administered with 0.63 nM dihydroartemisinin only, to enable the 
combinatory effects to be monitored. Infected blood and non-infected blood served as 
positive and negative controls respectively. Treated and control flasks were incubated 
under conditions described previously for 48 hours and analysed using SG-FCM. (Chapter 
2, section 2.2.3). 
   
4.2.3 MeSH annotation of hit compounds from LOPAC and ENZO libraries 
All compounds selected for the preliminary screen of the LOPAC library (n=5) against the 
multi-drug resistant K1 strain and the most potent 55/640 compounds from the ENZO 
library were searched using the NCIB PubChem database and their respective medical 
subject heading (MeSH) annotations were retrieved. This system was used as it is a 
reliable source and provides a controlled set of vocabularies to categorise compounds 
according to their known bioactivities and mechanism of action classifications (Plouffe et 
al., 2008). The frequency distribution of the top 60 compounds within the identified MeSH 
categories was then plotted to establish whether novel classes of antimalarial inhibitors 
could be identified. 
Figure 4.1 The structure of 
the 5 LOPAC compounds 
previously shown have 
antimalarial activity IC50 < 5 
nM against P. falciparum 
strain 3D7 (Lucumi et al., 
2010). Image: Sigma 
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4.2.4 Tanimoto similarity of MeSH compound with existing antimalarials 
Once annotated and grouped according to their previously defined mechanism of action, 
each MeSH category was subjected to structural clustering analysis using the 2D Tanimoto 
index (PubChem), to determine whether the novel scaffolds were structurally distinct from 
existing antimalarials. Compounds were compared within each MeSH category and with a 
range of existing antimalarials including artemisinin, fansidar (pyremethamine and 
sufadoxine), halofrantine, atovaquone, proguanil, five representatives of the quinolines: 
namely, chloroquine, mefloquine, amodaquine, primaquine and quinine, and two 
antibiotics previously used to treat malaria, clindamycin and doxycycline.   
4.2.5 Secondary phase screening of selected ENZO compounds 
Second-phase screening of ENZO compounds involved the generation of a preliminary 
dose response curve and IC50 determination using the SG-MicroPlate method. The dose 
range for each compound was based on the level of inhibition achieved during the 
preliminary screen at 2.5 µM. For compounds displaying >80 % inhibition, 2.5 µM was 
selected as the highest dose in the treatment series. For compounds with a lower level of 
inhibition between 60-80 % or < 60 % the highest dose was adjusted to 5 µM and 10 µM 
respectively.  Two-fold serial dilutions were used to achieve a 6 or 7 point dose range. A 
total of 10 ENZO compounds were screened in this manner including the existing 
antimalarial atovaquone, which served as a positive control.  A comparable level of DMSO 
was also serially diluted to ensure that the solvent was not responsible for any inhibitory 
effects observed. Duplicate treatments were set up for each compound, in complete media, 
at twice the final dose required (100 µl/well) and subsequently diluted 1:1 with parasitised 
culture (1 % trophozoite, 5% haematocrit). Following 48 h of incubation under the 
conditions described previously, samples were analysed using the SG-MicroPlate method 
(Chapter 2 section 2.2.2). 
4.2.6 Secondary phase screening of LOPAC compounds 
Out of the 5 compounds from the selected LOPAC library, three were taken forward for 
second-phase screening and preliminary IC50 determination. These were, emetine 
dihydrochloride hydrate, SKF 95282 dimaleate, and S (-)-UH-301 hydrochloride. Based on 
the previously determined IC50 values for the 3D7 strain (Lucumi et al., 2010) and the 
relatively low level of inhibition observed against the multi-drug resistant strain K1, wide 
dose ranges were selected for each drug. For emetine, SKF and SUH 1 nM-100 nM, 1 nM-
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200 nM and 10 nM-1000 nM concentration ranges, with up to 5 dose points, were selected 
respectively. Stock and working concentrations were prepared as detailed above. 
Treatments were set up in a 5 ml flask format and incubated for 48 hours under conditions 
described previously (Chapter 2).  As there were only 3 compounds for the analysis the 
more accurate SG-FCM method was used to determine parasite growth following drug 
exposure (Chapter 2, Methods 2.2.3).  
4.2.7 Accurate IC50 determination of selected compounds 
The most potent compounds from the second-phase screens of the ENZO and LOPAC 
libraries were taken forward for accurate IC50 determination. Three compounds from the 
ENZO library where selected for further interrogation: namely, clemastine (histamine 1 
receptor antagonist) propafenone (anti-arrhythmic) and one of the serotonin receptor 
antagonists (ondansetron). From the LOPAC library, SKF and SUH displayed a relatively 
huge shift in IC50 values against the K1 strain compared to their previously reported 
potency against 3D7. For this reason, only Emetine dihydrochloride hydrate was 
considered for further investigation. Dose ranges were selected in line with the previous 
effective window identified in the second phase screens.  For two of the ENZO 
compounds, propafenone and clemastine, the dose range selected was 0.04-2.5 µM. 
Ondansetron failed to show a dose response in the first three replicas of the experiment, 
therefore, the concentration range was gradually shifted until a clear dose response was 
apparent and an accurate IC50 calculation could be achieved. For emetine the dose 
response selected was 10-100 nM. All treatments were initiated at trophozoite stage with a 
starting parasitaemia 0.5-1 % and a 2.5 % (plate) or 5 % (flask) haematocrit. Treatments 
were set up in triplicate and incubated for 48 hours under conditions described previously. 
Parasite growth was analysed using the more accurate SG-FCM method and the IC50 was 
calculated using GraphPad Prism 5.0 (as described in Chapter 2, Section 2.2.4).  
4.3 RESULTS  
4.3.1 Preliminary screening of the ENZO library for antimalarial activity  
The preliminary screen of the ENZO library revealed a 9.5 % hit rate (compounds that 
showed > 50 % inhibition after 48 h treatment at 2.5 µM). Although the positive and 
negative controls were effective (Figure 4.2) and achieved a Z score of 0.68 (+ 0.06), 
additional validation of the assay came from known antimalarials within the initially 
blinded hit list (Table 4.1).  For additional data refer to Appendix IV. 
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Figure 4.2 An exemplar panel of the ENZO library preliminary screen against Plasmodium falciparum, strain K1. The complete collection of 640 compounds was screened 
at a rigorous concentration of 2.5µM. The treatment period was initiated when parasites entered at trophozoite stage and lasted for 48 hours.   Untreated, DMSO-only and 
dihydroartemisinin treated samples (2.5 µM) served as negative and positive controls, respectively. Background fluorescence from non-infected blood samples was 
deducted accordingly. The screening capacity was 70 test compounds per experiment.  Additional controls were included in the centre as well as at the periphery of the 
plate to ensure that edge-affects were not a confounding factor. The SYBR Green MicroPlate assay was used to analyse growth in test samples relative to controls. 
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Name % inhibition P. falciparum 
strain K1 
Mechanism of action 
Medical subject heading (MeSH) 
Artesunate 98.72 Antimalarial 
Cyclosporin A 93.96 Immunosuppressant 
Quinine·HCl·2H2O 91.54 Antimalarial 
Propafenone 91.18 Anti-arrhythmic 
Aclarubicin 87.69 Antiancer 
Ivermectin 86.48 Antiparasitic (worms) 
Clemastine 85.53 A histamine H1 antagonist 
Mitoxantrone 85.14 Anti-cancer 
Atovaquone 85.13 Antimalarial 
Puromycin 84.56 Antibiotic 
Sertaconazole 84.51 Antibiotic/ Antifungal 
Plicamycin 83.88 Antineoplastic antibiotic 
Doxorubicin·HCl 83.83 Anticancer/Anthracycline antibiotic 
Chloroquine 82.99 Antimalarial 
Artemisinin 81.32 Antimalarial 
Vorinostat 80.04 Anticancer 
Daunorubicin 80.03 Anticancer 
Quinacrine 79.10 Antimalarial 
Bortezomib 73.46 Anticancer 
Fluoxetine 72.65 Selective serotonin inhibitor 
Bromocriptine mesylate 68.98 Dopamine D2 agonist 
Mitomycin C 68.87 Anticancer 
Nisoxetine·HCl 67.59 Selective noradrenalin uptake inhibitor 
Bopindolol 67.46 Beta blocker 
Rifampicin 66.79 Antibiotic 
Loperamide·HCl 64.73 Antidiarrheal 
Niguldipine 63.92 Calcium channel blocker 
Trifluperidol 63.74 Antipsychotic 
Idarubicin 62.53 Anticancer 
Nicardipine·HCl 62.35 Calcium channel blocker 
Telmisartan 61.39 Angiotensin receptor blocker 
Fluspirilene 61.20 Antipsychotic 
Ergotamine 60.52 A vasoconstrictor-  migraine treatment  
Maprotiline·HCl 60.27 Antidepressant 
10-Hydroxycamptothecin 60.11 Anticancer 
Ondansetron 59.93 Serotonin type 3 receptor antagonist 
Dihydroergocristine 59.74 Vasodilator, Ergot alkaloid 
Tiotropium Bromide 59.14 Anticholinergic bronchodilator for COPD 
Trimethoprim 58.72 Antibiotic 
Pimozide 58.71 Antipsychotic 
Cilostamide 56.95 Phosphodiesterase PDE3 inhibitor 
Ketanserin 56.12 Selective serotonin receptor antagonist 
Rapamycin 55.84 Immunosuppressant 
Spironolactone 55.45 Competitive antagonist of aldosterone receptor 
Haloperidol 54.89 Antipsychotic 
Amiodarone·HCl 54.78 Antiarrhythmic 
Irsogladine 54.70 Mucosal protective drug (Treat peptic ulcer) 
Mesoridazine besylate 54.67 Antipsychotic 
Mycophenolic Acid 54.49 Immunosuppressant  
Etazolate 54.45 Phosphodiesterase inhibitor 
Pronethalol·HCl 54.07 non selective beta blocker 
Dibenzepine 53.21 antidepressant 
Thioridazine 53.16 antipsychotic 
Sulfadiazine 52.16 antiparasitic (Toxoplasmosis) 
Valaciclovir 51.59 antiviral 
Terfenadine 51.27 H1 receptor antagonist 
Table 4.1 The 56 most potent compounds identified from the ENZO Library preliminary screen.  Tabular data 
shows the % inhibition for the ENZO library compounds against P. falciparum strain K1 at a concentration of 2.5 
µM.  MeSH annotation of the compounds is also presented. The list includes 6 existing antimalarials.  
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4.3.2 Preliminary screening of the LOPAC compounds for antimalarial activity 
Five compounds from the LOPAC library, shown to display the most potent antimalarial 
activity by Lucumi et al. (2010) against P. falciparum strain 3D7, were screened in the 
current study for activity against the K1 strain. The data presented here infers all 5 
compounds were less potent towards multiple-drug resistant strain (Figure 4.3).  
  
 
 
 
 
Even at 10 x the IC50 values of the 3D7 strain, 50% growth inhibition was only achieved 
with one LOPAC compound, vincristine. The preliminary combination data between 
dihydroartemisinin and the LOPAC compounds: emetine dihydrochloride hydrate, SKF 
95282 dimaleate, S (-)-UH-301 hydrochloride, vinblastine and vincristine showed that the 
combination had a slightly more potent effect on growth inhibition than when either drug 
of a pair is used alone, at some but not all of the doses analyzed. In particular the 1 nM 
SKF + 1.25 nM DHA combination shows a considerable reduction (Figure 4.3). 
4.3.3 MeSH annotation of hit compounds from LOPAC and ENZO libraries  
MeSH annotation of hit compounds revealed that they fell into 15 distinct mechanisms of 
action classifications. Some of the most common, apart from the existing antimalarials, 
were the anti-cancer and antipsychotic compounds (Figure 4.4).  
Figure 4.3 SYBR Green-based Flow cytometric data for the treatment of P. falciparum malaria (strain 
K1) with dihydroarteminsin (DHA) and five LOPAC compounds. The LOPAC compounds Emetine 
dihydrochloride hydrate (EM), SKF 95282 dimaleate (SKF), S (-)-UH-301 hydrochloride (SUH), Vinblastine 
(VinB) and Vincristine (VinC) were either added alone or in combination with DHA for a 48hr treatment 
period.  Parasitised blood and parasites treated with a range of DHA concentrations served as controls. 
Non-infected blood was also included and background fluorescence was deducted from all samples 
accordingly. Parasitaemia was determined using SYBR Green based flow cytometry and 50, 000 events 
were recorded for each sample. 
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4.3.4 Tanimoto Similarity of selected MesH categories  
Tanimoto similarity of the most desirable novel classes revealed that they were structurally 
distinct from a range of existing antimalarial classes.  Compounds with an index of > 0.85 
were considered to have the same mechanism of action (Plouffe et al., 2008). The 
quinolines formed a distinct cluster displaying at least 0.65 similarity to each other and 
served to validate the similarity method employed (Figure 4.5).   Some of the novel classes 
also presented a high level of similarity to each other. Indeed, the calcium channel 
blockers displayed a similarity score of 0.896, whereas their highest similarity, when 
compared with existing antimalarials, was 0.517 and 0.515 for mefloquine and 
doxycycline, respectively (Figure 4.5 a). The anti-rhythmic compounds were only 0.787 
similar to each other, whilst their highest similarity to an existing antimalarial was 0.62 
with doxycycline (Figure 4.5 b). The highest similarity score for the serotonin and 
histamine receptor antagonists to the selected existing antimalarials was with halofantrine 
(0.636 and 0.706 respectively). The anti-parasitic category contained compounds that have 
different modes of action against different parasites. These compounds, therefore, also had 
varied degrees association to each other and the existing antimalarials (See Appendix V). 
Figure 4.4 MeSH category distribution of the top 60 ENZO and LOPAC hits. The 60 most potent 
compounds from the ENZO (55 compounds) and LOPAC (selected 5) library preliminary screens were 
grouped according to their previously defined mechanism of action classifications, as determined by 
Medical subject heading annotation (MeSH PubChem) to identify common classes with antimalarial 
activity. 
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a. Calcium channel blockers  
 
b. Anti-arrhythmic 
 
Figure 4.5 An example of the structural clustering for the previously defined MeSH categories with a 
range of existing anti-malarials. Namely, the calcium channel blockers and the anti-arrhythmic compounds.  
PubChem substructure fingerprint using the 2D Tanimoto similarity coefficient was employed to determine 
the similarity of the potentially novel anti-malarial classes with existing anti-malarials.  In accordance with 
Gamo et al. (2010) compounds with a similarity index of > 0.85 were considered to share a mode of action.  
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4.3.5 Second-phase screening of selected compounds 
The second-phase screen of the ENZO library indicated that compounds, propafenone and 
clemastine were the most potent with IC50’s of 0.12-0.16 µM and 0.4-0.5 µM respectively 
(Figure 4.6 a and b). For the remaining 7 compounds the IC50 estimates were 0.8-10 µM 
(Figure 4.6 c-f and Table 4.2) 
 
 
a b 
c d 
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The second-phase screen of the LOPAC compounds emetine dihydrochloride hydrate 
(Figure 4.7 a), SKF 95282 dimaleate (Figure 4.7 b), S (-)-UH-301 hydrochloride (Figure 
4.7 c), using the more accurate SYBR Green-FCM method, showed that 50% growth 
inhibition could be achieved at ~ 50 nM, >200 nM and ~750 nM respectively.  
Compound Name Class Preliminary IC50 (µM) 
Atovaquone Antimalarial (positive control) < 0.08  
DMSO N/A (Negative control) No inhibition 
Clemastine H1 receptor antagonist 0.4-0.5  
Propafenone Anti-arrhythmic 0.12-0.16  
Niguldipine Calcium channel blocker 0.9-1.1  
Nicardipine. HCL Calcium channel blocker 0.8 -1  
Fluoxetine Serotonin receptor antagonist 2-2.5  
Ondansetron Serotonin receptor antagonist 5-7.5  
Ketanserin Serotonin receptor antagonist > 10  
Nisoxetine. HCL Noradrenaline uptake inhibitor 1.5-2  
Telmisartan Angiotensin receptor blocker 0.9-1.1  
Figure 4.6 Second-phase screen of selected ENZO library compounds. Dose response curves were 
generated using the SG-MicroPlate method. The dose-range for each class was selected based on the 
potency of the preliminary screen. Classes analysed included anti-histamine receptor antagonist (this 
Figure also included the un-treated and the DMSO-only controls (a), anti-arrhythmic compound (b), 
calcium channel blocker (c), serotonin receptor antagonists (d), noradrenaline uptake inhibitor (e) and an 
angiotensin receptor antagonist (f). 
Table 4.2 Preliminary IC50 estimates based on the second phase SG-MicroPlate screen of 9 
compounds selected from the ENZO library. 
e f 
k 
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4.3.6 IC50 determination of selected compounds 
The results showed that, out of the ENZO and LOPAC compounds, emetine was by far the 
most potent (IC50 = 47 nM (Figure 4.8 d)). The two ENZO compounds clemastine and 
propafenone, selected for further study based their potency, were shown to have IC50s just 
below 500 nM (Figure 4.8 a and b respectively). Ondansetron, selected for its anti-emetic 
potential, was shown to be a very mild inhibitor of the Plasmodium falciparum K1 strain 
(IC50 ~ 39 µM (Figure 4.8 c)). 
Figure 4.7 Second-phase screen of 
three selected LOPAC compounds.  
The SG-FCM method was used to 
determine the dose response of 
Emetine dihydrochloride hydrate (a), 
SKF 95282 dimaleate (b) and S (-)-UH-
301 hydrochloride (c), against strain 
K1 in order to obtain board IC
50 
estimates. 
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Figure 4.8 Accurate IC50 determination of the four selected ENZO/LOPAC Library compounds. These 
included the ENZO Histamine receptor 1 antagonist clemastine (a), anti-arrythmic propapenone (b), 
serotonin receptor antagonist ondansetron (c), and the LOPAC compound emetine dihydochloride hydrate 
(d) against P.falciparum K1 using the SYBR Green flow cytometer method. The compiled figures show the 
standard dose response curve, and the GraphPad Prism 5.0 output for normalised data against log 
transformed drug concentrations (Sy.x indicates the standard deviation of residuals). 
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4.4 DISCUSSION 
4.4.1 Preliminary screening of the ENZO and LOPAC library for antimalarial activity  
The phenoptypic screen of the ENZO library presented a relatively high hit rate (9.5%), 
compared with previous screens, possibly, owing to the bioactive nature and drugability of 
the small compound library (Weisman et al., 2006).  A hit was defined as a compound 
inhibiting >50 % growth at a single dose point of 2.5 µM. These criteria are consistent 
with other single-dose screens (Plouffe et al., 2008; Lotharius et al., 2014). Some previous 
studies only included compounds presenting > 80 % inhibition, however, the single dose 
adopted in these studies was usually 3 or 4 fold higher than the concentration presented 
here (Gamo et al., 2010; Guiguemde et al., 2010; Lucumi et al., 2010; Weisman et al., 
2006). Although there was some toxicity incurred by the solvent concentration (0.625% 
DMSO), the data was adjusted accordingly so that only inhibition above that of the DMSO 
control was considered. Some false-negative were identified by the screen (Appendxi IV). 
For example, doxycycline is a known antimalarial inhibitor that did not appear in the hit 
list. The most likely reason for this is that assay time course selected for fast acting 
compounds. Antibiotics like doxycycline are known to induce a delayed death phenotype 
that would have been missed by the 48 SYBR Green screening assay. It is also unlikely 
that compounds were capable of promoting (in some cases more than double) parasite 
growth compared to the untreated controls (Appendxi IV). Thus the extreme values of 
negative inhibition maybe due to interference from coloured compounds with an inherent 
fluorescence. However, the blind screening procedure employed the re-identification of 
known antimalarials in the hit list and and a good Z score (0.68 + 0.06) served to validate 
the hits obtained. 
The results of the preliminary LOPAC screen indicated that there may be some resistance 
towards the 5 selected compounds in the multidrug resistant K1 strain when compared 
with the 3D7 data (Lucumi et al., 2010). Nevertheless, Emetine dihydrochloride hydrate, 
SKF 95282 dimaleate, S (-)-UH-301, vinblastine and vincristine showed additional 
suppression, at some but not all of the does tested, when they were co-administered with 
dihydroartemisin. Possibly, indicating that they may be useful in artemsinin-based 
combination therapy.  
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4.4.2 MeSH annotation of hit compounds  
The 15 MeSH categories identified as displaying antimalarial activity are in agreement 
with other reports, providing further validation for the data obtained. Indeed, antibiotic, 
anticancer, antipsychotic and immune-suppressant compounds have commonly been 
identified in numerous high-throughput phenotypic screens against cyclic blood stages of 
the disease (Gamo et al., 2010; Lotharius et al., 2014; Plouffe et al., 2008; Weisman et al., 
2006). This data should be viewed with caution as it must be pointed out that the MeSH 
distribution of hits, may actually represent the MeSH distribution of the whole library. 
However, it is noteworthy that the most potent compounds from the LOPAC library 
selected for further investigation were easily placed into MeSH categories outlined for the 
ENZO library. Further validating the categories as potentially novel antimalarial leads.  
4.4.2.1 Anticancer compounds for malaria 
The anticancer compounds were most commonly identified within the hit list (18% of 
hits). There has been recent interest in repositioning anticancer therapies for malaria 
treatment. Indeed, inhibitors of the novel malaria drug target farnesyltransferase were 
originally developed for cancer treatment.  The rationale for the exploitation of such cross 
discipline drug-targets highlights that the toxicity of any drug developed for cancer 
therapies will have been studied at considerably higher doses (Nzila et al., 2010).  Nzila et 
al., 2010 quotes Paracelsus’ law ‘Sola dosis facit venenum (only dose makes the poison)’ 
suggesting that all drugs are poisons it is only the dose that dictates the severity. 
Interestingly, two out of the 5 compounds investigated from the LOPAC library were 
previously used as anticancer therapies (Lucumi et al., 2010). Vinblastine and vincristine 
are chemical analogues originally isolated from the Madagascar periwinkle (Catharanthus 
roseus). Vinblastine is used for the treatment of Hodgkin’s disease and advanced breast 
and testicular cancer whilst vincristine is used for leukemia and other types of lymphoma 
treatment (Oksman-Caldentey and Inze, 2004). Both vinblastine and vincristine act by 
inhibiting microtubule formation, and have been suggested to target nuclear division in the 
malaria parasite. Additional target could include other cellular processes dependent on 
microtubule function such as merozoite formation and erythrocyte invasion by daughter 
merozoites (Usanga et al., 1986; Chakrabarti et al., 2013).Despite the relatively toxic 
nature of anti-cancer compounds, only vincristine appears to be potent against the K1 
strain. In order to reposition these compounds for malaria, doses that do not cause toxicity 
would have to be analysed for activity against malaria before vincristine could progress as 
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a viable candidate. Notably, vinblastine the least toxic of the two was shown to be less 
effective against K1. Indicating that general toxicity rather than parasite specificity may be 
the reason for the potency observed.  The high (83 %) similarity between mammalian and 
parasite tubulin (Chakrabarti et al., 2013) also infers that the general toxicity of such a 
target may be difficult to overcome.  
Drug candidates for widespread malaria treatment need to be well tolerated and safe for 
use in children. The repositioning of anticancer therapies for malaria is therefore hampered 
by persistent underlying concerns about toxicity, strong side effects and resulting 
compliance issues (Lotharius et al., 2014). The huge effort expended in developing a drug 
that could potentially have such problems is not feasible, particularly when other avenues 
for exploration have been presented. For this reason, despite the high prevalence of 
activity, anticancer compounds from the ENZO or LOPAC libraries were not considered 
further in the current study. 
4.4.2.2 Antipsychotics, immune suppressants and antibiotics for malaria 
Out of next most prevalent categories namely: the antipsychotics (15%), the immune 
suppressants (5%) and the antibiotics (9%) the former was not taken forward due concerns 
about adverse effects. The latter two classes have already been widely reported in the 
literature for consideration and use in repositioning therapy for malaria respectively. 
Immunosuppressant compounds such as Cyclosporin A and rapamycin in particular have 
been studied extensively for their antimalarial potential (Bell et al., 1994; Bobbala et al., 
2008). Unfortunately, their immunosuppressive properties are suggested to prevent 
repositioning of these compounds for malaria (Lotharius et al., 2014). Numerous 
antibiotics such as the tetracyclines and clindamycin, a licostamide antibiotic, have been 
used in combination therapy for malaria (Andrews et al., 2014), however, there are 
growing concerns that further exploitation of this important class of compounds will only 
accelerate the dwindling efficacy for its primary antimicrobial indication. 
Of the remaining categories the interesting groups that offered potentially novel 
antimalarial scaffolds were analysed for tanimoto similarity with existing antimalarials and 
other group members. The three remaining LOPAC compounds: Emetine, SKF and SUH 
aligned well with the selected categories: namely, antiamoebic (antiparasitic), histamine 
receptor antagonist and serotonin receptor antagonist respectively and were therefore 
included for structural similarity analysis. 
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4.4.3 Tanimoto similarity of hit compounds 
Various studies have employed similarity indexes to determine whether the chemical space 
occupied by novel antimalarial scaffold overlaps with the existing pharmacotherapies for 
malaria.  In addition, structural similarity between novel chemical scaffolds can help 
inform lead optimisation of candidates. Compounds with differential potencies within the 
same cluster can be used to identify, and potentially modify, the structural components 
responsible for both off-target and on-target effects (Guiguemde et al., 2010 Plouffe et al., 
2008). 
In the current study the Tanimoto similarity index was used, firstly, to compare each 
MeSH category with a range of existing antimalarials, and secondly, to analyse the 
similarity of the compounds grouped within the same MeSH category. Compounds that 
were singly responsible for the identification of a particular MeSH category were grouped 
into ‘other’ and analysed for their similarity with known antimalarials only. 
Encouragingly, none of the novel scaffolds displayed a high degree of similarity with 
existing antimalarials (defined as > 0.85 (Guiguemde et al., 2010 Plouffe et al., 2008)). 
Although data was further validated through the distinct cluster formed by the quinoline 
antimalarials their relative similarity coefficients were not particularly high. This is 
somewhat expected as structural alterations have been made to reduce the non-target 
effects of quinine, the parent compound, to make the synthetic derivatives such as 
chloroquine and mefloquine more tolerable. 
 Overall, the similarity clustering between compounds within each MeSH category was not 
that informative, possibly due to the diversity of the library and the particularly small 
compound set analysed (n ~55).  The only MeSH category to report a high level of 
similarity between the compounds was the calcium channel blockers, niguldipine and 
nicardipine. HCL (0.896).  The similarity of the other compound clusters was clearly 
affected by the specificity of the MeSH category. For example, the serotonin and histamine 
receptor antagonist classifications contained different families of antagonist that target 
different receptor types (H1 and H2 or 5-HT1, 5-HT2 and 5-HT3 respectively). It is 
therefore perhaps not unexpected that compounds in these broad spectrum categories did 
not present a high degree of similarity to each other.  Furthermore, although structure is 
related to activity, the reverse is not always so easily applicable. Indeed compounds that 
have the same function (activity) may bind to and inhibit different targets within a pathway 
for which the appropriate structure may be completely different (Plouffe et al., 2008). 
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Indeed the angiotensin inhibitor telmisartan and spironolactone are known to act on the 
same pathway but are dissimilar in structure. Whereas, the high similarity of the calcium 
channel blockers would predict that they act on the same target.  
In order to further refine the hit list for second-phase validation through dose response 
analysis, the most potent ENZO compounds from each category (propafenone, clemastine 
and telmisartan) were taken forward. Along with the three remaining LOPAC compounds 
that showed potential as ACT candidates.  For the calcium channel blockers both 
compounds (nicardipine. HCL and niguldipine) were considered due to their high degree 
of structural similarity and the possibility of identifying structural activity relations. 
Although the preliminary screen indicated only a slight variation in potency, second-phase 
analysis may reveal a more profound difference. For the serotonin receptor scaffold, all 
compounds (fluoxetine, ondansetron and ketanserin) were taken forward for further 
validation. This cluster not only represented a relatively large proportion of hits (7%), but 
members of the class have previously been proposed as novel antimalarial candidates 
(Gamo et al., 2010). The dissimilarity between the compounds and the lack of a huge 
variation in potency precluded the selection of fewer representatives (56-73% inhibition). 
From the ‘other’ category the most potent compound a noradrenaline uptake inhibitor, 
nisoxetine. HCL, was also considered. 
Once hit compounds have been validated, a more informative structural similarity analysis 
of the whole library would permit comparisons between active and inactive compounds.  
One foreseeable problem is that the relatively small library boasts a high level of diversity 
which may ultimately limit cluster size. However, the growing amount available data in 
the public domain, on preliminary screens, could be used for a larger scale in silico 
analysis of compounds designated to promising MeSH categories (Guiguemde et al., 2012; 
Spangenberg et al., 2013). This would not only to increase cluster size, but also help build 
structural activity relations and instruct structural lead optimisation. 
4.4.4 Secondary phase screening selected compounds  
The second phase-screen of the ENZO library was in agreement with the preliminary 
screen. All of the selected compounds were validated as malarial inhibitors. The most 
potent compounds were the anti-histamine receptor antagonist, clemastine, and the anti-
arrhythmic compound propafenone, both with estimated IC50‘s between 0.12-0.5µM 
(Table 4.2).  This is consistent with the literature, as compounds from these classes have 
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previously been identified as submicromolar inhibitors of malaria (Chong et al., 2006; 
Derbyshire et al., 2012; Plouffe et al., 2008; Weisman et al., 2006). For the other 
categories: namely, angiotensin receptor antagonist, calcium channel blockers, 
noradrenaline uptake inhibitors and serotonin receptor antagonist the IC50 estimates were 
between 1-10 µM (Table 4.2). In addition to the erythrocytic stage antimalarial activity 
presented here, Derbyshire and colleagues have shown that telmisartan is also inhibitive to 
liver stage parasites (Derbyshire et al., 2012).  Unfortunately, the calcium channel blockers 
failed to show a distinct variation in potency hence would not be suitable for SAR 
investigations. The serotonin receptor antagonist, despite being the one of the most 
common classes, (although structurally diverse) were the least potent compounds in the 
second-phase screen. While these candidates are not ideal in their current formulations, 
they should be considered as novel antimalarial scaffolds for lead optimisation. To fit the 
criteria of an antimalarial candidate, compounds should display potent antimalarial 
activity, be effective against drug resistant strains, free of significant side effects and have 
good pharmacokinetic properties (Rottmann et al., 2010). Indeed, these candidate are 
known to be bioactive, have been screened against a multidrug resistant strain and fall 
within the criteria outlined by MMV that suggest and IC50 of < 1 µM as a good starting 
point for lead optimisation (Lotharius et al., 2014). 
The wider dose range selected for the second-phase screen of the 3 selected LOPAC 
compounds permitted a clearer estimation of the IC50 against the multiple drug resistant 
strain K1. Despite the finding that the IC50 fell within the < 1 µM range, two of the 
compounds the histamine receptor antagonist SKF 95282 dimaleate, and the serotonin 
receptor antagonist S (-)-UH-301 hydrochloride displayed a large shift when compared 
with the IC50 obtained for 3D7 strain. Although multiple replicas were completed for SKF 
95282 dimaleate no growth inhibition was observed at 200 nM, 200 x the previous 
reported IC50 value (1 nM) for 3D7 (Lucumi et al., 2010).  For S (-)-UH-301 
hydrochloride Lucumi et al., (2010) reported an IC50 value of 5 nM against 3D7, here we 
show that this level of inhibition is only achieved at a concentration of  ~ 750 nM against 
K1 (150 x). Although Lucumi et al. (2010) used luciferase-based assay and the current 
study adopted SYBR green-based flow cytometry, the IC50 values determined for existing 
antimalarials were comparable between the two studies. Furthermore, as little as a 10 fold 
increase in IC50 value is often reported as clinically significant resistance (Gelb, 2007). 
Thus the 200 x and 150 x shift significantly limits these compounds for further 
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antimalarial development. The most potent of the LOPAC compounds was Emetine 
dihydrochloride hydrate. Despite also showing an increase in the IC50, the potency against 
a multidrug resistant strain was well within guidelines of a good antimalarial candidate and 
even conformed to the more stringent EC50 < 100 nM potency cut-off outlined by 
Biamonte et al. (2013).  
 It was not within the remit of this study to investigate every hit obtained. Therefore based 
on potency, three compounds from the ENZO and LOPAC libraries were taken forward 
for the next phase of interrogation (accurate IC50 determination using the SG-FCM 
method). These included clemastine propafenone and emetine dihydrochloride hydrate. 
One compound from the serotonin class (ondansetron) was also progressed, not because of 
its potency against the malaria parasite, but for a secondary function as potential anti-
emetic for combination with emetine. As its name suggested emetine induces strong 
emetic effects which would evidently cause serious compliance issues if it was deployed 
for the treatment of malaria. Combination with an anti-emetic may help nullify the adverse 
effects while bestowing the additional benefits of a combinatory regime, such drug 
synergy and a prolongation of resistance development. 
4.4.5 Accurate IC50 determination of selected compounds 
The IC50 obtained for 3 out of the 4 selected compounds was within the expected range, as 
predicted by the second-phase screens. Representatives of two classes of ENZO 
compounds, the anti-histamines and the anti-arryhtmics, have previously been reported to 
inhibit P.falciparum. The data presented here therefore further confirms their utility as 
antimalarial candidates. Clemastine and propafenone achieved an IC50 of 427 nM and 475 
nM respectively, therefore further lead optimisation will be required. As Guiguemde et al., 
(2010) emphasised, it is not claimed that hit compounds identified from such phenotypic 
screens are clinical candidates in their current formulation but they are reasonable starting 
points.  
4.4.5.1 Antihistamines for malaria 
With regard to the histamine receptor antagonists, astemizole, was previously identified as 
the most promising candidate from a screen of 2,687 compounds against the erythrocyte 
stage parasite (Chong et al., 2006). Since then there has been other studies reporting its 
potential as a hybrid with chloroquine against chloroquine-resistant strains (Musonda et 
al., 2009) and its effectiveness against liver stage parasites (Derbyhire et al., 2012). As of 
yet there is no empirical evidence indicating that astemizole or its derivatives have entered 
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clinical trials. Evidently the slow progress for this compound, compared with both the 
spiroindolone and Imidazolopiperazines derivatives that have advance quite rapidly 
(Guiguemde et al., 2010; Guiguemde et al., 2012), has been hampered by underlying 
cardiotoxicity issues (Lotharius et al., 2014). This is not to say that work is not ongoing. 
More recently Roman and colleagues have managed to achieve 200 fold selectivity 
towards the parasite over hamster cells with benzimidazole analogues, structural 
derivatives of astemizole (Roman, Crandall and Szarek, 2013). 
The antihistamine clemastine, shown here to be effective against blood stage malaria, has 
also been shown to be potent against liver stages parasites (Derbyshire et al. 2012). Unlike 
astesmizole, this compound is still available over the counter. Interestingly, astemizole is 
considered to act via a similar mechanism to the quinolines, therefore not representing a 
novel antimalarial chemotype (Plouffe et al., 2008; Lotharius et al., 2014), however, the 
highest similarity reported against the quinoline derivatives, for clemastine was 0.495 with 
Amodiaquine. Indicating that some antihistamines may offer a novel mode of action.  
Finding a safe compound with potent effects against both the blood and liver stages would 
be ideal and is suggested to be a necessity if eradication goals are to be achieved 
(Derbyshire, Mota and Clardy, 2011). Indeed, the liver stage is a bottle neck in the parasite 
life cycle and until recently identification of compounds active against this stage was 
impeded by the lack of a high throughput screen. Out of the existing antimalarials, only 
primaquine and atovaquone are effective against the liver stage (Derbyshire et al., 20012). 
Hence the unique opportunity of a safe novel drug scaffold that can potentially elicit a two 
pronged attack is a valuable asset.  
4.4.5.2 Antiarrhythmic compounds for malaria 
Anti-arrhythmic compounds, including propafenone have been reported elsewhere to be 
active against blood-stage parasites (Plouffe et al., 2008; Lowes et al., 2011; Weisman et 
al., 2006). This activity was also shown at relevant doses to the therapeutic window of its 
prior indication (Weisman et al., 2006). Again cardiotoxicity was a concern, however, lead 
optimisation efforts have begun to create derivatives that address its cardiac ion channel 
and pharmacokinetic liabilities (Lowes et al., 2011). Further work has focused on 
improvements in the bioavailability, toxicology and pharmacokinetics of the anti-
arrhythmic compounds (Lowes et al., 2012). Interestingly, propafenone has also been 
shown to be more potent in the drug resistant strain, K1 when compared with the 
susceptible strain, 3D7 (Lowes et al., 2011).  
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4.4.5.3 The anti-emetic, serotonin receptor antagonist for combination with emetine 
The third ENZO compound, the serotonin receptor antagonist ondansetron, on the other 
hand presented considerably lower activity than inferred by both the preliminary and 
secondary screens. A new powder stock was purchased for this compound and dissolved in 
water (as indicated by sigma) as opposed to the previous suspension of the ENZO library 
in DMSO. This suggest that either the initial screens were inaccurate or there was a 
dissolvability problem with the newly purchased stock. This kind of discrepancy is not 
uncommon among phenotypic screens that often report a re-confirmation rate of only 75-
80 % when a new stock is purchased (Guiguemde et al., 2010; Plouffe et al., 2008). 
Multiple dose response attempts were made (Appendix VI) but an IC50 level of inhibition 
was not achieved until the dose range was significantly increased. Due to a lack of activity 
and the obvious detriment to the chances of a safe therapeutic window ondansetron may 
not be suitable for combination with emetine. Unless further work can validate the potency 
observed in the preliminary screens. 
 
4.4.5.4 The anti-amoebic compound for malaria  
The high activity of the LOPAC compound Emetine dihydrochloride hydrate (IC50 = 47 
nM) was also re-confirmed. Although the compound has been identified repeatedly as a 
potent antimalarial in numerous high through-put screens, it has been largely overlooked 
as a potential candidate due to fears of toxicity. Emetine, originally derived from the root 
of Carapichea ipecacuanha (Ipecac), was previously used as a potent intestinal and tissue 
amoebicide. Adverse effects of the treatment included nausea and vomiting (emesis-hence 
its name). In fact, the drug was often exploited medicinally to induce vomiting. However 
after the 1980’s its use was abandoned due to serious cardiotoxic complications, seen in a 
small proportion of patients (high cumulative doses), and availability of a safer alternative 
metronidazole. Initial toxicity issues are in fact a common affliction amongst novel classes 
of compounds identified as antimalarial inhibitors. The majority of libraries screened 
contain compounds for which the primary indication was a human disease and are 
therefore inherently active against human targets. Derivatization to reduced cardiotoxic 
effects of anti-histamine and anti-arrhythmic compounds has led to safer alternatives. With 
emetine as a potent starting point it may be possible to also use derivatization to overcome 
such issues. Furthermore the value of Emetine, a natural product compound used 
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previously for the treatment of a parasitic infection, with potentially multiple targets that 
could circumvent resistance should not be discounted. 
4.4.6 Conclusion 
Given that 90 % of drug candidates fail during development (Ashburn and Thor, 2004), 
and the fact that there are no novel antimalarials in the foreseeable pipeline, drug-
repositioning offers a much needed interim solution. The data presented here clearly 
supports the strategy as a viable option for antimalarial drug discovery.  From a screen of 
< 700 hundred compounds we have identified at least 3 potent antimalarial candidates. In 
addition to that, other novel scaffolds have been shown to have antimalarial activity at < 1 
µM (MMV guidelines, Lotharius et al., 2014). To make drug repositioning a valuable tool 
it is important that these hits are characterised on a more systematic basis with equal 
velocity and enthusiasm. Else, initial screening efforts that promise to help speed up drug 
development and rapidly progress candidates to the front line will be futile (Baniecki, et 
al., 2007). The high activity of emetine against a multidrug resistant strain, K1, justifies its 
selection for further interrogation. Unlike the anti-histamine and anti-arrhythmic 
compounds its antimalarial potential has been commonly overlooked. In order to progress 
emetine as a viable antimalarial candidate intensive in vitro investigations to elucidate the 
killing profile, stage specificity and its suitability for combination with existing 
antimalarials will be employed. Once optimised the outlined workflow for emetine could 
be applied to other candidates.  The more intensive in vitro investigations afforded by the 
focus of academic study rather than large scale industrial development should permit better 
in vitro to in vivo translation of hits. 
Undoubtedly, the current voids in the malaria drug market highlight the fact that mankind 
could be faced with a potentially horrific, uncontrollable, resurgence of the disease if drug 
production does not meet the on-going demand. Therefore to make drug repositioning a 
viable short term option for anti-malarial drug discovery, hit compounds, like emetine, 
should be quickly advanced to second-phase screening programs. Where more detailed 
interrogation of the compound can be completed.  The importance of effective interaction 
studies cannot be overemphasised as combination therapy is the future for malaria 
treatment. Without rapid progress of candidate antimalarials, the benefits of a fast-track 
drug discovery program will undoubtedly be lost.  
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CHAPTER 5 
ANTIMALARIAL ACTIVITY OF EMETINE DIHYDROCHLORIDE HYDRATE 
5.1 INTRODUCTION 
For almost 50 years, emetine was used as a standard, affordable treatment for amoebiasis 
and amoebic dysentery, caused by the protozoan parasite Entamoeba histolytica (Akinboye 
and Bakare, 2011). The natural plant-derived product was also given ‘over the counter’ in 
the form of Syrup of ipecac to induce vomiting in cases of poison (Akinboye et al., 2012). 
Unfortunately the curtailment of its medicinal use, due to adverse cardiotoxic effects and 
the availability of a safer anti-amoebic drug (metronidazole), has precluded interest in the 
compound for antimalarial repositioning, despite being identified as a recurring hit in 
recent high throughput screens (Andrews et al., 2014; Lucumi et al., 2010; Plouffe et al., 
2008). However, its bioactive potential for other parasitic diseases has been considered.  
As early as 1966 the value of emetine as and antischistosomal compounds was realised 
when schistosomal haematuria’s disappeared in patients treated for amoebic dysentery 
(Dempsey and Salem, 1966).  More recently emetine has been identified as a potent 
trypanocidal compound against both Trypanpsoma cruzi, complete inhibition at < 5 µg/ml 
(Cavin et al., 1987) and T. brucei with IC50 < 1 µM (Mackey et al., 2006) or < 10 µM 
(Merschjohann et al., 2000), the causative agents of Chagas disease and Sleeping Sickness 
respectively. In vitro activity against Leishmania donavani at 0.03 µg/ml (Muhammed et 
al., 2003) and Toxocara canis at 109 µmol/L (Satou et al., 2002) has also been 
demonstrated. However in most cases, the limited margin of safety against human cell 
lines was a cause for concern (Mackey et al., 2006; Merschjohann et al., 2000; Rosenkranz 
and Wink, 2008; Satou et al., 2002).The reasons for perusing the compound for malaria 
repositioning are two-fold; firstly, the potential for a favourable dose-related toxicity 
profile against the malaria parasite and secondly the existence of a safer derivative. Most 
of the toxicity studies for emetine were carried out in the 1960’s, therefore, revisiting this 
area with post genomic technologies may offer new insight.  
A review of existing literature suggests that the side effects of emetine are dose dependent 
(Akinboye and Bakare, 2011). One of the more recent studies showed that in vitro 
sensitivity of various amoebiasis strains ranged from 25-35 µM (Bansal et al., 2004), 
which is 700-fold higher than the antimalarial potency presented here against K1, 35,000-
fold higher than IC50 for 3D7 (Lucumi et al., 2010), and 1750-fold higher than the IC50 for
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 W2 (Genomics Institute of the Novartis Research Foundation database). This in vitro data 
has beneficial implications for its margin of safety as an antimalarial and indicates that the 
dose-dependent toxicity profile should be re-evaluated at a ‘malaria appropriate’ dose 
range. The majority of in vivo data and information about drug plasma concentrations is 
also dated. However, Asano et al., (2001) recently provided some information about the 
pharmacokinetic and pharmacodynamic properties of the compound in humans. Healthy 
male volunteers were given 5, 10, 15, 20, 25 or 30 ml of a solution containing 0.503 mg/ml 
of emetine. This equates to a single dose of 2.5, 5, 7.5, 10, 12.5 and 15 mg respectively. 
Authors reported that between 10-84% of the initial oral preparation of emetine was found 
in vomit. If we consider that the highest dose would induce the most vomiting then it can 
be assumed that potentially only 16 % of the solution was absorbed equating to a total dose 
2.4 mg (16 % of 15 mg). From this, a concentration of 6.2 ng/ml was measured in human 
plasma after 12 hours. Our in vitro investigations suggest that the IC50 for emetine against 
the multi drug resistant strain K1 is 50 nM which is equivalent to 27.7 ng/ml (4.5 x more 
than 6.2 ng/ml). Notably, the 1 nM 3D7 efficacy reported by Lucumi et al. (2010) would 
equate to 0.55 ng/ml (which is 11.3 x less than 6.2 ng/ml). Asano et al (2001) showed that, 
once vomiting is corrected for, there was a linear relationship between the emetine dose 
ingested and the concentration in the blood plasma. Therefore in order to achieve and a 
plasma concentration equating to IC50, the emetine dose given should be 10.8 mgs (4.5 x 
2.4). This dose is well within the previously recommended dose for amoebiasis treatment 
of up to 60 mg per day for 6 days followed by 3 further treatments after day 9 (Ganguli, 
2002). Obviously the aim is to achieve 100 % parasite killing, but up to 5 x this dose is 
achievable within the window of safety and our work showed that just 2 x the IC50 dose 
was capable of inducing 90% inhibition (Figure 4.8). Due to the sporadic nature of the 
previously reported cardiotoxic events, mostly related to cumulative dosing after day 6, it 
is plausible that such issues could be avoided during malaria treatment, particularly if a 
shorter treatment periods were adopted. In the study by Asano et al. (2001) emetine was 
undetectable in blood plasma after 168 hour but persisted in the urine for up to 12 weeks. 
This is consistent with previous reports of detection in urine after 60 days and agrees with 
evidence that the compound accumulates in the liver and other organs.  Indeed 
accumulation in organs is most likely responsible for cardiotoxic issues. What is more, 
such persistence could mean that parasites will be exposed to sub-optimal concentrations, 
encouraging the likelihood of resistance development. Conversely, the issue may be 
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advantageous for treatment of P. vivax infections if the hepatic concentrations could be 
exploited attack the dormant liver stages of this species.    
Fortunately, prior to the introduction of metranidozole for ameobiasis treatment, efforts 
were made to develop a safer alternative to the parent compound emetine. A synthetic 
modification of the drug (2, 3-dehydroemetine (DHE, Roche)) was shown to retain its 
amoebicidal properties while producing fewer side effects (Figure 5.1 Table 5.2). Other 
advantages were that it had a shorter period of bioactivity and was excreted more rapidly 
from most body organs including the heart. The oral resonate, although incompletely 
absorbed and thus requiring higher concentrations of the compound, was shown to be more 
tolerable and in fact more effective than the injection (Dempsey and Salem, 1966).  
Furthermore daily doses of up to 90 mg per day (intramuscular) have been recommended 
for the safer alternative (Nozaki and Bhattacharya, 2014), inferring that lethal Plasmodium 
falciparum doses could be achieved providing that DHE has comparable antimalarial 
activity to emetine. In practical terms, gastric irritation due to emetine could be further 
minimised by the adoption on novel drug formulation methods. Various coating options 
could be empolyed to ensure slow or pH-dependent release of the compound. For cerebral 
malaria intramuscular injection could also be an option when in-hospital patient 
monitoring is routine. Future biotechnological advances could also provide the option of 
nano delivery systems for emetine, to avoid the troublesome emesis and cardiotoxic side-
effects (Allen and Cullis, 2004).  
 
 
 
The synthetic deriverative dehydroemetine is stated is commercially unavailable as 
production has been discontinued. The complex re-synthesis of the compound is not within 
the remit of the current study and therefore its antimalarial potency has not been evaluated. 
However, the existence such a derivative demonstrates that emetine is amenable to useful 
Table 5.1 A Summary of the in vitro anti-malarial efficacy and selectivity of emetine and its analogues. 
(NT: not tested, NC: Not cytotoxic at max dose 10 µg/mL, SI: Selectivity Index IC50 VERO/IC50 Pf. Data 
collated from Matthews et al., 2013, Lucumi et al. 2010, Freidrich et al., 2007, Wright et al., 1991, Sauvin et 
al., 1992, Muhammad et al., 2003, Akinboya and Bakare 2011)      
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chemical modification with the potential to deselect for toxicity.  Furthermore, studies on 
closely related naturally occurring, structurally similar analogues of emetine support the 
hypothesis that minor structural differences in the molecule result in significant differences 
in pharmacology, toxicology and selectivity. For this reason the closely related natural 
anologue, cephaeline (Figure 5.1 table 5.2) will be compared it’s for potency and toxicity 
against the malaria parasite and a mammalian cell line respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
Lipinski’srule of 5 Emetine Cephaeline  Dehydroemetine 
< 5 hydrogen bond donors 3* 1 3* 2 1 
< 10 hydrogen bond acceptors 7 6 6 6 6 
Molecular weight < 500 553.6 g/mol 480.6 g/mol 539.5 g/mol 466.6 g/mol 478.6 g/mol 
LogP <5 --- 4.7 --- 4.4 3.7 
 
 
The potential of emetine derivatives to provide a novel antimalarial class and the wealth of 
pre-existing information about structural activity relations justifies a more detailed 
interrogation of the compound as an antimalarial candidate. Towards this aim, the killing 
profile of emetine will be defined against the multidrug resistant Plasmodium falciparum 
parasites strain K1. Knowing a compounds killing profile should not only help inform 
decisions about appropriate pharmacokinetically-matched combinatory options but also 
Table 5.2 Parameters for lipinski’s rule of 5 are shown for emetine, cephaeline and dehydroemetine. 
Violations of lipinski’s rules are indicated in red. *Compounds used in the current study emetine 
dihydrochloride hydrate and cephaeline hydrochloride (Source: PubChem). 
Figure 5.1 The structure of emetine dihydrochloride hydrate, cephaeline hydrochloride and 
dehydroemetine for comparison (Source: PubChem). 
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provide better in vitro to in vivo translation. Indeed, the recent upsurge of antimalarial hit 
compounds in the literature and the availability of better in vitro assays has meant that 
acquiring accurate in vitro pharmacokinetic data is imperative to prioritise candidates for 
in vivo evaluation. 
5.2 METHODS 
5.2.1 Determination of cephaeline IC50 in P.falciparum strain K1  
The ipecac alkaloid cephaeline hydrochloride (Sigma, UK) was analysed for antimalarial 
activity against the K1 strain. Following an initial preliminary screen (Appendix VII) an 8 
point two-fold dose series from 0.78-100 nM was set up. Treatment conditions and IC50 
determination were consistent with those described previously (Chapter 2). The emetine 
dose-response was completed in parallel to permit direct comparisons between the two 
compounds. Tanimoto similarity was also determined for the two analogues as detailed in 
(Chapter 4).  
5.2.2 Comparison of cephaeline and emetine cellular toxicity  
HepG2 cells were maintained in RPMI 1640 media containing 2mM l-glutamine, HEPES 
and substituted with 1 % non-essential amino acids, 10 % fetal calf serum (FCS) and 1 % 
Pen/strep. Incubations were at 37 
o
C under 5 % CO2. Confluent cells were counted and 
seeded at 4000 cells/well and 2000 cells/well for 48 and 120 hour exposures, respectively. 
The drugs were added 24 hours after seeding to permit cell adherence prior to drug 
exposure. An initial experiment opted for a wide dose-range (25 µM-3 nM) so that the 
inhibitory concentrations were not overlooked (Appendix VIII). A 25 µM-0.39 µM two-
fold dose series of cisplatin (Sigma-Aldrich) was included on each plate as a positive 
control. Once the appropriate dose-range for cephaeline and emetine had been determined 
(200 nM-3.125 nM 2-fold dose series) the experiment was repeated to obtain accurate IC50 
values. 
5.2.3 Time-course analysis of emetine and dihydroartemisinin against K1 parasites 
In order to gain further insight into the mode of action of emetine an in vitro time-course 
assay was completed. Parasites were treated with either IC50 DHA, IC50 emetine, or a 
combination of both compounds (IC50 DHA + IC50 Eme). Untreated controls were also 
analysed in parallel to the drug treatments.  Duplicate treatments were initiated at late 
trophozoite stage and analysed for growth at 24, 48 and 72 hour time points using SG-
FCM (Chapter 2 section 2.2.3). Parasite progression through the erythrocyte cycle stages 
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was also monitored due to the capability of the method to differentiate between 
mononuclear and multinuclear parasite forms.  The proportion of multinuclear cells 
(schizonts) was then displayed as a percentage of the total number of parasitised cells 
recorded for each treatment at each time point. Giemsa staining was used for parasite stage 
confirmation. 
5.2.4 Stage-specificity of emetine 
Parallel cultures previously synchronised at either ring or trophozoite stage were diluted to 
~1 % parasitaemia. The culture was subdivided into control, or emetine treatments of IC50 
(55 nM) and 10 x IC50 (550 nM) concentrations (2.5 % haematocrit) and incubated in 
accordance with standard conditions. Following a 6 hour treatment period 2 ml was 
removed from each condition, washed 3 x in complete media to remove the drug and re-
suspended in an equal volume of complete media to restore the haematocrit to 2.5 %.  Two 
hundred microliters of each condition, including the samples washed at 6 hours and the 
remaining samples that had not been washed and thus remained exposed to the drug, were 
then transferred to a 96 well plate. For each condition there were at least 4 replicates. The 
plate was placed in the humidifying chamber, gassed and incubated for 48 hours. 
Following the incubation period triplicate samples for each condition were analysed using 
the SG-FCM method as described previously. 
5.2.5 Determination of the killing profile for emetine against K1 parasites  
A more in depth method to determine the emetine killing profile against P. falciparum was 
employed. All procedures were consistent with those described by Sanz et al., 2012. In 
brief, drug treatment was initiated at 10 x the IC50 (550 nM emetine) against an initial 
inoculum of 10
6
 ring stage parasites/ml at 0.5 % parasitaemia 2 % haematocrit. The flask 
culture was incubated for 5 days (120 h). At 24 hours intervals the drug treatment was 
replenished to maintain a constant drug pressure and parasite recovery was analysed by 
limiting serial dilution. At each time point (0, 24, 48, 72, 96, and 120) an aliquot 
corresponding to 10
5
 parasites was removed (1 ml) washed 3 x in complete media to 
remove the drug (centrifuged at 3000 rpm), and re-suspended in an equal volume to restore 
the original haematocrit. A 96 well plate was prepared from rows 2-12 by adding 100 µl of 
2 % haematocrit blood in complete media. To row 1 of the plate 150 µl of the washed 
aliquot was added in quadruplicate. A 1:3 limiting serial dilution was performed by 
transferring 50 µl of the parasitised culture in row 1 to row 2 (containing 100 µl freshly 
prepared erythrocytes) mixing and again transferring 50 µl to the adjacent well (row 3). 
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All wells were serially diluted in this manner. Half (50 µl) of each well was then 
discarded. Double the volume required was used for the serial dilution to ensure that 
evaporation and drying of a small volume in the flat bottom 96 well plate, whilst preparing 
the dilution, did not confound the results. Each well then received an additional 100µl of 
complete media so that the final volume was 150 µl and the haematocrit was reduced to 
0.667% per well.  The plate was placed in a humidifying chamber, gassed and incubated 
for 28 days under conditions described previously. During the course of the experiment 
each container was gassed every 3-4 days. Spent media was removed on days 7, 14 and 20 
and replaced with fresh media and blood (see Table 5.3).  
Day Volume removed Volume added Haematocrit 
(fresh blood) 
Final haematocrit 
per well 
7 100 µl 150 µl 0.667 % 200 µl at 1 % 
14 150 µl 150 µl 0.667 % 200 µl at 1.5 % 
20 100 µl 200 µl 1.5 % 300 µl at 2%*  
 
 
On day 21 and 28 triplicate samples were analysed for growth using the SG-FCM method. 
Parasitaemia plots for each well were used to determine which dilution was the last to 
render growth following exposure to emetine for the aforementioned treatment periods (0, 
24, 48, 72, 96, and 120 h).  The number of viable parasite was then back-calculated using 
the formula X
n-1
 (where X is the dilution factor and n is the number of wells able to render 
growth). Log transformed values (Log(X
n-1
) + 1) were plotted for the time-course. Two 
key mode of action parameters: namely the parasite reduction ratio (PRR) and parasite 
clearance time (PCT) were then calculated from the graph. 
5.2.6 Preliminary comparison of JC-1 and SYBR Green staining 
Used also as a read out for parasite survival, the JC-1 assay was completed in parallel with 
the SYBR Green flow cytometer method to permit direct comparison. Briefly, a 
continuous culture of Plasmodium falciparum was diluted to ~1 % parasitaemia and split 
into two cultures flasks.  The first flask served as an untreated control whilst the second 
flask was exposed to IC50 DHA (2.5 nM). Following a 48 hr incubation period 50 µl of the 
respective control and treated culture flasks were transferred to eppendorf tubes. An 
additional 50 µl was taken from the untreated control sample and treated with 0.5 µl 
Carbonylcyanide m- chlorophenylhydrazone (CCCP -positive control and inducer of loss 
Table 5.3 Dilution procedure with fresh erythrocytes (varying haematocrits) at days 7, 14 and 
20.  *half removed (150 µl) and transferred to a second plate for day 21 analysis. 
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of mitochondrial membrane potential) and incubated for 5 min in a humidifying chamber 
at 37 
o
C and 5 % CO2. Following a single washing step with PBS JC-l (Molecular probes, 
Invitrogen, USA) was added to each tube to a final concentration of 6 µM (1.5 µl of stock 
solution into 50 µl parasite suspension). The samples were then incubated for 30 mins in a 
humidifying chamber at 37 
o
C and 5 % CO2. Parallel samples (Control, CCCP treated, and 
DHA treated) were also taken for SYBR Green staining (Chapter 2 section 2.4).  
Following staining samples were washed 3 x with PBS and analysed using flow cytometry 
(BD FACsVerse flow cytometer). The FITC and PI channels were used for JC-1 Green 
and JC-1 Red staining respectively.  Red staining was also confirmed by fluorescence 
microscopy (Nikon Eclipse TE2000-S) see Appendix IX. 
5.2.7 JC-1 and SYBR Green following chloroquine treatment  
In order to establish whether loss of mitochondrial membrane potential could be detected 
prior to any evidence of parasite death (as determined by SYBR Green staining) a short 
treatment time-course was set up. Trophozoite stage parasites (2 % parasitaemia) were 
treated with a 0.3 µM, 3 µM and 30 µM chloroquine dose range for 7 hours. These 
parameters were consistent with those reported by Ch’ng et al. (2010) previously shown to 
induced loss of loss of mitochondrial membrane potential. Duplicate samples were set up 
for each treatment including untreated controls. The JC-1 and SYBR Green staining 
procedures were consistent with the methods described above (Section 5.2.5). CCCP 
exposure of additional untreated control samples also served the positive control. 
5.2.8 Loss of mitochondrial membrane potential after atovaquone and emetine treatment 
The experiment was initiated at ring stage with 2 % parasitaemia and 2.5% haematocrit. 
Parasites were treated for 24 or 72 hours with pre-determined IC50 doses of atovaquone 
(0.8 ng/ml or 2.3 nM) and emetine (50 nM). Loss of mitochondrial membrane potential 
was determined by JC-1 staining (Section 5.2.5) concurrently with parasitaemia estimates 
using SG-FCM (Chaper 2 Section 2.2.3). Prior to staining parasite were exposed to CCCP 
treatment (positive control) for 5 minutes as described previously (Section 5.2.5) 
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5.3 RESULTS 
5.3.1 Comparison of cephaeline and emetine dose response 
Despite displaying a tanimoto similarity score of 0.943 with emetine, cephaeline was 
shown to be 6 x more potent against the drug resistant strain with an IC50 of 8 nM 
compared with 47 nM previously reported for emetine (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.2 Comparison of cephaeline and emetine cellular toxicity 
 The HepG2 cell line was used to evaluate the cellular toxicity of cephaeline and emetine. 
At both the 48 and 72 hour time points, there was a shift in the dose-response curves 
between two compounds (Figure 5.3). IC50 determination confirmed that the human cell 
line was more sensitive to cephaeline exposure when compared with emetine. The IC50 
values obtained for the positive control, Cisplatin, were in line with estimates reported 
elsewhere (McAlpine et al., 2014) and served to validate the data (Table 5.4). 
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Figure 5.2 Dose response of cephaeline against P.falciparum, strain K1. The compiled image shows the 
parallel comparison of cephaeline and emetine dose response curves (a). Cephaeline dose response for 
log transformed drug concentrations (b). Nonlinear regression analysis output for accurate IC50 
determination of cephaeline (c) using GraphPad Prism 5.0 (Sy.x indicates the standard deviation of 
residuals).  
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5.3.3 Time-course analysis of dihydroartemisinin and emetine dihydrochloride hydrate  
The results of the time-course indicate that like dihydroartemisinin the effects of emetine 
only become apparent once a subsequent erythrocytic cycle has been entered. These effects 
were further pronounced upon successive cycle progression. However, apart from 
variations in potency, DHA and Eme showed no difference in the time of drug action 
(Figure 5.4). 
 HepG2 IC50 
 Cisplatin 
+ control (µM) 
Emetine 
(nM) 
Cephaeline 
(nM) 
48 h 5.1 + 1.37 25.2 + 2.42 10.8 + 0.64 
120 h 3.6 +  0.33 20.6 + 1.32 9.7 + 0.41 
Figure 5.3 Dose response curves for emetine and cephaeline against HepG2 cells following 48 (a) and 
120 (b) hours of exposure. Cell viability was determined using the standard MTT assay. Error bars 
represent triplicate data. 
Table 5.4 IC50 values for the positive control, cisplatin, and the two test compounds emetine and 
cephaeline against the HepG2 cell line. Both the 48 and 120 hour time points were evaluated. IC50 values 
were determined using nonlinear regression (GraphPad Prism 5.0) Averages are based on triplicate data. 
Standard error values for each estimate are also shown. 
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  0 h   24 h           48 h                                72h 
Late Troph/Early  Schizont     Early Ring           Late Ring/ Trophozoite         Schizont/ Ring 
Figure 5.4 Time-course analysis of dihydroartemisinin (DHA) in parallel with emetine (Eme) and the combination.  The respective 
IC50 doses of DHA, Eme and the combination (IC50 + IC50) were added at late trophozie/schizont stage and analysed at 24 hour intervals 
during a 72 hour time-course. Drug susceptibility was analysed using the robust SYBR Green flow cytometer method to permit 
differentiation between mononuclear and multinuclear parasite stages. Giemsa staining of control samples was also used for 
confirmation of parasite progression through erythrocytic cycle. 
 
 
 
5µm 
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Further investigation into stage-specific analysis (mononuclear vs multinuclear) revealed 
interesting variations in parasite progression patterns during the course of drug treatment. 
For dihydroartemisinin-treated samples, progress into the multinucleated schizont form 
imitated that of the untreated control samples. Emetine-treated samples, on the other hand 
showed a reversed pattern, representing a delay in parasite development. This data was 
corroborated by the fact that the combined effect of the drugs appeared to display a true 
amalgamation of the two (Figure 5.5). 
 
 
Figure 5.5 In vitro stage progression of P. falciparum K1 parasites following exposure to 
dihydroartemisinin and emetine Trophozoite stage parasites were treated with IC50 DHA (2.5 nM) and IC50 
emetine (50 nM) either alone or in combination for a 24, 48 and 72 hour time-course. The percentage of 
multinuclear cells (schizont) as a proportion of the total parasitaemia was recorded for each condition at 
each time point. The total parasitaemia is indicated by the numbers above bars. 
 
5.3.4 Stage-specific effects 
Stage-specific effects show that treatment directed specifically against ring or trophozoites 
stage parasites for only a 6 hour period is capable of significantly reducing growth relative 
to controls by about ~ 20% in both cases (Figure 5.6).  
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5.3.5 Determination of the parasite killing profile for emetine against P. falciparum K1  
SG-FCM was used to analyse productive re-growth upon removal of the drug after 20 and 
28 days of recovery. The data showed that the most diluted well able to render growth was 
dependent on the initial drug treatment period (Figures 5.7 and 5.8) Triplicate data was 
generally consistent between samples. Discrepancies only appeared where it was evident 
that the last viable parasite had been transferred to the subsequent dilution, in some cases 
leaving no evidence of growth in the previous dilution.  Parasitaemia estimates from each 
replica were displayed separately. This was to prevent data based on averages confounding 
the definition of parasite growth at each dilution in a presence or absence manner. Both the 
21 day (Figure 5.7) and 28 day (Figure 5.8) data indicated that emetine induced a lag phase 
in parasite killing of approximately 48 hours (Figure 5.9). Parasites were not able to 
withstand emetine exposure for 96 and 120 hours periods (Figure 5.9). The direct measure 
of parasite killing rate, the parasite reduction ratio (PRR) was determined by a decrease in 
parasite killing during 48 hours of the maximal killing phase, and the parasite clearance 
Figure 5.6 Stage-specific cytostatic/ cytocidal analysis of emetine. Ring (a) and trophozoite (b) stage 
parasite were treated for 6 hours before washing and removal of the drug and a further incubation of 42 
hours. A parallel 48 hour exposure to emetine was also set up. Different letters indicate data that is 
significantly different as determined by one-way ANOVA (GraphPad Prism 5.0) 
A 
B 
C 
D 
E E
a 
Trophozoite stage
Washed Not washed
0.0
0.5
1.0
1.5
Control
IC50
10 X IC50
P
a
ra
s
it
e
 g
ro
w
th
 (
%
)
A 
A 
B B 
C C 
Chapter 5: Antimalarial activity of emetine dihydrochloride hydrate 
101 
 
time (PCT), the time needed to clear 99.9% of the parasite population, are shown in Table 
5.5. When compared with a panel of existing antimalarials, the killing profile of emetine is 
most consistent with that of atovaquone. 
 
 
Figure 5.7 The recovery of parasite productive growth following emetine exposure, day 21 analysis. 
SYBR Green Flow cytometry was used to determine parasite regrowth on day 21. Parasites were 
subjected to the limiting serial dilution (aliquots corresponding to 10
5
 parasites) following emetine 
exposure for either 0, 24, 48, 72, 96 and 120 hours treatment periods. Triplicate data points are 
shown separately to permit accurate determination of parasite growth at each dilution in a presence 
or absence manner. Axis breaks are present where data was not collected due to the consistency of 
the surrounding readings.  
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Figure 5.8 The recovery of parasite productive growth following emetine exposure, day 28 
analysis.  Day 28 data provides confirmation of parasite regrowth at day 21. Following treatment 
with emetine for either 0, 24, 48, 72, 96 and 120 hours an aliquot of 10
5
 parasites was washed 3 x to 
remove the drug and subjected to limiting serial dilution. Parasitaemia was determined after a 28 
day recovery period using SYBR Green Flow cytometry. The raw data was used to determine the last 
dilution at each time point able to render growth. Axis breaks are indicative of absent data points.  
Chapter 5: Antimalarial activity of emetine dihydrochloride hydrate 
103 
 
 
 
 
 
 
 
 
 
Figure 5.9 Plasmodium falciparum strain K1 viability time-course for treatment with emetine 
dihydrochloride hydrate after 21 days and 28 day of recovery. Error bars represent triplicate data and the 
experiment was repeated twice. The Y axis shows (log viable parasite +1) to allow representation of 
logarithms when number of viable parasites is equal to zero. 
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5.3.6 Parallel staining with JC-1 and SYBR Green  
Figure 5.11 shows the gating procedure used, for JC-1 stained malaria parasites on the 
BDFACsVerse flow cytometer system, to obtain the percentage data shown Figure 5.12. 
The results indicated that the percentage of fluorescent events was comparable between the 
SYBR Green and JC-1 controls and DHA treated samples. In the CCCP treated sample, 
however, staining with SG and JC-1 was not consistent (Figure 5.12). The results showed 
that CCCP was effective in inducing loss of mitochondrial membrane potential in the 
malaria parasite, as shown by the reduction in JC-1 red fluorescence staining, while SYBR 
Green stained DNA remained intact (Figure 5.12). The lack of staining in the CCCP 
treated sample is also visible in fluorescence images taken in parallel (Appendix IX).The 
results showed some level of background fluorescence in the uninfected blood sample, 
particularly with the red analysis channel (Figure 5.11). Both JC-1 and SG staining 
appeared reduced in the DHA sample, after 48 hours of treatment, when compared with 
the untreated control (Figure 5.12).  
 
 
 
a b Infected 
Figures 5.11 Flow cytometer analysis of JC-1 stained P. falciparum. Dot plots of FITC against Propidium 
Iodide are shown for JC-1 stained blood only (a) infected control (b) CCCP treated (c) and DHA (d) 
samples. Colours indicate the gating procedure used to obtain statistical data. 
d c 
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5.3.7 JC-1 and SYBR Green following high-dose chloroquine treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results showed that loss of mitochondrial membrane potential can be induced by high 
concentrations of chloroquine (Figures 5.13). The positive control (CCCP treatment) was 
effective in the current experiment and background staining in the uninfected blood sample 
did not interfere with the results. While JC-1 staining was reduced, SYBR Green staining 
remained constant throughout the treatment series (Figure 5.13). 
 
Figure 5.12 The percentage of fluorescent events recorded for parallel JC-1 and SYBR green staining 
of P. falciparum using the BDFACsVerse flow cytometer. Parasites were exposed to 
dihydroartemisinin (DHA) or CCCP (positive inducer of los of mitochondrial membrane potential). 
Blood only and infected blood served as controls. JC-1 staining was determined using the FITC (JC-1 
green) and Propidium Iodide (JC-1 red) channels. The gating procedure is shown in figure 5.11.  SYBR 
Green staining was performed in parallel to confirm percentage parasitaemia. Fifty-thousand events 
were recorded for each condition in both assays. 
Figure 5.13 Parallel JC-1 and SYBR Green staining of P. falciparum following 7 hour exposure to a high 
dose series of chloroquine. Strain K1 parasites were treated with high doses of chloroquine in an attempt 
to replicate finding of the Ch’ng et al (2010) and induce loss of mitochondrial membrane potential 
(reduction in JC-1 staining) during a short < 8 hour treatment period. The number of fluorescent events 
recorded for red and green JC-1 staining was pooled and compared with overall parasitaemia as 
determined by SYBR Green flow cytometry.  
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5.3.8 The effect of emetine on mitochondrial membrane potential 
The results of the JC-1 assay showed that after 24 hours of incubation, emetine is capable 
of inducing loss of mitochondrial membrane potential in P. falciparum K1 parasite strain 
at a physiologically relevant IC50 dose. What is more, the extent of mitochondrial 
depolarization was similar to that of atovaquone, a drug known to act via the mitochondria. 
Both drugs failed to induce mitochondrial depolarization at a level comparable to the 
positive control, CCCP. The SG-FCM data showed that parasitaemia remained consistent 
between the control, CCCP and atovaquone samples. However, the emetine treatment 
showed a 15-30 % reduction in parasitaemia (Figure 5.14 a). The 72 hour data provided 
confirmation that following parasite death the JC-1 assay can be used as a readout for 
parasite survival by staining the remaining live parasites. The decrease in red/green ratio 
was less marked in the ATQ and Eme treatments at this time point (Figure 5.14 b). 
 
 
 
 
 
 
 
 
Figure 5.14 Parallel JC-1 and SYBR Green staining of parasites exposed to IC50 doses of atovaquone 
and emetine for 24 hours. Drug treatment as initiated at ring stage and analysed at 24 (a) and 72 (b) 
hour time points for mitochondrial depolarization using the JC-1 assay. SG-FCM was completed to 
determine parasitaemia. CCCP treatment and untreated samples served as positive and negative 
controls, respectively. CCCP treatment was initiated immediately before staining for 5 minutes. As an 
indicator of loss of mitochondrial membrane potential the ratio of JC-1 Red/ JC-1 Green fluorescence 
was determined and plotted on a secondary axis. Error bars represent duplicate data. 
 
Chapter 5: Antimalarial activity of emetine dihydrochloride hydrate 
107 
 
5.4 DISCUSSION 
5.4.1 Comparison between emetine and its natural derivative, cephaeline 
The data showed that despite a tanimoto similarity score of 0.94, the slight structural 
difference between cephaeline and emetine resulted in a 6-fold shift in potency against the 
malarial parasite. Indeed cephaeline has been shown elsewhere to have potent activity 
against P. falciparum strains W2 and D6 (Muhammad et al., 2003). The increase in 
potency presented here was, however, accompanied by a 2-fold increase in toxicity against 
the mammalian cell line HepG2, indicating that the structural difference between the two 
compounds does not favour the antimalarial development of cephaeline. This is in contrast 
to the finding of Muhammad et al. (2003) who showed that against Leishmania donavani, 
cephaeline is equally potent and 12 x less toxic against VERO cells when compared with 
emetine. Although, the study did show cephaeline to be toxic against four different human 
cancer cell lines (Muhammed et al., 2003). Due to the recent interest in emetine for the 
treatment of other parasitic diseases, particularly the trypanosome infections, more in vitro 
toxicity information about emetine in human cell lines has become available. While IC50 
values for bloodstream forms of Trypanosoma brucei (39-40 nM) were comparable to 
animalarial potency, there was a 24-fold increase in the IC50 (900-970 nM) against the 
human promyelocytic leukemia cell line, HL60 (Meschjohann, 2000; Rosenkranz and 
Wink, 2008). The Novartis-GNF screen, from which compounds were selected for the 
malaria box, determined IC50 values for emetine, against P. falciparum  3D7 (drug 
susceptible) and W2 (chloroquine, quinine, pyrimethamine, cycloguanil, and sulfadoxine-
resistant) strains as well as Huh7 (human hepatocellular carcinoma cell line), as 10 nM, 20 
nM and 116 nM respectively. Taken together, the parasite potency and cytotoxicity data 
presented elsewhere provides a slightly better safety margin than would be predicted by 
our current study. In accordance with the data presented here, however, Akinboye et al. 
(2012) reported IC50 values for emetine of 24-33 nM against the prostate cancer cell lines 
PC3 and LNCaP, but showed that they were able to reduce cytotoxicity through 
derivatisation of the N-2 position of the compound. In order to increase the therapeutic 
index of emetine for anticancer therapy the group created pH dependent prodrugs by 
modifying the N-2 position with thiourea, urea, sufonamide, dithiocarbamate, carbamate 
and amide analogs. The derivatives were shown to less cytotoxic in vitro (0.079-10 µM 
IC50). Further in vivo investigation of two of the analogs revealed no side effects in mice 
administered with 100 mg/kg for 5 days, while the comparable dose of emetine killed the 
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mice within 48 hours (Akinboye et al., 2012.). However the N-2 position along with N-5 
and C-9 have been reported as important functional moieties for biological activity 
(Akinboye and Bakare, 2011). Whether this is also the case for antimalarial activity is yet 
to be determined. This data along with the existence of the less toxic derivative, 
dehydroemetine, infers that small structural changes can alter on-target and off-target 
effects of this class of compounds. For this reason, emetine is a good starting point for a 
novel class of antimalarials. Further work, therefore, focused on the characterisation of 
emetine’s antimalarial killing profile.  
5.4.2 Time-course analysis of emetine  
The necessity of combination therapy for malaria treatment and the need for appropriate 
pharmacokinetic matching of compounds has emphasised the importance of defining a 
compound’s killing profile.  As artemisinins are known to be a fast acting antimalarials 
(Krishna et al., 2004; Sanz et al., 2012) the killing profile of emetine was compared with 
that of dihydroartemisinin during a 72 hour time-course. Both drugs were shown to induce 
a slight reduction in parasitaemia after 24 hours and the effect became more pronounced as 
the time-course progressed. On closer inspection of parasite stages, it can be noted that the 
drug induced reductions in parasitaemia were detected once the parasites had entered a 
subsequent erythrocytic cycle. The increase in parasitaemia between the 24 and 48 hour 
time points is possibly reflective of parasites during the schizont to ring transition at 24 
hours becoming fully established and therefore detectable by SG-FCM at 48 hours.  The 
result presented here would indicate that emetine is as equally fast acting as 
dihydroartemisinin, whether this is an artefact of the SG-FCM assay or true reflection on 
mode of drug action is questionable. Indeed, Wein and colleagues (2010) suggest that a 72 
hour treatment period is required to achieve accurate results with the SYBR Green-based 
methods (Wein et al., 2010). The issue is that arrested or dying parasites may be recorded 
as live due to the residual intact DNA inside the red blood cells. However, it is not only the 
selected drug susceptibility read-out that can be deceptive, but also drug mode of action. 
The phenomenon known as the post antibiotic affect (as it most commonly in response to 
antibiotic treatment) occurs when organisms are considered alive even though they are 
condemned/committed to death (Renneberg and Walber 1989; Zhannel et al., 1991). In 
some cases, even after a short drug exposure period, drug effects are not observed until a 
second or third round of replication (Pasini et al., 2013). The reverse can also be true, 
cytostatic organisms can appear dead but are dormant and can in fact resume productive 
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growth once the drug has been removed (Gorka et al., 2013; Sanz et al., 2012). Although 
there may be a limit to length of drug exposure when the commitment to death is 
irreversible. In contrast to Wein et al. (2010) we have shown elsewhere (Chapter 3) that 
standard IC50 values can be achieved after 48 hour drug exposure providing, SG-FCM 
analysis is completed after the parasite entered into a subsequent erythrocyte cycle.  
Indeed, accurate results have been obtained when experiments were initiated at trophozoite 
stage and analysed 48 hours later, when the parasites were at trophozoite stage in the 
subsequent erythrocytic cycle. Rather than multiplication, viability is determined by 
maturation and the ability to continue development by successfully invading new red 
blood cells. Discrepancies in 48 hour data occur when samples are analysed during 
schziont to ring transition as shown here between the 24 and 48 hour readings. The time-
course data presented here provides confirmation of this method, as the dose of DHA used 
in the current study achieved ~ 25 % inhibition at both the 48 and 72 analysis points. The 
lack of a comparable increase in parasitaemia for the emetine treated parasites at 72 hours 
resulting in different levels of inhibition at the 48 and 72 hour readings (~50% and ~70% 
respectively) could indicate a different mode of action to DHA, where parasite are delayed 
or arrested in their development cycle. Indeed, delayed parasite progression in emetine-
treated samples, compared with the dihydroarteminin treatment, was confirmed by further 
stage-specific interrogation (% multinuclear parasites). Parasites treated with the 
combination, on the other hand, appeared to display interference between the two 
compounds, ultimately leading to further reduction in parasitaemia. It must be noted that 
the combination dose used for each drug was equal to that of the drug alone, so reduced 
growth, following exposure to a drug combination that is not antagonistic, should be 
expected. This preliminary indication of different modes of antimalarial activity justifies a 
potential role for the drug in artemisinin combination therapy. However, the time-course 
data cannot dictate whether the delayed parasite progression induced by emetine is 
cytostatic or cytocidal as a subsequent recovery period in the absence of drug exposure 
was not analysed. Stage-specificity can also not be determined as the drug was present 
throughout all stages of the life cycle. 
5.4.3 Stage-specific effects and cytosytatic vs. cytocidal activity of emetine 
The subsequent experiment aimed to address issues in determining stage specificity and 
cytostatic vs, cytocidal activity. This was achieved by treating either ring or trophozoite 
stage parasites for 6 hours followed by washing and growth in absence of the drug for 48 
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hours. A parallel continuous 48 hour exposure was also set up for comparison. Consistent 
with the method outlined by Gorka et al. (2013) the data would suggest that emetine was 
cytocidal to approximately 20% of parasites after just 6 hours of exposure while the 
greater inhibition at 48 hours could be confounded by the cytostatic activity of the 
compound.  Differences were not huge between IC50 and 10 x IC50 doses and the drug 
appeared similarly effective against both ring and trophozoite stage parasites.  The 
inference that emetine is potentially a fast acting compound who’s target is present in 
multiple parasite stages is consistent with Wong et al, 2014 who established the cryo-EM 
secondary structure for emetine bound to the Pf80s ribosomal complex, verifying the target 
binding site and mechanism of action of emetine against P. falciparum. Given the 
numerous actions of emetine reported in the literature, including but not limited to antiviral 
and anticancer properties (Akinboye and Bakare, 2011) it is possible that the cytosolic 
ribosome is not the only target of drug in the malaria parasite.  Indeed, protein translation, 
one of the key targets of emetine in other organisms occurs in two other centres in the 
malaria parasite: namely, the mitochondria and the apicoplast (Wong et al., 2014). Wong 
et al. (2014) suggest that emetine has a similar binding site to the antibiotic pactamycin.  
In the eukaryotic malaria parasite other antibiotics are known to target two prokaryotic 
structures, the apicoplast and the mitochondria (Schlitzer, 2007). It is therefore possible 
that emetine may also have an effect on protein translation in these organelles. In fact, 
drugs known to target the apicoplast have displayed a delayed death effect similar that of 
the post-antibiotic effect described above (Fiddock, 2008; et al., Kremsner and Krishna, 
2004). This would also imply a cytocidal rather than cytostatic mode of action after 6 
hours treatment with the compound.  Others suggest that emetine specifically targets 
eukaryotic protein synthesis and is not classified as an antibiotic (Mackey et al., 2006).  
Grollman on the other hand showed that emetine acts in a similar manner to glutarimide 
antibiotics and is capable of interfering with ribosomal protein synthesis in mammalian, 
yeasts and plant cells. The resemblance further extended to the finding that extracts of 
E.coli resisted protein synthesis inhibition to both ipecac alkaloids and glutarimide 
antibiotics (Grollman, 1966). However protein synthesis has been shown to be a common 
target in protozoans including Entamoeba histolytica. Therefore, whether the emetine has 
single or multiple targets, of prokaryotic or eukaryotic origin, and the effects that these 
may have on the malaria parasite killing profile remains to be disputed. Contradictory to 
the suggestions of Gorka and colleagues (2013), it cannot be assumed that parasites would 
recover from a cytostatic period, of unknown duration, and achieve parasitamia equating to 
Chapter 5: Antimalarial activity of emetine dihydrochloride hydrate 
111 
 
that of the untreated controls within the 48 hour time-course. The lower parasitaemia in 6 
hour treated samples could reflect parasites that have become dormant, possibly even 
continued with cycle progression but at a slower rate than the unaffected counterparts. 
These parasites may not have entered a subsequent erythrocytic cycle at the time of 
analysis but may be viable and thus capable of doing so in the near future. A longer 
recovery period, in the absence of drug exposure, would therefore be necessary to 
accurately define the action of a compound as cytocidal. The required duration of the assay 
will depend on drug mode of action and rate of kill. Indeed even one of the fastest 
antimalarials, DHA has been known to induce a dormancy response lasting up to 20 days 
(Sanz et al., 2012). For this reason, a more intensive investigation, lasting up to 28 days, 
was set up to determine emetine’s speed-of-kill against P. falciparum strain K1. 
5.4.4 Detailed killing profile analysis of emetine against P. falciparum strain K1 
Although the data revealed that emetine has a relatively slow killing profile, which is 
arguably less desirable due to the potential for resistance development if parasites are 
exposed to sub-optimal concentrations, it was within the remit of the existing 
antimalarials. In fact its speed of kill was pharmacokinetically similar to the actions of 
atovaquone. Like atovaquone, emetine was also shown to have a 48 hour lag phase. The 
parasite reduction ratio and parasite clearance times were also similar for the two 
compounds ranging from 2.9-3.7 and 90-93 hours respectively. Sanz et al. (2012) showed 
that when IC50 or in some cases 3 x IC50 doses were used for slow, medium and fast acting 
compounds the of killing rate of the compound was compensated by growth in the treated 
culture. Thus in agreement with their finding the current study adopted 10 x the IC50 of 
emetine to achieve the maximal killing rate. The advantages of the killing profile assay 
described by Sanz et al. (2012), and replicated here, are that it accurately measures parasite 
viability over time in response to drug treatment. The extended recovery period of up to 28 
days means that the assay avoids erroneous interpretations of the dormancy response or 
post-antibiotic effect that often arises when metabolism, the accumulation of specific 
molecules or, as described above, DNA content are used as surrogates for parasite viability 
during or immediately after drug treatment. Indeed, drug treatment commonly induces an 
uncoupling of such parameters. Due to evidence of a good correlation between in vitro and 
in vivo PRR, the assay also permits some predictions about the in vivo situation. The in 
vitro PRR, a direct measure of parasite viability tends to be higher than the in vivo estimate 
that measures clearance of the parasite by the organism and is thus affected by a multitude 
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of pharmacokinetic and pharmacodynamic factors. Furthermore, as the lag phase is not 
affected by drug concentration and the killing rate and clearance times are not related to 
drug potency. The method also provides some information about the intrinsic mode of 
action of a compound. Sanz et al., 2012 showed that compounds with similar rates of kill 
have similar modes of action. Indeed, two artemisinin derivatives, artesunate and 
artemether and two compounds known to impair mitochondrial function GW648495X and 
GW844520X, displayed similar reduction ratios and clearance times to artemisinin and 
atovaquone respectively. It is therefore possible that emetine has a similar mode of action 
to atovaquone.  Atovaquone is known to act via the bc1 complex of parasite mitochondria 
through electron transport inhibition, ultimately impairing pyrimidine biosynthesis (Sanz 
et al., 2012). Destabilization of the bc1 complex causes proton leakage and leads to 
mitochondrial depolarization (Srivastava and Vaidya, 1999).  As an inhibitor of 
RNA/DNA and protein synthesis, the bacteria-like translation machinery of the 
mitochondria may therefore be another target of emetine. In cancer cells Boon-Unge et al. 
(2007) showed that emetine regulates alternative splicing in the Bcl-x gene, shown to be 
dependent on protein phosphatase 1, resulting in alterations in pro-apoptotic (Bcl-xS) and 
anti-apoptotic (Bcl-xL) ratio promoting apoptosis (Boon-Unge et al., 2007). The drug has 
also been linked to the induction of mitochondrial-dependent apoptosis in T. brucei. 
Rosenkranz and Wink, 2008 also showed that loss of mitochondrial membrane potential 
was accompanied with other programmed cell death phenotypes such as DNA 
fragmentation (Rosenkranz and Wink, 2008). 
5.4.5 The effect of emetine on malaria parasite mitochondria 
A study investigating mitochondrial depolarization in response to atovaquone treatment 
showed that parasites were able to withstand mitochondrial membrane disruption for up to 
48 hours before the commitment to death was irreversible (Painter et al., 2010). This is 
consistent with the 48 hour lag phase of atovaquone determined by the Sanz group (Sanz et 
al., 2012).  As emetine treatment also presented a similar lag phase to atovaquone, it is 
unlikely that the previous experiment of 6 hours of emetine exposure was due to cytocidal 
effects of the drug.  Painter and colleagues (2010) suggested that apoptosis did not ensue 
after mitochondrial disruption due to differences between metazoan and protozoan 
apoptosis pathways. In the protozoan parasite however, Ali and colleagues (2010) showed 
that induction of loss of mitochondrial membrane potential is accompanied with other 
markers of apoptosis such as caspase activity, although an apoptosis pathway independent 
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of the mitochondria may also exist (Ali et al., 2010; Matthews et al., 2012). It is possible 
that in some cases, rather than being a direct target of the mitochondria, loss of 
mitochondrial potential occurs as an indirect effect of parasite death, particularly when 
high, physiologically irrelevant doses are used. Indeed, a number of compounds have been 
reported to affect mitochondrial physiology at high concentrations (Srivastava and Vaidya, 
1999). In order to analyse whether a drug is acting via the mitochondria, the time-course 
and dose will be important. 
Mitochondrial depolarization can be determined by the JC-1 assay. Recently the assay has 
also been used as a readout for parasite viability (Pasini et al., 2013). In this case JC-1 
fluorescence is an indicator of the intact mitochondria of live parasites. The preliminary 
data presented here shows a comparable decrease in JC-1 and SYBR green staining 
following a 48 hour treatment period with DHA compared with non-treated controls. The 
results also confirmed that 5 minutes of treatment with CCCP (positive inducer-known to 
effect protein synthesis in the mitochondria) is capable of inducing loss of mitochondrial 
membrane potential in Plasmodium falciparum parasites without effecting DNA. This is 
consistent with the chronology of apoptosis where loss of mitochondrial membrane 
potential is an early early-onset feature of programmed cell death and DNA degradation is 
the end point (Ch’ng et al., 2010).  The comparability between SG and JC-1 staining 
served to validate the assay and the staining procedure adopted in the current study. In 
order to determine whether the assay can be used to help decipher antimalarial mode of 
action, loss of mitochondrial membrane potential was induced in a dose-dependent manner 
after 7 hours of incubation with chloroquine. These parameters were consistent with the 
Ch’ng group (2010) who induced loss of mitochondrial membrane potential within 6 
hours, using higher concentrations of chloroquine. During the short time-course of 
chloroquine exposure presented here the reduction in JC-1 staining was not accompanied 
by a decrease in SYBR Green. This  provides proof-of-concept that parasites can display 
physiological changes like loss of mitochondrial membrane potential in response to drug 
treatment prior to death as determined by DNA content. These high concentrations are 
confounded by toxicity issues and are therefore unlikely to reflect the true mode of drug 
action (Srivastava and Vaidya, 1999). 
Therefore, in the subsequent investigations, physiologically relevant concentrations of 
emetine were used to establish whether the drug has an effect on parasite mitochondria. 
Ring stage parasite were treated with the IC50 dose of the drug for 24 hours. Atovaquone, a 
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drug known to act via the mitochondria, with which emetine shares a similar killing profile 
was included in the assay at its respective IC50.  A 24 hour time point was selected as 
atovaquone has been shown to be capable of mitochondrial disruption for up to 48 hours 
before parasite death ensues. SG-FCM staining was used in parallel to ensure that any 
effects observed were not due to reductions in parasiteamia. The results showed that after 
24 hours, a reduction in JC-1 staining and a shift from red to green fluorescence (as 
determined by the red/green ratio) was observed at a similar magnitude for both ATQ and 
Eme. Staining in untreated control samples however was consistent between the SG and 
JC-1 assays. The positive control CCCP showed a more pronounced reduction in JC-1 
staining and a greater shift from red to green fluorescence than either of the drug treated 
samples. As parasites were only subjected to a 5 minute treatment period with CCCP, a 
shorter time-course for treatment with the test compounds may permit more informative 
data. Indeed, Srivastavava and Vaidya (1999) analysed mitochondrial membrane 
disruption in response to atovaquone and other existing antimalarials by staining parasite 
with the DiOC6(3) (3,3'-Dihexyloxacarbocyanine Iodide) probe for 20 minutes followed 
by a drug treatment period of 20 minutes before analysis (Srivastava and Vaidya, 1999). 
Although the JC-1 ratio was consistent between the atovaquone and emetine samples, 
some reduction in parasitaemia as indicated by SG, was observed in the emetine treated 
sample, potentially inferring that in addition to effects on the mitochondria emetine may 
also be operating via other targets in the parasite. The 72 hour data confirmed parasite 
death in response to drug treatment. The comparability between SG and JC-1 staining 
inferred that the 72 hour analysis was indicative of the remaining live parasites. The 
reduction in red/green ratio was also much less pronounced at this time point, indicating 
that parasites affected by ATQ and Eme treatment had already died. The data therefore 
further validates the JC-1 assay as a read-out for parasite viability, providing an 
appropriate time-course is adopted. 
5.4.6 Conclusion 
Taken together the current data suggest that emetine has a similar killing profile to the 
existing antimalarial atovaquone. Primary data presented here infers that like atovaquone, 
emetine may target the mitochondria in the malaria parasite. However given the bioactive 
nature of the compound it is likely that other targets, in addition to the 80s cytosolic 
ribosome, exist. The detailed in vitro analysis of emetine provides a good background for 
defining appropriate treatment regimes for in vivo analysis of the drug. In the in vivo 
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situation it is important to maintain the inhibitory concentration for longer than the parasite 
is able to stay alive (Painter et al., 2010). As an ameobicide, emetine was given for 6 days 
with further treatments after day 9. The data presented here confirms that 99.9% of malaria 
parasites are killed after 90 hours of treatment with the drug which has beneficial 
implications for the safety profile of emetine. Reducing the number of doses may help 
avoid cardiotoxic issues due to high cumulative concentrations of the compound. 
Derivitisation and novel drug delivery system may also lead to safer alternatives. Details 
about the pharmacokinetic profile presented here can also be used to inform decisions 
about appropriate combinatory options for the drug, with the aim to further reducing drug 
doses. The wealth of existing information on emetine and its analogues and the potential 
for investigations into structral activity relationships suggest that this molecule, discovered 
through repositioning, is uniquely placed to be advanced through rational drug design with 
the aim of delivering an affordable, effective and safe natural product drug class for 
malaria.
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CHAPTER 6 
DRUG INTERACTION ANALYSIS OF EMETINE DIHYDROCHLORIDE HYDRATE 
6.1 INTRODUCTION  
The high priority for effective combinatorial regimes means that the analysis of drug 
interactions has become an important part of the antimalarial drug development pipeline 
(Bell, 2005). There is a limited number of chemotherapies available and novel candidates 
are usually combined with existing treatments (Bhattacharya et al., 2009; Kremsner and 
Krishna, 2004; Sahu et al., 2014). This is because the development of two novel 
compounds is doubly challenging and the benefits of the recent high-throughput 
phenotypic screens are yet to be realised. The current combination therapies recommended 
and available for malaria treatment are discussed elsewhere, along with their 
pharmacokinetic and resistance profiles (Chapter 1). Indeed, the ideal partner drugs for 
malaria treatment should have matching pharmacokinetics, synergise against drug resistant 
strains, be free of significant side effects, be relatively inexpensive and have no other 
antimicrobial activity (Canfield et al., 1995; Kremsner and Krishna, 2004). In order to 
predict whether a particular combination will be efficacious, detailed interaction studies 
should be conducted. The values of combination therapy; namely, (1) better therapeutic 
efficacy, (2) the potential to impede or delay the onset of resistance, (3) dose reduction 
whilst maintaining potency and avoiding and adverse effects, and (4) the potential for 
selective synergism or toxic antagonism, were realised much sooner for disease like 
cancer, AIDS and tuberculosis (Chou, 2010; Fivelman et al., 2004; Kremsner and Krishna, 
2004). Thus, it follows that the numerous methods to analyse drug interactions have 
evolved and been evaluated over the last century (Harasym et al., 2010) (Table 6.1).  
However, the complexity of the task has meant that interpretations of the data has been 
varied resulting in confusion and conflict (Chou, 2006). The the issue predominantly lies 
with determining and defining synergy (Bell, 2005; Chou, 2006). Indeed, synergy can 
occur as a result of the drugs interacting physically or most often as a consequence of each 
drug interacting at the molecular level with (same or different) components of the target 
(Bell, 2005; Zimmermann et al., 2007). Furthermore, a mutual event such as synergism 
has to be disassociated from one-sided events, where one of the drugs has no effect when 
used alone, such as enhancement, potentiation and augmentation (Chou, 2010). It is 
therefore too simplistic too suggest a synergistic outcome is when the combination of 
drugs A and B is greater than either drug alone (A+B > A or A+B > B). For example,  
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if drug A and B each inhibit 60 % the combination cannot inhibit 120 % (Chou, 2006). 
 
 
 
 
 
 
 
 
 
In attempting to identify the desirable occurrence of synergy, experimenters have realised 
that the definition of additivity is most important. Synergism and antagonism are referred 
to as a more than expected or less than expected additive effect, respectively (CalcuSyn 
manual, Biosoft). The majority of interaction methods are therefore based on two 
definitions of additivity Bliss independence and Loewe additivity (Feng et al., 2009; Yeh 
et al., 2009).  Bliss independence (fractional product method) assumes that each drug acts 
independently. Therefore the issue of both drugs inhibiting 60% is resolved by the 
definition that additivity = 1- [(1-A)(1-B)] in this case 1-[(1-0.6)(1-0.6)] = 0.84 so to be 
additive A + B would be expected to achieve 84% inhibition and deviation above or below 
this would be considered as synergistic or antagonistic respectively. Loewe additivity on 
the other hand dictates that a drug cannot interact with itself. Therefore if in fact A and B 
were the same drug the interaction can only be additive so 0.5 A and 0.5 B should be 
expected to achieve the same effect as drug 1 A or 1 B.  Drug combinations are therefore 
additive if inhibition is constant along a line of equal effective dose. Hence the approach 
uses a line of constant inhibition (isobole) to define additivity. Deviations above the line 
(convex) are antagonistic and deviations below the line (concave) synergistic (Yeh et al., 
2009; Zimmermann et al., 2007). After nearly 100 years of use the isobologram method 
remains one of the most trusted and widely accepted methods for determining synergy 
(Bell, 2005).  Most commonly the malaria community have adopted either the 
checkerboard or fixed ratio methods to obtain data for isobologram preparation (Abiodun 
et al., 2013, Bhattacharya et al., 2009; Fivelman et al., 2004; Fugi et al., 2010; Gupta et 
Drug interaction evaluation models Date 
Isobologram  1870 
Loewe additivity  1926 
Bliss independence response surface approach 1939 
Fractional product method of Webb   1963 
Multivariate linear logistic model  1970 
Approach of Gessner   1974 
Method of Valeriote and Lin  1975 
Method of Drewinko et al.   1976 
Interaction index calculation of Berenbaum  1977 
Method of Steel and Peckman  1979 
Median-effect method of Chou and Talalay  1984 
Method of Berenbaum   1985 
Method of Greco and Lawrence  1988 
Method of Pritchard and Shipman  1990 
Bivariate spline fitting (Sühnel) 1990 
Models of Greco et al.  1990 
Models of Weinstein et al.  1990 
Table 6.1 Various drug interaction models that have been developed and used since (1870) 
(After: Harasym et al., 2010) 
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al., 2002; Sahu et al., 2014). The two methods employ different treatment regimes to 
characterise the drug interactions. In the checkerboard method the concentration of drug 
‘A’ remains constant while the concentration of drug ‘B’ is varied and vice versa. While 
the fixed ratio method, originally developed to test drug interactions against bacteria, 
involves the serial dilution of both drugs at a range of fixed ratios (Fidock et al., 2004). In 
addition to the isobologram, the sum of the fractional inhibitory concentration (∑FIC) is 
calculated and the numerical output used to categorise the nature of the interaction at a 
particular level of inhibition (IC50, IC90). A value <1 is synergism, equal to 1 is additivity, 
>1 is antagonism).  However the lack of standardised methods between different research 
groups, in particular the ∑FIC cut-offs for classifying an interaction as synergistic, 
additive or antagonist has meant that inconsistent inferences have appeared throughout the 
literature (Canfield et al., 1995; Fivelman et al., 2004; Gorka et al., 2013; Mariga et al., 
2005). This is not unique to malaria drug interactivity studies and has in fact plagued the 
field of combinatory drug analysis over many decades. The lack of consensus, prompted 
efforts by Chou and Talalay to attempt resolution of the problem. Initially Chou aimed to 
define additivity in accordance with the theories outlined above and emphasised that 
equations can only be used to define additivity (Chou, 2010). Chou also argues that 
synergy is a physiochemical rather than statistical issue. Instead, Chou employed the 
physiochemical principle of the mass-action law and the mathematical principle of 
induction and deduction to create the median effect equations (Figure 6.1) (also referred to 
as the general theory of dose-effect analysis). Remarkably, the general theory of dose and 
effect has been proven to be a unified theory of four existing physiochemical equations 
namely; Henderson-Hasselbalch (pH ionization), Hill (higher order ligand binding 
saturation), Michaelis-Menten (enzyme kinetics), and Scatchard (receptor binding). After 
35 years of research, the complex algorithms of median effect analysis were incorporated 
into a series of software programmes (CalcuSyn, CompuSyn), to permit the automated 
analysis, now widely employed in biomedical science (Chou, 2010; Feng et al., 2009; 
Harasym et al., 2010), even for other parasitological diseases (Corral et al., 2014; Keiser et 
al., 2011; Keiser et al., 2012; Hu et al., 2010)  The advantages of the programmes are that 
they are capable of performing multiple-drug dose-effect calculations using the median 
effect method based on both the inputted data and values predicted by the mathematical 
models. Unlike the other methods, the entire shape of the growth inhibition curve is taken 
into account and the effects of the drug combination are quantified to see if they have 
greater effects together than expected from a simple summation of their individual effects 
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(Chou, 2010).  Read-outs for this method are similar to that of the fixed ratio method and 
include the combination index, the isobologram plot and the dose reduction index, the 
equations for which are derived from the median effect equation (Figur 6.1). Although cut-
off criteria for the combination index are comparable to those used for the ∑FIC 
calculation, the different degrees of synergism, additivity and antagonism are clearly 
defined providing a more stringent and accurate categorisation of the interaction 
(CalcuSyn manual 1996-2006).  Applying an automated, non-subjective method to malaria 
drug interaction studies would help standardise interaction classifications and permit more 
reliable comparisons between research groups. 
 
 
In order to triage the potent antimalarial candidate emetine dihydrochloride hydrate, the 
nature of its interaction with the existing antimalarials chloroquine, dihyhdroartemisin and 
atovaquone will be determined. Initially, the study will aim to validate the CalcuSyn 
method for malaria. This will be achieved by comparison with one of the existing methods, 
previously adopted by the malaria community, to analyse the interaction between emetine 
and dihydroartemisin. For this, the fixed ratio method was nominated due to the following 
Figure 6.1 The derivation of the Median-Effect Principle and its extensions to Multiple Drug Effect 
Equation (After: Chou, 2006) 
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advantages: it is not affected by the day to day variations of predetermined IC50 values, 
fewer calculation steps are required, IC50 calculations and regression curve fits are more 
accurate due to the generation of dose-response curves for each ratio calculated on the 
basis of 100-0 % parasite inhibition (Fivelman et al., 2004).  The combination will then be 
repeated using the CalcuSyn method so that comparisons can be drawn. Secondly, 
atovaquone-proguanil combination, known to be synergistic against malaria and 
commonly used in the field, will be evaluated using CalcuSyn to establish whether the 
expected classification will be assigned. 
6. 2 METHODS 
6.2.1 Fixed ratio drug interaction assay 
To investigate whether the combined effects of emetine hydrochloride hydrate were 
synergistic, additive or antagonistic, an interaction assay previously described by 
Bhattacharya et al., (2009) was employed. Dihydroartemisinin and emetine 
dihydrochloride hydrate were combined in four fixed ratios 4:1, 3:2, 2:3 and 1:4. In 
addition, each drug was administered alone for direct comparison with the combinations, 
hereafter referred to as the 5:0 and 0:5 ratios.  Approximately eight-fold IC50 values were 
used as 100% (8 x IC50 DHA = 20 nM and 8 x IC50 Eme = 400 nM). Thus for the first 
dilution the combinations were as follows for DHA (nM) : Eme (nM) 20:0, 16:80, 12:160, 
8:240, 4:320 and 0:400 respectively. For each dilution thereafter drug concentrations were 
serially diluted two-fold. The IC50 for each compound (at the 5:0 and 0:5 ratios) therefore 
lay within the fourth dilution. Once drug stocks had been prepared in RPMI 1640, 
trophozoite stage parasites were diluted to ~ 0.5 % parasitaemia and transferred into 
individual 5 ml treatment and control flasks at 5 % haematocrit. Parasites were then treated 
with the various drug combinations, gassed (as described previously) and incubated for 48 
hours at 37 
o
C. Duplicate preparations were set up for each ratio at each dilution. 
Following treatment, samples were analysed using SG-FCM. Giemsa staining of thin 
blood smears was also employed to permit parasite stage confirmation. 
6.2.2 Isobologram preparation and analysis for fixed ratio data 
Drug interaction studies for emetine dihydrochloride hydrate and dihydroartemisinin were 
performed using a modification of the fixed ratios method, employing 4 fixed ratios of 4:1, 
3:2, 2:3 and 1:4. IC50 values were determined for each compound at each ratio as described 
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above and used to calculate fractional inhibitory concentration for each ratio using the 
equation below. Drug interactions were analysed both at IC50 and IC90 values. 
FIC = Fraction of drug concentration require to produce IC50 when used in combination   
                Fraction of drug concentration require to produce IC50 when used alone 
 
The FIC values for dihydroartemisinin at each ratio were then plotted against those 
calculated for emetine to obtain the isobologram trends. To investigate the interaction 
between dihydroartemisinin and emetine at each ratio the calculated FIC values for each 
compound were then added together to obtain the sum of the fractional inhibitory 
concentration (∑FIC) as per equation below.  
 
SumFIC (∑FIC) = IC50 of A in mixture + IC50 of B in mixture 
                              IC50 of A alone             IC50 of B alone 
Criteria consistent with Bhattacharya et al. (2009) were used to determine whether the 
effects of the combination were synergistic, additive or antagonistic. In brief, when the 
sum FIC calculations ∑FIC < 1 synergism, ∑FIC > 1 and < 2 additive, interaction, ∑FIC > 
2 and < 4 slight antagonism, ∑FIC > 4 marked antagonism. 
6.2.3 Application of the CalcuSyn assay to define antimalarial drug interactions 
The CalcuSyn software program was developed to quantitatively assess drug interactions 
(Chou, 2010). The method, commonly used in cancer research, requires a different 
treatment regime than those described previously for the checkerboard and fixed ratio 
assays. In the current study, CalcuSyn was used to provide a different perspective on the 
interaction between dihydroartemsinin and emetine dihydorchloride hydrate. A constant 
drug ratio design was set up for the analysis. In brief, the IC50 concentration for each drug 
was taken as a starting point. Below the IC50 three 1:1 dilutions and above the IC50 three 
doubling concentrations were selected to provide a sufficient dose range for each drug. For 
dihydroartemisinin, the doses ranged from 6.3 nM to 40 nM. For emetine the doses ranged 
was from 63 nM to 400 nM. Co-administration of the compounds occurred at each level, 
for example the IC50 of dihydoartemisnin was combined with the IC50 of emetine and 2 x 
IC50 DHA was combined with 2 x IC50 Eme and so forth.  Parasites were treated at 
trophozoite stage and incubated for 48 hours in a 96 well plate format. SYBR Green flow 
cytometry was used to determine drug susceptibility. Triplicate data was converted to an 
average percentage and analysed for the median effect using CalcuSyn software (Biosoft). 
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6.2.4 Validation of the CalcuSyn assay for malaria 
6.2.4.1 Optimisation of drug dosing and treatment period 
In order to validate the CalcuSyn method as a useful tool for analysing drug interactions 
against the malaria parasite, the known synergistic drug combination, Atovaquone and 
proguanil (Malarone), was used.  The initial experiment adopted the treatment regime 
outlined above and the doses selected were based on the respective IC50 values obtained 
previously for atovaquone and proguanil (Chapter 3). Refer to Table 6.2 for the individual 
dosage and plate set up. Triplicate samples were analysed by SG-FCM after 48 hours, the 
quadruplicate samples were used for Giemsa staining.  
  
 
 Due to the lack of a synergistic interaction predicted by the initial data numerous 
optimisation steps were trialled: firstly, the activity of the drug stocks was checked 
(Appendix X) and the experiment was repeated with an increased atovoaquone dose series 
to account for a slight shift in the IC50 (Table 6.3). Samples were analysed for parasite 
growth as described above for the ATQ-PG first experiment.  
  
 
The second experiment was also unsuccessful in demonstrating synergy. A third 
experiment was designed to analyse the effect of treatment duration and the potential for 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Control Control Control 
B ATQ 0.0875 ng/ml 0.0875 ng/ml +0.575 ug/ml PG 0.575 ug/ml 
C ATQ  0.175 ng/ml 0.175 ng/ml + 1.15 ug/ml PG  1.15 ug/ml 
D ATQ  0.35 ng/ml 0.35 ng/ml + 2.3 ug/ml PG  2.3 ug/ml 
E ATQ  0.7 ng/ml 0.7 ng/ml + 4.6 ug/ml PG  4.6 ug/ml 
F ATQ  1.4 ng/ml 1.4 ng/ml + 9.2 ug/ml PG 9.2 ug/ml 
G ATQ  2.8 ng/ml 2.8 ng/ml + 18.4 ug/ml PG 18.4 ug/ml 
H ATQ  5.6 ng/ml 5.6 ng/ml + 36.8 ug/ml PG 36.8 ug/ml 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Control Control Control 
B ATQ 0.175 ng/ml 0.175 ng/ml +0.575 ug/ml PG 0.575 ug/ml 
C ATQ  0.35 ng/ml 0.35 ng/ml + 1.15 ug/ml PG  1.15 ug/ml 
D ATQ  0.7 ng/ml 0.7 ng/ml + 2.3 ug/ml PG  2.3 ug/ml 
E ATQ  1.4 ng/ml 1.4 ng/ml + 4.6 ug/ml PG  4.6 ug/ml 
F ATQ  2.8 ng/ml 2.8 ng/ml + 9.2 ug/ml PG 9.2 ug/ml 
G ATQ  5.6 ng/ml 5.6 ng/ml + 18.4 ug/ml PG 18.4 ug/ml 
H ATQ  11.2 ng/ml 11.2 ng/ml + 36.8 ug/ml PG 36.8 ug/ml 
Table 6.3 The second dose plate set up for analysis of the atovaquone (ATQ) proguanil (PG) 
interaction using the constant ratio design for CalcuSyn.  The ATQ doses were shifted while the 
PG concentrations remained consistent with the previous experiment. 
Table 6.2 The first dose plate set up for analysis of the atovaquone (ATQ) Proguanil (PG) 
interaction using the constant ratio design for CalcuSyn. 
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an order effect. The experiment was simplified by selecting only three dose points (low, 
mid and high) for each compound: namely 0.8, 1.6 and 3.2 ng/ml for atovaquone and 2.4, 
4.6 and 9.2 µg/ml for proguanil.  Parallel treatments were set up for two conditions 
‘together’ or ‘separate’. In the ‘together’ condition compounds were added to the plate 
prior to the addition of the parasitised culture. In the ‘separate’ condition the parasitised 
culture was added to the plate followed by the addition of each compound separately. 
Additional alterations to the previous treatment regime was that the experiment was 
initiated against ring stage parasites not trophozoite and incubated for 72 not 48 hours. In 
the fourth experiment the atovaquone dose was reduced, the drugs were administered 
‘together’ and treatment period employed in the previous experiment (initiated at ring 
stage and analysed 72 hours later) was maintained (Table 6.4). 
 
 
 
 6.2.4.2 Non-constant ratio design 
In order to determine whether the atovaquone-proguanil combination represents true 
antagonism at the ED75 and ED95 levels of inhibition, or whether there was a problem with 
the reliability of the read out method employed, a non-constant ratio design was set up. In 
brief, three dose points were selected for each compound that were previously shown to 
equate to IC25 IC50 and IC75 levels of inhibition for a 72 hour treatment period  (0.05, 0.2 
and 0.8 ng/ml for atovaquone and 2.4, 4.6 and 9.2 µg/ml for proguanil). Each of the three 
doses of atovaquone was combined with each of the three doses of proguanil.  Each dose 
was also administered singly was a control. Untreated and acetonitrile controls were also 
included in the experiment. All treaments were set up in triplicate. The plate was incubated 
under conditions described previously and analaysed at 72 hours using the SG-FCM 
method. Data was plotted to allow visualisation of the absence or presence of a dose 
response for one drug when combined with a constant dose of the second compound. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Control Control Acetonitrile:water 
B ATQ 0.0975 ng/ml 0.0975 ng/ml +0.575 ug/ml PG 0.575 ug/ml 
C ATQ 0.195 ng/ml 0.195 ng/ml + 1.15 ug/ml PG  1.15 ug/ml 
D ATQ 0.39 ng/ml 0.39 ng/ml + 2.3 ug/ml PG  2.3 ug/ml 
E ATQ 0.78 ng/ml 0.78 ng/ml + 4.6 ug/ml PG  4.6 ug/ml 
F ATQ 1.56 ng/ml 1.56 ng/ml + 9.2 ug/ml PG 9.2 ug/ml 
G ATQ 3.12 ng/ml 3.12 ng/ml + 18.4 ug/ml PG 18.4 ug/ml 
H ATQ 6.24 ng/ml 6.24 ng/ml + 36.8 ug/ml PG 36.8 ug/ml 
Table 6.4 Fourth dose plate set up for analysis of the atovaquone (ATQ) proguanil (PG) 
interaction using the constant ratio design for CalcuSyn.  The ATQ doses were reduced but the 
PG concentrations consistent with the previous experiments. 
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6.2.4.3 Recovery of parasites treated with the atovaquone-proguanil combination 
As an extension to the non-constant ratio design experiment, following the 72 hour 
treatment period, the drug was removed and a limiting serial dilution was performed for 
each sample (in triplicate). In brief, 50 µl samples of each treatment were transferred to 
microcentrifuge tubes and washed 3x in 1 ml of complete media. The pellet was re-
suspended in 100 µl of complete media so that the haematocrit was adjusted from 2.5 % to 
1.25 %. Four 96 well plates were prepared by adding 200 µl of 1.25 % haematocrit to each 
well. Seven 10-fold limiting serial dilutions were performed by adding 20 µl of each 
sample to row A, mixing thoroughly and transferring 20 µl to row B and so forth until row 
H where the excess 20 µl was discarded. On day seven, 100 µl of spent media was 
removed from each well and replaced with fresh media and blood at 1 % haematocrit. 
Adjusting the final haematocrit to 1.75 %. The plates were and incubated for a further 10 
days and analysed for growth using the SYBR Green procedures described elsewhere. 
6.2.5 CalcuSyn analysis of emetine with existing antimalarials 
Following validation of the CalcuSyn method using the atovaquone-proguanil 
combination, the interaction between emetine and dihydroartemsinin was re-analysed 
using the optimised treatment regime. Subsequently the combinations between chloroquine 
and emetine, and atovaquone and emetine were also analysed using CalcuSyn. The doses 
used for each compound were based on previously determined IC50 values and are shown 
in the Table 6.5. 
 
Dose Dose nM 
Level Dihydroartemisinin Chloroquine Atovaquone Emetine 
A 0 0 0 0 
B 0.625 28.75 0.136 6.25 
C 1.25 57.5 0.272 12.5 
D 2.5 115 0.544 25 
E 5 230 1.088 50 
F 10 460 2.175 100 
G 20 920 4.35 200 
H 40 1840 8.7 400 
Ratio     
AM: Eme 1:10 4.6:1 1:46 --- 
Table 6.5 Drug doses used for the existing and antimalarial combinations with emetine using 
the CalcuSyn analysis method. The ratio of the drug doses is also shown for Antimalarial (AM) to 
Emetine dihydrochloride hydrate (Eme) combinations. 
Chapter 6: Drug interaction analysis of emetine dihydrochloride hydrate 
 
125 
 
6.3 RESULTS 
6.3.2 Fixed ratio combination of dihydroartemisinin and emetine  
The fixed ratio interaction assay was employed to decipher whether the combination 
between dihydroartemisinin and emetine was synergistic, additive or antagonistic. The 
dose response curves of each ratio are displayed in Figure 6.2. Dihydroartemisinin (a) and 
emetine (b) dominant combinations were plotted separately. The emetine dominant 
combinations, at the 1:4 ratio in particular, reduced parasite growth compared to the drug 
alone counterparts. Growth inhibition for the other drug ratios showed similar trend to that 
of the DHA-only or Eme-only dose response curves.  Although the 4:1 drug ratio reduced 
growth less than the other combinations none of the fixed ratio treatments showed marked 
reductions in growth inhibition. This is consistent with the findings of the fractional 
inhibitory concentration analyses.  In accordance with the criteria presented by 
Bhattacharya et al., (2009) the sum 50% and 90% fractional inhibitory concentration 
(∑FIC 50, 90) data suggested that the combination between dihydroartemisinin and emetine 
is predominantly additive (indifferent). SumFIC values ranged from 0.9-1.4 at the 4 ratios 
tested (Table 6.6). A synergistic interaction was detected only at the FIC90 3:2 ratio and no 
antagonistic interactions were recorded for the combination using the ∑FIC50, 90 values as 
the determinant. Analysis of the isobologram plots, however, revealed a relatively 
prominent convex curve for the FIC50 level on inhibition indicative of antagonism (Figure 
6.3 a).  The FIC90 plot is consistent with the ∑FIC90 data also showing an additive 
interaction between dihydroartemisinin and emetine (Figure 6.3 b). 
 
 
 
 
 
 
 
 
Figure 6.2 Fixed ratio dose response curves for the dihydroartemisin-emetine combination 
Dihydoartemisinin dominant 5: 0, 4: 1 and 3: 2 (a) and emetine dominant 2:3, 1:4 and 0:5 (b) 
combinations are displayed separately. Error bars represent data completed in duplicate. 
a b 
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6.3.3 Analysis of the interaction between dihydroartemisinin and emetine using CalcuSyn 
Median effect analysis of the dihydroartemisinin-emetine combination was also 
completed.  Dose response curves were generated using the CalcuSyn software 
programme. Growth inhibition for the combination appeared comparable to that of the 
DHA treatment series (Figure 6.4). Good correlations coefficients of the median effect plot 
were reported for dihydroartemisinin (R=0.91135), emetine (R=0.92543) and the 
combination (R=0. 0.88689) indicating accurate data measurement and good conformity to 
the mass-action law (Fig 6.5.b).The fraction of affected cells in response to each treatment 
was thus utilised to perform interaction analysis where both drug potency and shape of the 
dose effect curve are considered. The CalcuSyn isobologram results were slightly above 
the line of additivity at the 50% growth inhibition level (Figure 6.4.c). In agreement, the 
Ratio CompA 
(DHA) 
FIC50 
CompA 
(DHA) 
FIC90 
CompB 
(Eme) 
FIC50 
CompB 
(Eme) 
FIC90 
∑FIC50s, 
interaction 
∑FIC90s, 
interaction 
5:0  1  1  0  0  n/a  n/a  
4:1  0.914829  0.97142 0.412807  0.482675 1.327636, ADD  1.454094, ADD  
3:2  0.638616  0.464741 0.837115  0.422492 1.475731, ADD  0.887233, SYN  
2:3  0.421106  0.310655 1.059061  0.71155 1.480167, ADD  1.022206, ADD  
1:4  0.238412  0.212022 1.167547  1.064742 1.405959, ADD  1.276764, ADD  
5.0  0  0  1  1  n/a  n/a  
Table 6.6 The interaction between dihydroartemisinin and emetine against P. falciparum (strain K1) at 6 
different preparations. SumFIC50 and SumFIC90 values have been calculated (SYN: synergy and ADD: 
additive) 
 
 
Figure 6.3 Isobolograms showing the FIC50 and FIC90 interactions between dihydroartemisinin and 
emetine. The fixed ratio method was used to analyse the interaction between dihydroartemisinin and 
emetine dihydrochloride hydrate initiated against trophozoite stage parasites. Treatments were set up in 
duplicate for 48 hours and analysed using the SG-FCM. The mean FIC50 (a) and mean FIC90 (b) 
concentrations were determined and used to plot the isobolograms. 
 
a b 
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Combination Index (CI = 1.147) was also at the borderline of the nearly additive and slight 
antagonism classifications. However the CalcuSyn isobologram (Figure 6.4.c) and CI data 
indicated moderate antagonism and antagonism at the 75% (Combination index = 1.316) 
and 90% (Combination index = 1.526) levels of parasite inhibition respectively (see Table 
6.7 for detailed criteria). 
  
 
 
 
 
 
 
 
 
Range of CI Symbol  Description 
<0.1  +++++  Very strong synergism 
0.1-0.3  ++++  Strong synergism 
0.3-0.7   +++ Synergism 
0.7-0.85   ++ Moderate synergism 
0.85-0.90  +  Slight synergism 
0.90-1.10 ±  Nearly additive 
1.10-1.20   – Slight antagonism 
1.20-1.45  – –  Moderate antagonism 
1.45-3.3  – – –  Antagonism 
3.3-10 – – – –  Strong antagonism 
>10 – – – – –  Very strong antagonism 
 
 
Table 6.7 Recommended symbols and descriptions for defining synergism or antagonism using the 
combination index method. The more broadly defined criteria suggests that the combination index, CI < 1, = 
1, and >1 indicate synergism, additive effect and antagonism, respectively (Source: CalcuSyn manual, Biosoft). 
Figure 6.4 Dose effect analysis of the 
dihydroartemisinin-emetine interaction, 
using the CalcuSyn software program.  
Output data included the dose-effect curve 
(a), median-effect plot (fraction 
affected/fraction unaffected (fa/fu) against 
the drug dose (D)) (b) and the isobologram (c) 
for the ED50 ED75 and ED90 levels of inhibition. 
Dose ranges for individual and combined 
drugs were completed in triplicate.  
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Further interrogation of the treatment regime employed to permit interaction analysis via 
the CalcuSyn software program revealed basic empirical evidence of an additive 
(indifferent) interaction between dihydroartemisinin and emetine 
 
 
 
 
 
 
 
 
In brief, the level of inhibition achieved by the administration of the single agents A 
(DHA) and B (Eme) was compared with the combination of the two compounds at half the 
respective dose (0.5 A + 0.5 B). The level growth inhibition incurred via the combination 
commonly fell between that of the compounds administered separately. Only at the 80 % 
inhibition level did growth in the combination sample exceed that of the single compound 
treatments (Figure 6.5).  
6.3.4 Validation of the CalcuSyn assay for malaria 
6.3.4.1 Optimisation of drug dosing and treatment period 
The known synergists, atovaquone and proguanil, were analysed via the constant ratio 
combination method in order to establish whether CalcuSyn, using SG-FCM as a read out 
for parasite viability, can reliably determine the nature of an interaction between two 
compounds against erythrocytic stage malaria.  The results of the initial combination 
experiment were inconclusive.  Atovaquone failed to induce the expected response for the 
Figure 6.5 Basic graphical representation of the interaction between dihydroartemisinin and emetine. 
Comparable inhibitory concentrations of drugs A (DHA- Green bars) and B (Eme-Blue bars) are plotted 
against 0.5 A + 0.5 B (red bars) from 0.25x IC50 up to 8x IC50 values. Parasitaemia (%) was calculated relative 
to the infected control which was set at 100 %. Error bars are based on the SEM of duplicate data points. 
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dose series selected and a clear synergistic interaction was not apparent between the two 
compounds (Figure 6.6).  
 
 
 
 
The second experiment aimed to increase the atovaquone dose to address the query as to 
whether its ineffectiveness was responsible for the lack of synergism observed. Although 
the dose shift permitted up to 80 % inhibition, a similar response pattern to the first 
experiment emerged.  The dose response for the combination was in fact comparable to 
that of proguanil alone (Figure 6.7).  
 
  
Figure 6.6 Atovaquone-proguanil combination against P. falciparum malaria, strain K1. Trophozoite stage 
parasites were treated with a dose series of Atovaquone (ATQ), Progunail (PG) or a combination of the two 
(ATQ+PG). The 2-fold serial dilution ranged from 0.09-5.6 ng/ml for ATQ and 0.6-36.8 µg/ml for PG so that 
the mid-point (Dose E) equated to the previously determined IC50 value for each drug. After a 48 hour 
incubation period samples were analysed using the SG-FCM method. Parasitaemia was determined relative 
to untreated controls which were set at 100 %. Error bars represent standard error of the mean (SEM) for 
triplicate data. 
Figure 6.7 Atovaquone-proguanil combination using a higher doses-series of atovaquone. Trophozoite 
stage parasites (strain K1) were treated with a dose series of Atovaquone (ATQ), Progunail (PG) or a 
constant ratio combination of both drugs (ATQ+PG).  Doses ranged from 0.18-11.2 ng/ml and 0.6-36.8 
µg/ml for ATQ and PG respectively. SG-FCM method was used to analyse parasite growth after 48 hours of 
treatment. The parasitaemia of drug treated samples was determined relative to untreated controls (100 % 
parasitaemia). Triplicate samples were used to derive error bars based on the  standard error of the mean 
(SEM). 
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The next enquiry was concerned with drug order and addition as well as the length of the 
treatment period. The two parameters were adjusted in the same experiment. All controls 
were shown to be effective in the study. In particular, the Acetonitrile: water control 
indicated that the solvent was not inhibitory to the parasite the highest dose used. 
Confirming that the atovaquone and proguanil concentrations were responsible for any 
inhibition observed. Whether the compounds were added before the addition of parasitised 
culture (together) or after (separately) appeared to have no effect on drug potency or 
combinatory outcome (Fig 6.9).   
 
 
 
 
The increase in treatment period from 48 to 72 hours, however, revealed a more potent 
atovaquone phenotype (Figure 6.9). It was also evident that there was slightly more 
inhibition incurred by the combination of atovaquone and proguanil than the drug alone 
comparisons.  It appears that the effect may have been masked by the high potency of 
atovaquone that achieved ~80% inhibition for the lowest dose used in the study. 
Figure 6.8 The effect of drug addition method on combinatory outcome of the atovaquone-proguanil 
combination. Ring stage parasites were treated for 72 hours with three doses of either atovaquone (ATQ), 
proguanil (PG) or a combination of the two. The drugs were either added to the 96 well plate prior to the 
addition of the diluted parasitised culture in the ‘together’ condition. In the separate’ condition the culture 
was added to the plate first, followed by the addition of each drug individually (including the combination 
treatments). The inhibitory effect of an equivalent amount of the progunail solvent, 1% acetonitrile: water 
(60:40) at the highest dose (PG 9.2 µg/ml) used in the study was also analysed. Parasite growth was 
determined by SG-FCM. Error bars representing the standard error of the mean are shown for samples with 
replicas. 
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Taken together the above data indicated that the constant ratio combination method may be 
used to accurately identify nature of the interaction between atovaquone and proguanil if 
the atovaquone dose is reduced and a 72 hour treatment regime is adopted. Including these 
alterations in the subsequent experiment did expose a dose response pattern that alluded to 
potential synergism (Fig 6.11) and most importantly provided sufficient data for CalcuSyn 
analysis. It should be noted that some inhibition was also incurred by the highest dose of 
acetonitrile: water included in the present study.   
 
Figure 6.9 The effect of incubation time on combinatory outcome of the atovaquone-proguanil 
combination. Ring stage parasites were treated for 72 hours with a 2-fold dose series of either 
atovaquone (ATQ, 0.8, 1.6 and 3.2 ng/ml), proguanil (PG 2.3, 4.6 and 9.2 µg/ml) or a combination of the 
two. SG-FCM was used to analyse parasite survival. Parasitaemia in drug treated samples was relative to 
untreated controls that were equated to 100%. Error bars are based on the SEM for quadruplicate 
samples. 
Figure 6.10 Dose response curves for atovaquone (ATQ), proguanil (PG) and the constant ratio 
combination of the two drugs. The highest dose of the acetonitrile: water (60:40) solvent for proguanil was 
also included as a control. Ring stage parasites were treated for 72 hours and analysed using the SG-FCM 
method. 
ATQ and PG dose series 
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CalcuSyn analysis of the dose-effect data also confirmed that the combination was more 
potent than either ATQ or PG alone (6.12.a). The Median-effect plot (Figure 6.11 b) 
indicated that the drugs act via different modes of action due to the lack parallel lines 
which reflect a difference in the shape of the dose effect curve (hyperbolic/ sigmoidal). 
The isobologram showed synergy at the ED50 and ED75 levels but antagonism at the ED90 
level of inhibition (Figure 6.11 c).  
 
 
 
 
 
 
The Combinatory index indicated that there was indeed very strong synergy for the 
atovaquone-proguanil combination at the ED50 level of inhibition. However, at the ED75 
and ED90 levels of inhibition the combinatory index and isobologram data defined the 
interaction as antagonism and very strong antagonism respectively (Table 6.8).   
 
 
Drug CI Values at 
 ED50 ED75 ED90 Dm m R 
ATQ N/A N/A N/A 0.10622 0.54763 0.87866 
PG N/A N/A N/A 3.18043 1.40769 0.96199 
ATQ + PG 
(1:5897) 
0.01490   1.74528 204.97422 7.9943e-006 0.19804 0.82530 
Figure 6.11 CalcuSyn analysis of the atovaquone-
proguanil combination. Data (Figure 6.10) was 
converted to the fraction of affected cells and 
analysed ising CalcuSyn. The output included the 
Dose-effect curve (a), Median-effect plot, showing 
the fraction of affected cells/fraction of unaffected 
cells (fa/fu) plotted against the drug dose (D) (b) 
and the Isoblogram (c).  For the isobologram a 
relative constant drug ratio (1:1) based on IC50 
atovaquone: IC50 proguanil was used rather than 
the absolute drug concentrations due to the huge 
potency difference between the compounds. 
 
a b
 a 
 
c 
Table 6.8 The combinatory index values (CI) for the ATQ + PG constant ratio combination (1:15987) at the 
ED50, ED75 and ED90 levels of inhibition. The Dm, m and r values are also shown for all sets of data. Dm 
indicates potency and depicts the median effect dose at the ED50 level of inhibition. The m value refers to 
the kinetic order and shape of the curve m = 1, > 1, and < 1 indicates hyperbolic, sigmoidal, and negative 
sigmoidal shape, respectively. The r values is the linear correlation coefficient for the median effect plot and 
indicates conformity to the mass action law.  
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6.3.4.2 Non-constant ratio of combination of Atovaquone and Proguanil 
 
 
 
 
Figure 6.12 The non-constant ratio combination of atovaquone and proguanil. Ring stage parasites 
were treated for 72 hours with predetermined IC25, IC50 and IC75 doses of atovaquone and progunail 
either alone or in combination.  Combinations consisted of a constant dose of one drug with a varied 
dose range for the second drug and vice versa. Parasite growth was analysed using the SG-FCM method. 
Parasitaemia was calculated relative to the control (infected) which was equated to 100 %. Error bars 
represent the SEM of triplicate data from two separate experiments. 
a 
b 
c 
d 
e 
f 
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The data from the non-constant ratio design experiment consistently showed that when 
parasites were treated with one drug, no matter what the concentration, addition of a 
second drug induces further effects (Figure 6.12 a-f). Although the dose dependency effect 
was more obvious at lower doses, a dose response pattern was apparent for the second 
drug even under constant drug pressure of the IC75 concentration for the first compound. 
The constant ratio design data (completed in parallel) was consistent with the dose 
response pattern observed in previous experiments (Figure 6.13). The atovaquone dose 
range used in the study did not achieve greater than 40% inhibition. However, the 72 hour 
treatment period permitted detection of additional suppression and possible synergy in the 
combination sufficient for re-growth analysis following removal of the drug in the second 
part of the experiment. 
 
 
 
 
 
 
 
 
 
 
 
6.3.4.3 Recovery of parasites treated with the atovaquone-progunail combination 
The regrowth experiment showed that the combinations were more lethal than the drug 
alone treatments (Fig 6.15). Indeed, no growth was detected after 20 days in the IC50 + IC50 
and IC75 + IC75 combinations. In fact only the IC25 + IC25 combination permitted the 
recovery of parasites. None of the Non-constant ratio combination supported parasite 
growth above that of the IC25 + IC25 combination (Appendix XI). A dose response pattern 
could be observed in the drug alone treatments after 20 days of incubation confirming the 
reliability if the data. Although there appears to be the same level of regrowth at the IC25, 
IC50 and IC75 levels of inhibition for proguanil (growth present in the first two dilutions for 
all concentrations) the parasitaemia showed a dose response pattern. First dilution 
Figure 6.13 Constant ratio data for the atovaquone proguanil combination after 72 hours. Ring stage 
parasites were treated with IC25, IC50 and IC75 dose of each drug or the corresponding combination at each 
level. Growth inhibition was analysed at 72 hours using the SG-FCM method. Triplicate data was used to 
construct error bars from the SEM. 
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parasitaemias were 3.4 %, 2.2 % and 0.41 % and second dilution parasitaemias were 0.83 
%, 0.46 % and 0.23 % for IC25, IC50 and IC75 doses respectively (control 4.4 first dilution 
3.7 second dilution). Overall, the data infered that the interaction between the two drugs 
was not antagonistic, recovery in all the combinations was less than even the highest doses 
of the drug alone counterparts.  Therefore indicating, the background staining of dead 
parasites, or those committed to dying, had confounded the data at the higher doses. 
 
 
 
 
 
 
 
 
 
6.3.5 Combination of emetine and existing antimalarials using the CalcuSyn constant ratio 
method 
The combination of emetine and dihydroartemisn was reanalysed using the optimised 72 
hour treatment regime. The constant ratio method was also used to analyse the interaction 
between emetine and chloroquine and emetine and atovaquone. Ratios were selected based 
of the respective predetermined IC50 values for each compound. The data for all of the 
combinations showed good conformity to the mass action law (r = 0.85-0.97 refer to 
Tables 6.9, 6.10 and 6.11). The DHA-Eme combination was classified as antagonistic for 
the 1:10 ratio at all inhibitory levels analysed in the current study (See isobologram 
(Figure 6.15 d) and combinatory indexes (Table 6.9). The interaction between CQ-Eme, 
for the 72 hour treatment period at a 4.6:1 ratio, was classified as antagonism, antagonism 
and mild antagonism for the ED50, ED75 and ED90 levels inhibition respectively (Figure 
6.16 and Table 6.10).  For the ATQ-Eme (ratio 1:46) combination the ED50 level of 
inhibition was classified as synergism, the ED75 moderate synergism and ED90 moderate 
antagonism (Figure 6.17 and Table 6.11). 
Figure 6.14 Constant ratio data for the atovaquone-proguanil combination after 20 days. The 
experiment was initiated with ring stage parasites in a 96 well plate format. Drug pressure was removed 
after 72 hours of treatment, parasites were subjected to 8, 10-fold limiting serial dilutions and incubated 
for a further 17 day. Spent media was replaced with fresh media and erythrocytes on day 7. The presence 
or absence of growth in wells was determined used the SYBR green methods (chapter 2). Error bars 
represent the SEM for 3 replica samples.  
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Dihydoartemisinin Emetine combination 
 
 
 
 
 
 
 
 
 
 
Drug             CI Values at      
              ED50          ED75  ED90  Dm  m  r 
DHA              N/A         N/A  N/A  3.07235 1.32229 0.92816 
Eme               N/A         N/A   N/A  37.07047 1.26772 0.86364 
DHA + Eme       1.80297         1.80543   1.80847 3.02898 1.29514 0.89936 
(1:10) 
 
 
 
 
 
 
Figure 6.15 The constant ratio combination of dihydroartemisin and emetine. Parasites were treated 
with dihydroartemsin: emetine combination at a constant ratio of 1:10 for 72 hours. P. falciparum strain 
K1 parasite survival was determined using the SG-FCM method. The complied image shows the dose 
response curve based on the raw data (a) and the CalcuSyn output including: dose effect curve (b), median 
effect plot (fraction affected/fraction unaffected (fa/fu) against the drug dose (D)) (c) and isobologram (d). 
 
Table 6.9 The combinatory index values (CI) for the dihydroartemisin-emetine combination at a constant 
ratio of 1:10. Determinants of potency at ED50 (Dm), Shape of the curve (m =1, > 1, and < 1 signify 
hyperbolic, sigmoidal, and flat sigmoidal respectively) and the linear correlation coefficient (r) are also 
presented in the table. Tabular data accompanies the CalcuSyn output presented in Figure 6.15 for the P. 
falciparum, strain K1 exposure to the dihydroarteminin- emetine combination for 72 hours. 
 
 
 
a 
b 
c d 
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Chloroquine Emetine combination 
 
 
 
 
 
 
 
 
 
 
 
 
Drug CI Values at      
    ED50               ED75             ED90  Dm  m  r 
CQ    N/A                N/A              N/A  391.33597 3.01961 0.91788 
Eme    N/A               N/A              N/A  49.17856 1.55407 0.89619 
CQ + Eme 1.58798 1.47786 1.41581 227.64205 2.21787 0.86713 
(4.6:1)     
 
Figure 6.16 The constant ratio combination of chloroquine and emetine. The Chloroquine emetine 
combination was analysed using the constant ratio (4.6:1) design for CalcuSyn median-effect based 
analysis. The experiment was initiated at ring stage and parasite were exposed to drug alone and drug 
combination dose series for 72 hours. Growth inhibition was analysed using the SG-FCM method. The 
dose response curve (a) and CalcuSyn output curves: namely, dose effect (b), median effect (fraction 
affected/fraction unaffected (fa/fu) against the drug dose (D)) (c) and isobologram (d) are shown. 
Table 6.10 The dose effect parameters for the chloroquine-emetine combination. The combinatory index 
values are shown for the combination at the ED50, ED75 and ED90 levels of inhibition. Dm, m and r values 
are also reported and indicate potency of the compounds tested, shape of the median effect curve and 
the correlation coefficient of the data to the mass action law, respectively. 
a b 
c d 
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Atovaquone Emetine combination 
 
 
 
 
 
 
 
 
 
Drug CI Values at      
    ED50               ED75                 ED90         Dm                         m                           r 
ATQ    N/A               N/A            N/A         1.13857            1.26701              0.97767 
Eme    N/A               N/A            N/A         70.64774               2.35775            
0.93572 
Combi    0.51595           0.83394           1.40272         0.33735            0.94992              0.91194 
(1:46) 
Figure 6.17 The constant ratio (1:46) combination of atovaquone and emetine. Parasite viability was 
analysed after 72 hours using the SG-FCM method. A basic dose response curve is shown (a) as well as 
CalcuSyn dose effect curve, and median effect plot (fraction affected/fraction unaffected (fa/fu) against 
the drug dose (D)) which are based on the faction of affected parasites. The isobologram is also shown and 
indicate the nature of the interaction between the two compounds at the ED50 ED75 and ED90 levels of 
inhibition (Marker below the line = synergistic, on the line = additive and above the line antagonistic). The 
degree of the classification is indicated by the distance of the marker from the respective (colour coded) 
line. 
a b
 a  
c d 
Table 6.11 The combinatory index (CI) values for the atovaquone emetine combination at the ED50, 
ED75 and ED90 levels of inhibition. Dm, m and r values (as described in table 6.8-10) are also displayed 
for the atovaquone-emetine combination at a 1:46 ratio against P. falciparum strain K1. Tabular data 
accompanies the CalcuSyn output plots presented in Figure 6.17.  
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6.4 DISCUSSION 
It is now widely accepted that combination regimes have significant therapeutic 
advantages when compared to monotherapy (Fivelman et al., 2004). The aim of this study 
was therefore to evaluate the combinatorial theraputic potential of the novel antimalarial 
candidate, Emetine dihydrochloride hydrate with existing antimalarials. As an initial 
stepping stone to such investigations, in vitro interaction assays are used. Unfortunately, 
poor standardisation has meant that discrepancies have often appeared in the malaria 
literature (Canfield et al., 1995; Fivelman et al., 2004; Gorka et al., 2013; Mariga et al., 
2005). For this reason, an automated interaction analysis programme, CalcuSyn, was 
optimised for use in malaria and employed to determine the nature of the interaction 
between emetine and three antimalarials: namely, dihydroartemisin, chloroquine and 
atovaquone. 
6.4.1 Comparison of the fixed ratio and CalcuSyn methods for drug interaction analysis 
To provide a more in depth pharmacodynamic perspective of the dihydroartemisinin-
emetine interaction detailed in vitro analyses were carried out. In the current climate the 
DHA-Eme interaction is of particular importance due to the worldwide dependence on the 
artemisinin class and the essentiality of preventing resistance development.  As the active 
metabolite of all artemisinin derivatives, dihydroartemisinin, was used for all 
combinatorial investigations with emetine in the study. Initially, the fixed ratio method 
was employed in accordance with Bhattacharya et al. (2009).  Dihydroartemisinin and 
emetine were combined at four fixed ratios and the dose response curves generated for 
each ratio were compared with those of the individual compounds. There are two 
indicators of the fixed ratio method that serve to clarify the nature of an interaction 
between two compounds. Firstly, the sum of the fractional inhibitory concentration (∑FIC) 
is calculated and its value is integrated into predefined criteria that correspond to 
synergism, additivity or antagonism. Secondly, the isobologram plot where the FIC values 
at each ratio for drug ‘A’ are plotted against the FIC values at the corresponding ratios for 
drug ‘B’. A concave curve represents a synergistic interaction while a convex curve 
indicates antagonism.  Additivity is referred to as an indifferent interaction and represented 
by a straight line. Unfortunately, data representing the two read-outs from the fixed ratio 
method were in conflict. SumFIC50, 90 values predicted that the drug ratios predominantly 
fell within the additive range when applying criteria used by Bhattacharya et al. (2009). At 
the ∑FIC90 level of inhibition a single case of synergy was also reported (ratio 3:2). 
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However, while the FIC50 isobolograms showed an antagonistic trend, the FIC90 
isobolograms followed an additive trend.  Although variation between ratios is expected, 
different measures of the interaction at the same ratio should be in agreement. Such 
contradictions call into question the reliability of the methods of interpretation.  
Particularly when ∑FIC cut off values are not standardised in published literature. For 
example, Vivas et al., (2007) and other critiques of the method, interpret additivity as an 
indifferent interaction for which the ∑FIC values should strictly equal ‘1’. Anything below 
or above 1 should be defined as synergy and antagonism respectively (Canfield et al., 
1995). As such narrow limits are difficult to achieve in biological systems others such as 
Abiodun et al., (2013) have selected broader categories to incorporate a region of error (ie. 
∑FIC < 0.8 = synergism, ∑FIC > 0.8-1.4 = additive, ∑FIC > 1.4= antagonistic). Applied, 
to the current study these criteria would suggest that the interactions at both ∑FIC50 and 
∑FIC90 would fall within the additive to mildly antagonistic range. However this is not 
the case for Bhattacharya and colleagues (2009) as the additive window they adopt is not 
around 1 but equal to or above 1. Furthermore, for their selection of interaction criteria 
they only on quote their previous work and a paper Odds (2003) which they seem to have 
misinterpreted. In fact Odds (2003) is actually making the point that broad criteria for 
defining drug interactions cannot be considered as an equivalent to experimental error or 
confidence intervals. They suggest that only extreme cases <0.5 for and > 4 of synergism 
and antagonism, respectively should be accepted, to encourage more conserved 
interpretations, rather than authors subjectively putting a positive spin on their data (Odds, 
2003). The issue of selecting appropriate guidelines is avoided if the CalcuSyn method is 
employed as the cut-off criteria are clearly outlined. In order to permit automated analysis 
of the dihyroartemsinin-emetine combination with CalcuSyn, a constant ratio method was 
adopted. The data generated by the software focuses on the effective dose (ED50), a term 
that is often used interchangeably with the IC50. The CalcuSyn output described the 
interaction between dihydroartemisinin and emetine borderline ‘nearly additive’/’slightly 
antagonistic’ at the ED50 level, ‘slightly antagonistic’ at the ED75 level and ‘antagonistic’ 
at the ED90 level. Combination index data and the isobologram plot were found to be in 
complete agreement using CalcuSyn analysis software demonstrating the superior 
accuracy of the method. Possibly owning to the more stringent guidelines and automation, 
the analysis prevents the user bias of selecting criteria to suit the desired outcome of an 
interaction. Indeed, if the criteria defined by Canfield and colleagues (1995) were  applied 
to the fixed ratio analysis all ratios would be classified as antagonistic at the ∑FIC50 level, 
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while at the ∑FIC90 level, the ratios would vary from synergistic to antagonistic which is 
in better agreement with the isobolograms obtained for the same set of data. One would 
expect that more stringent guidelines should endorse more accurate data. However, 
achieving such narrow limits in biological systems is problematic and could result in the 
exclusion of potentially effective combinatory options. For example, visual scrutinisation 
of the DHE-Eme interaction under the constant drug ratio design (Figure 6.5) employed 
for its compatibility with CalcuSyn, indicated that drug doses could be halved when used 
in combination. Only at the 2.5 nM DHA + 25 nM Eme was this phenomenon not 
observed. This could potentially suggest that, a toxicity reduction advantage of 
combination therapy could be achieved by the dihydroartemisinin-emetine interaction 
despite its classification. This highlights, a significant advantage of combinations 
classified as additive, due to the obvious impact of delayed resistance acquisition. 
Nevertheless, it is evident that in order to obtain a standardised system stringent non-
subjective criteria, like those defined by Chou-Talay for CalcuSyn should be adopted. It is 
therefore a separate issue that candidates with classification around the additive or mildly 
antagonistic window, like emetine, should not be disregarded. Particularly, since 
differences in in vitro and in vivo interactions are commonly reported (Fivelman et al., 
2004; Keiser et al., 2012; Synder et al., 2007).  Indeed recent in vivo studies have 
demonstrated that weak antagonism does not necessarily translate to slower parasite 
clearance times when compared to individual compounds (Synder et al., 2007).  
Furthermore, the RBx11160 (OZ277) and piperaquine interaction was in fact shown to be 
reduced from antagonistic in vitro to additive in vivo indicating that pharmacokinetics play 
an important role (Fivelman et al., 2004; Synder et al., 2007).   
Due to the limited number of options available for malarial treatment, it is therefore 
evident that, the idealistic synergistic interaction between two drugs may need to be 
compromised if the benefits bestowed by a two pronged attack: namely toxicity reduction 
and a delay in the onset of resistance, outweigh the therapeutic disadvantage of a mere 
additive classification. Furthermore, given the complex nature of the parasite life cycle, 
including its stage and strain specific variations, other factors besides simplistic 
mechanistic deductions based on parasite clearance should be investigated (Bell, 2005). 
Interactions described as additive, verging on mildly antagonistic, should be analysed 
further before potential combinatory partners are discarded prior to in vivo studies (Vivas 
et al., 2007).  
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However, the value of in vitro studies to refine the candidate list would be lost if every 
compound was considered for further in vivo investigations.  One would expect that the 
classification of candidates as strongly synergistic or strongly antagonistic should not be 
misjudged, thus, studies should aim to rule out any strongly antagonistic combinations. A 
major issue with the DHA-Eme data is that although the application of more ridged criteria 
to the fixed ratio data meant that the ED50 classification was in agreement with the 
CalcuSyn analysis (slightly antagonistic), for the EC90 level they are completely 
contradictory. The data range from synergy to strong antagonism. Numerous factors may 
have affected the outcome of the classifications, such as, experimental conditions whether 
the interaction is ratio, dose or effect dependent (CalcuSyn manual 1996-2006; Bell, 
2005). Indeed, different drug ratios were used for the fixed ratio and CalcuSyn methods. 
For the ED50 level of inhibition this was not a problem as the same outcome was reported 
for all ratios used, but at the EC90 level, variations are reported for the different ratios 
adopted in the fixed ratio method. Another foreseeable problem with the CalcuSyn study 
was that the parasitaemia was low, even in control samples; meaning at the highest levels 
of inhibition background interference was likely, particularly as the analysis takes into 
account the entire shape of the curve. As this data is inconclusive and the reliability of the 
CalcuSyn method cannot be confirmed, further work was focused on using antimalarial 
compounds with a known interaction outcome to validate the method. 
6.4.2 Validation of the CalcuSyn method for malaria using the malarone combination 
The Atovaquone and progunail combination was selected as known antimalarial synergists 
to validate the CalcuSyn method for malaria (Khositnithikul et al., 2008; Radloff et al., 
1996). A constant ratio design, compatible with the CalcuSyn software, was set up in 
accordance with their previously determined IC50 values (Chapter 3). In the first two 
experiments the combination failed to show a marked increase in growth suppression when 
compared with the drug alone counterparts (Figure 6.6 and 6.8). Initially, the low activity 
of atovaquone was thought to be responsible for the lack of synergism observed, possibly 
attributable to solubility issues of the compound also reported by Canfield and colleagues 
(1995). The dose increase in the second experiment achieved up to 80% inhibition yet no 
evidence of synergy could be observed. As the interaction is known to be synergistic there 
appeared to be a problem with the experiment set up and drug treatment regime. A 
preliminary experiment had shown some additional growth inhibition in a flask experiment 
where the compounds are added to the culture, as opposed to in the 96 well plate set up, 
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where plates were dosed prior to the addition of the parasitised culture, thus providing the 
opportunity for a physical interaction between the two compounds. Another possibility 
was that the 48 hour time-course is too short to detect an interaction between the two 
compounds particularly as atovaquone is known to be one of the slowest acting 
antimalarials available (Sanz et al., 2012).  Both parameters were tested in the subsequent 
experiment and the data confirmed that the treatment period was responsible for the lack 
synergism observed in the initial experiments. Had the effect not been masked by the 
higher potency of atovaquone at the 72 h time point, the observed increase in growth 
inhibition for the combination may have alluded to synergy. Accordingly, the reduction of 
the atovaquone dose in the subsequent experiment revealed the expected synergistic 
interaction.  
Canfield et al. (1995) also reported differences between interaction classifications in their 
preliminary data (48 h) and their more detailed experiments (72 h). However, they attribute 
these differences to changes in the treatment regime and the solubility of atovaquone rather 
than the shift to a 72 hour treatment period. The findings presented here are contradictory 
to those of Fivelman et al., (2004), who showed the atovaquone proguanil combination to 
be synergistic within a 48 hour treatment period using the hypoxanthine incorporation 
method, indicating that the problem was not related to the drug killing profile but the 
growth detection method used. Indeed Wein et al., (2010) suggest that while the 
hypoxanthine incorporation method can be used at 48 h, the SYBR green-based methods 
require a 72 hour treatment period to obtain accurate data, suggesting that the read out is 
affected by drug mode of action. A further issue is that despite the correct identification of 
a synergistic interaction at the ED50 level, at the ED75 and ED90 levels of inhibition the 
combination was deemed slightly antagonistic and antagonistic respectively. Such an 
outcome is unlikely considering the effectiveness of the combination in the field. Another 
variable must, therefore, be confounding the data at the higher doses. One possibility is 
that inhibition incurred by highest concentration of acetonitrile: water solvent influenced 
the interaction outcome. Notably, additional growth inhibition was not observed after dose 
point F which is in fact comparable with the highest dose used in the previous experiment 
where no inhibition was observed. Another possibility is that dead parasites, or those 
committed to dying, are being detected as live. It is likely that the amount of intact DNA, 
detected by the SG-FCM, is affected directly or indirectly by drug mechanism of action 
(Wein et al., 2010). This notion is supported by the observations that no drug dose used in 
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the study achieved 100% inhibition and different drugs plateau at different levels of 
inhibition, with the combination mirroring the most DNA degrading of the two 
compounds. In order to determine whether the combination is in fact antagonistic at high 
doses, the parasites were treated with a high constant concentration of one drug in 
combination with a dose range for the second drug (IC25, IC50 and IC75). Lower constant 
doses were also included for comparison.  Despite the finding that dose dependency effect 
was more pronounced in combinations with the lower constant concentrations, a trend was 
still apparent with the higher constant concentrations. The data consistently showed that 
further effects can be achieved by the addition of a second drug no matter what the 
concentration of the first. Although the effects are not huge they are not indicative of a 
strongly antagonistic interaction. Again inhibition did not exceed 90% indicating the 
possibility of 10% background effects. In order to determine whether the parasites are dead 
or committed to dying, parasite recovery and regrowth was monitored. In the replica 
experiment after 72 h of treatment the drugs were removed, parasites were subjected to a 
limiting serial dilution and allowed to recover for a further 17 days. The assumption being 
that if the drugs are antagonistic then recovery/growth should be higher in the 
combinations than in the singly treated controls. Interestingly, despite showing some 
remaining live parasites after 72 hours of treatment, none of the parasites recovered once 
the drug combination was removed during the regrowth period. Although after 72 hours 
the highest dose of proguanil achieved nearly the same level of inhibition as the 
combination singly treated parasites were able to recover (after 17 days) whilst those 
subjected to the combination were not. Taken together the data indicates that the 
combination is not antagonistic a high does. Data from the SG-FCM assay at higher levels 
in inhibition should be viewed with caution as background interference likely. 
Furthermore, the variations at what level of inhibition each compound plateaus appear to 
be dependent on intrinsic mode of action, inferring that different drugs will affect the SG 
readout differently. 
6.4.3 CalcuSyn analysis of emetine with existing antimalarials 
Three existing antimalarials: dihydroartemisin, chloroquine and atovaquone were 
investigated for their interaction with emetine. After 72 hours of incubation the DHA-Eme 
interaction was classified as antagonistic which is contradictory to the initial findings at 48 
hours which were nearly additive/slight antagonism, moderate antagonism and 
antagonism. Given the slow killing profile of emetine (Chapter 5) it is likely that the 72 
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hour data is more accurate and the compound needed more time antagonise the faster 
acting DHA component. A discrepancy also arose between the shape of the median effect 
curve as indicated by unparallel and parallel lines for each of the drugs at 48 and 72 hours 
respectively. Parallel lines are indicative of a similar killing profile inferring a similar 
mode of action. However this would be contradictory to the extensive killing profile data 
obtained for emetine in Chapter 5. The variation between the two time points presented 
here implies that a timing issue and the misinterpretation of dormant and dead parasites by 
SG-FCM may have confounded the current data. The suggestion that emetine has a similar 
killing profile to atovaquone and possibly a mitochondrial mode of action is corroborated 
by the interaction data presented here as artemsininin atovaquone combinations have also 
been defined as antagonistic elsewhere (Fivelman et al., 2004; Vivas et al., 2007). There is 
a possibility that the mode of action of these compounds overlap particularly as both 
emetine and artemisinin have been predicted to have multiple targets in malaria. Amongst 
numerous theories that have been put forward for the mechanistic actions of artemisinins 
one has implicated the involvement of the mitochondria electron transport chain as a 
source of reactive oxygen species (Haynes and Krishna, 2004; Mercer et al., 2011; 
Krungkrai et al., 2010; Wang et al., 2010). It is evident that the predominant actions differ 
due to the differences in their speed of kill (chapter 5). The data infer that it is unlikely that 
emetine will be a good combinatorial candidate for ACT. 
The interaction between chloroquine and emetine was shown to be antagonistic and 
antagonism between CQ-ATQ has been also reported elsewhere (Gorka et al., 2013).  
Some authors suggest that antagonism implies action on the same target. However like 
emetine, chloroquine has also been used previously to treat amoebiasis and in this 
protozoan parasite the drugs were found to act on different parasite targets. Chloroquine 
was shown to inhibit DNA synthesis in the vegetative forms of the parasite while emetine 
killed the trophozoite stage by inhibiting protein synthesis (Bansal et al., 2004).   The lack 
of parallel trend lines on the median effect plot also infers a difference in mode of action.  
One possibility is that in both cases of antagonism (DHA-Eme and CQ-Eme combination) 
there is some overlap in the death progression phenotypes incurred by direct or indirect 
actions of the multiple-targeted compounds. 
The interaction between atovaquone and emetine was classified as synergistic (ED50) and 
mildly antagonistic (ED75 and ED90). Indeed other studies have reported sporadic cases of 
antagonism in combinations that are otherwise synergistic (Mariga et al., 2005). Due to the 
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previous issues at high levels of inhibition it is however likely that background effects are 
responsible of the contrary classifications in the current investigation. Due to the 
pharmacokinetic matching of the compounds (Chapter 5), the synergistic outcome presents 
an exciting option for antimalarial therapy. The similarity in the killing profiles of 
atovaquone and emetine suggest both drug may be acting on different targets in the 
mitochondria, thus working together to potentiate drug action (Sanz et al., 2102; 
Zimmermann et al., 2007). For emetine the most likely mitochondrial target is protein 
synthesis in the mitochondrial ribosome.  Such theories would require a more detailed 
inquiry and cannot be deduced from the data presented here. Clearly, further investigations 
will be needed to establish whether the combination will be efficacious in vivo.  
6.4.4 Conclusion and future directions 
Taken together the data presented here provides support that the CalcuSyn constant ratio 
method offers a more standardised, simple, reliable user friendly alternative to the 
checkerboard and fixed ratio methods to analyse antimalarial drug interactions. One 
potential drawback is that in a single experiment only one ratio is analysed. However other 
studies have used the method to evaluate different fixed ratios (Corral et al., 2014; Feng et 
al., 2009). In the current study, drug ratios were based on pre-defined IC50 values which 
presented huge ratio variations due to the differential potency of the different compounds. 
Some studies base ratios on mass while others use IC50 information (Keiser et al., 2011; 
Hu et al., 2010). The ratio of the compounds in vivo will most likely be affected by 
pharmacokinetics and pharmacodynamic aspects if the individual compound, making the 
selection of an appropriate ratio at the in vitro level difficult. For this reason, either a wide 
range of ratios should be tested or basic interaction data could be obtained initially, then 
further characterised once more detailed information on in vivo pharmacokinetic profile of 
a drug candidate becomes available. In most cases different ratios present different 
interaction classifications (Harasym et al., 2010), however, the value of identifying 
desirable interactions is redundant if such ratios cannot be achieved in the in vivo situation. 
Despite being validated as reliable (Co et al., 2009), the current study also highlighted 
issues with the SG-based methods for analysing drug interactions, particularly at high 
levels of inhibition. It is likely that other viability assays are also affected by drug mode of 
action and as a result attribute erroneous classification to drug combinations. It is probable 
that such issue are responsible variations in interaction classifications reported in the 
literature. For this reason, it may be a better option to analyse drug interactions based on 
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lethal dose inhibition. This could be achieved by removing the drug after 72 hours of 
exposure and analysing parasite re-growth after an extended recovery period (Gorka et al., 
2013; Painter et al., 2010; Sanz et al., 2012). As parasite killing is the ultimate goal, such 
modifications to the current protocols should provide better in vitro to in vivo translation. 
Overall findings of the current study indicate that emetine dihydrochloride hydrate should 
be considered as a viable antimalarial candidate and should be progressed for more 
detailed in vitro and in vivo analyses. Further work is needed to establish whether the 
compound is suitable for use as a partner drug with atovaquone. Failing that, other 
combinatory options with other repositioned compounds could be explored. Further work 
should aim to evaluate the combinatorial potential of less toxic derivatives of the molecule, 
such as dehydroemetine, providing the antimalarial potency is comparable. In the current 
climate of malaria drug discovery it is vital that such potentially valuable candidates are 
taken forward and not overlooked or summarily discarded. 
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CHAPTER 7 
GENERAL DISCUSSION 
This study has investigated drug repositioning as a fast-track option for antimalarial drug 
discovery.  In doing so, the work has provided information in greater detail regarding the 
use of SYBR Green methods for antimalarial drug susceptibility and characterisation 
assays. The findings of this work have further highlighted the issues concerning current in 
vitro practises for antimalarial drug development, to which alternatives, that may offer 
better in vitro to in vivo translation, have been proposed. Drug repositioning, as an option 
for antimalarial drug discovery, shows promise. From a screen of ~700 bioactive 
compounds, novel antimalarial drug classes inhibitory towards the multidrug resistant 
strain K1, have been identified. Additionally, the work has added to the understanding of 
the selected hit compound, emetine dihydrochoride hydrate, and its action against the 
malaria parasite, through characterisation of its killing profile and drug interaction 
analyses. One issue with the antimalarial development of the compound was the concern 
regarding dose-related toxicity. Data from the current study has presented a solution to the 
problem through combination with atovaquone. In addition to the other benefits of 
combination therapy, such as an obstacle to resistance development, the synergistic 
interaction between emetine and atovaquone, revealed here, would permit further dose 
reductions of the repositioned compound. Some preliminary indications about the parasite 
targets of the emetine have also been ascertained. 
7.1 SYBR Green-based methods for antimalarial drug screening and development 
7.1.1 SYBR Green-based methods for drug susceptibility 
Since 2009 there has been a growing body of evidence implicating the use the DNA stain, 
SYBR Green 1, for determining malarial parasite viability in response to drug treatment 
(Bacon et al., 2007; Johnson et al., 2007; Karl et al. 2009; Vossen et al., 2010). The 
reliability of the SG-based methods was confirmed in the current study, by good 
conformity with the traditional Giemsa microscopic test. Corroborating the findings of 
Wein et al. (2010), further interrogation revealed that it is important to monitor and control 
the parasite stage in relation to the drug treatment time-course. Although Wein et al. 
(2010) suggest a 72 hour treatment period is required to obtain reliable results with the SG 
assays, we show that a 48 hour treatment may also be used, providing that, it spans 
schizont rupture, re-invasion and entry into the subsequent erythrocytic cycle. However, 
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when drug action and speed of kill is unknown, a 72 hour treatment period, initiated at ring 
and analysed at trophozoite stages, may be the best option to permit the action of slower 
acting antimalarials and ensure that parasites are fully established in the subsequent 
erythrocytic cycle at the time of analysis. 
 In the current study, issues also arose concerning background fluorescence in the SG-
MicroPlate method, for which complete media, containing albumin, was found to be 
responsible. This issue has not been commonly reported in the literature and was not 
particularly problematic for dose response curves where staining is relative and a trend, 
rather than absolute values, is expected to be observed. However, washing steps to remove 
to complete media were necessary to obtain reliable results from the screening of drug 
libraries, where parasitaemia can be reduced to minimal amounts and thus, is easily 
confounded by background effects. Whether this issue is specific to the Albumax used in 
the current study is unknown. Plouffe et al. (2008) also briefly mention issues with 
Albumax that result in a small protein shift of fluoresence. Yet other studies that have used 
human serum to supplement the media, have reported the dilution SYBR Green with 
complete media (Gorka et al., 2013).  
7.1.2 SYBR Green-based methods for drug interaction analysis 
The use of SYBR Green 1 for drug interaction analysis has also been evaluated more 
recently in the literature (Co et al., 2009; Gorka et al., 2013). These studies adopted a 96-
well plate reader method for the analysis, and reported no issues with background effects. 
Using an unsynchronised culture Gorka and colleagues adopted a 48 hour treatment 
regime, and analysed the IC50 and LD50 levels of inhibition to consider cytostatic and 
cytocidal effects respectively. The study did not include analysis of known antimalarial 
drug combinations, making it difficult to determine reliability and draw comparisons with 
the current data. In contrast, Co et al. (2009) used a 72 hour treatment period and 
replicated antimalarial drug combinations with known interaction outcomes. This showed 
that such classification could be obtained using the SYBR Green method. As interaction 
data for the ED75 and ED90 levels of inhibition are not presented by Co et al. (2009) the 
ED50 classification reported here, using the more accurate SG-FCM method and the 
interaction analysis software CalcuSyn, was in agreement with their findings at the IC50 
level of inhibition. This, and the correct assignment of synergy to the known atovaquone-
proguanil combination in the current study, served to validate the use of CalcuSyn as a 
reliable automated determinant of antimalarial drug interaction classifications. 
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Unfortunately, the value of using such as system was slightly concealed in the current 
study by interference of inherent drug-mode-of-action factors with the SYBR Green 
detection of live parasites. Firstly, a 72 hour time-course was necessary to detect synergy 
between atovaquone and proguanil using SG-FCM. Secondly, antagonism was incorrectly 
assigned to interactions at ED75 and ED90 levels of inhibition (not considered in the 
previous studies), as confirmed by an extended regrowth assay. It is likely that this issue is 
not limited to the SYBR green assay, and is probably common to all drug susceptibility 
assays. Indeed, readouts such as the measurement of metabolic parameters can commonly 
be uncoupled from parasite viability and are differentially affected by drug mode of action 
(Sanz et al., 2012 and Wein et al., 2010). In these cases two inverse misinterpretations 
may arise: (1) cytostatic parasites may be considered dead, even though they are capable of 
resuming productive growth once the drug has been removed, (2) parasites may be 
considered alive, although already committed to death, after exposure to a cytocidal 
compound that induces a delayed death profile (Sanz et al., 2012). 
7.1.3 Conclusions and future directions for drug susceptability assays 
Taken together, the data presented here provides a greater understanding of SYBR Green 
determination of parasite viability and how the readout can be affected by drug mode of 
action. Clearly, appropriate treatment regimens for the different drug susceptibility assays 
available, should be adopted and standardised between groups using the same assay, so 
that reliable comparisons can be drawn. Although the currently available in vitro assays 
are sufficient for identifying compounds with antimalarial activity, drug mode of action 
and, particularly, speed-of-kill should be considered during more detailed in vitro 
characterisations. The necessity of combination therapy has meant that underlying issues 
with current in vitro drug susceptibility assessment practises have transposed into the 
interaction assays where, as highlighted by the current study, the relationship between drug 
mode of action and viability readout becomes more problematic.  
Inconsistent definitions in the literature call in to question the reliability of the available 
drug interaction data and provide a possible explanation of poor in vitro to in vivo 
translation (Abiodun et al., 2013; Bhattacharya et al., 2009; Fivelman et al., 2004; Keiser 
et al., 2012; Synder et al., 2007).   For this reason, it may be necessary to revaluate assay 
design for determining antimalarial drug interactions. Evidently, investigations using the 
SG-based methods for drug interaction analysis should adopt a 72 treatment regime. Such 
screening assays should be considered preliminary interaction data and ED75 and ED90 data 
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in particular should be viewed with caution. As the killing of parasites is the ultimate goal, 
future work should explore the possibility of adopting an interaction assay based on the 
cytocidal effects of drugs. Gorka et al. (2013) considered drug interactions based on 
cytocidal activity, however, the analysis was completed after 48 hours. The current data 
suggest that these outcomes may have been differentially conflicted by drug mode of 
action. Analysing parasite viability following a longer regrowth period (limiting serial 
dilution), in the absence of drug pressure, would serve to eliminate the disconnection 
between the susceptibility assays and parasite viability. This design may provide better 
predictions about in vivo drug interaction outcomes. Such intensive investigations may 
limit the practical number of testable drug ratios. Indeed, one limitation of the CalcuSyn 
method is that repeated experiments are needed to test different drug ratios, as the software 
is compatible only with the input of a single fixed ratio dose series. Non-constant ratios 
can be inputted manually, but the procedure is time consuming. Undoubtedly, the current 
situation, where different groups report different classifications justified by the use of 
different drug ratios, is not acceptable and poorly serves the goal of prioritising candidates 
for further development.  Selecting the optimum ratio that would be achievable in vivo 
may be better informed by in vivo pharmacokinetic data. This idea is in agreement with the 
most recent proposal of the antimalarial drug development pipeline.  Indeed, rather than 
being linear, the ideal lead optimisation phase involves a feedback loop between in vitro, 
in vivo, toxicology and pharmacokinetic studies (Figure 7.1). 
 
Figure 7.1 Drug development strategy for novel antimalarial drugs (Source Flannery et al., 2013) 
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7. 2 Drug repositioning for malaria 
A more systematic version of the traditional serendipitous approach to drug discovery was 
used in the current study to identify novel antimalarial leads (Medina-Franco et al., 2013). 
Compound libraries (ENZO and LOPAC), with known bioactivities and a high degrees of 
drug likeness, were phenotypically screened against Plasmodium falciparum red blood cell 
stage malaria.  From the screen of < 700 compounds more than 50 were shown to inhibit 
parasite growth by 50% at a concentration of 2.5 µM. A particularly high hit rate (9.5 %) 
when compared with other, less focused, library screens. Corroborating the growing body 
of literature on similar screening initiatives, MeSH categories, namely: anticancer, 
antipsychotic and antibiotics were the most commonly re-identified antimalarial inhibitors 
in the screen (Gamo et al., 2010; Lotharius et al., 2014; Plouffe et al., 2008; Weisman et 
al., 2006). Identification of existing antimalarials and other previously reported hits such 
as emetine and propafenone, further confirmed the reliability of the results obtained. As 
the ENZO library was screened blindly, the compound overlap, particularly, with a liver-
stage screen completed by Derbyshire et al. (2012) was initially unknown, but served to 
validate commonly identified hits as multi-stage, multi-strain inhibitors. Indeed, in 
addition to the activity of clemastine (over-the-counter anti-histamine) reported against 
liver-stage parasites Derbyshire et al. (2012) also reported activity of the compound in 
blood-stage screens against P. falciparum strains 3D7 and Dd2. The current study 
provided further corroboration, and demonstrated activity (< 500nM) against the multidrug 
resistant K1 strain. Other liver stage-active compounds, telmisartan (Angiotensin receptor 
blocker) and ketanserin (Serotonin receptor antagonist), were also identified as K1 
inhibitors.  Conversely, Derbyshire et al. (2012) showed telmisartan to be inactive against 
3D7 and Dd2 erthrocytic stages at a concentration of 5 µM. Interestingly, the group also 
showed that analogues more specific for the human angiotensin II receptor target than 
telmisartan, were less active against the parasite. This suggests that off-target effects may 
be responsible for the activity of repositioned compounds in their novel indication 
(Derbyshire et al. 2012).  The current study, therefore further validated the MeSH 
catagories detailed above, specifically the antihistamines and antiarrhythmic compounds, 
as potential starting points for novel antimalarial drug classes. Furthermore, antimalarial 
potencies against the multi drug resistant K1 strain were consistent with the criteria (< 1 
µM) outlined by MMV (Lotharius et al., 2014). This provides evidence that small-scale 
focused screens against the whole parasite can identify valuable antimalarial hits. These 
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hits, through their occupation of diverse chemical space compared to existing therapies, 
offer the potential of much needed novel antimalarial targets.  
7.2.1 Conclusions and future directions for antimalarial drug repositioning 
This study along with the fast pace of development of some of the early identified 
candidates supports drug-repositioning as a valuable strategy of antimalarial drug 
discovery (Guiguemde et al., 2010; Guiguemde et al., 2012). The whole parasite, 
phenotypic screen presented here has permitted the identification of antimalarials with, 
potentially, multiple parasite targets. Furthermore, the compound classes that have been 
shown to be active against liver-stage parasites (Derbyshire et al., 2012) and have been re-
confirmed, by the current study, as inhibitors of blood-stage, K1, multiple drug resistant 
parasites, would be valuable assets to the eradication agenda. Future work should therefore 
focus on lead optimisation of the novel antimalarial classes identified in the current screen 
and elsewhere.  The expansion of publically available antimalarial screening data should 
permit wide scale in silico analysis to determine structure activity relations and therefore 
help further inform structural modifications.  
7.3 Antimalarial activity of emetine dihydrochloride hydrate 
Before this study, the antimalarial activity of emetine had been established (Andrews et 
al., 2014; Lucumi et al., 2010; Plouffe et al., 2008) but, hindered by concerns over 
possible toxicity and the identification of other attractive options, the compound was not 
considered for further development. However, a literature survey revealed the potential of 
a clinically more promising dose-related toxicity profile when antimalarial potency was 
compared with in vitro Entamoeba histolytica inhibitory concentrations (Bansal et al., 
2004). Furthermore, the existence of the safer dehydroemetine alternative and the 
informative structural activity relationships between emetine and its natural analogs, 
shown here by shifts in antimalarial potency and HepG2 cellular toxicity of emetine and 
cephaeline, provide a good platform for derivertisation of the compound.  Taken together 
with its high potency against the multiple drug resistant P. falcipaum K1 strain the 
antimalarial potential of the compound warranted further investigation.  
Detailed characterisation of emetine revealed a similar killing profile to the existing 
antimalarial atovaquone (Sanz et al., 2012). Like atovaquone, emetine displayed initial 
cytostatic activity during a 48 hour lag phase. Once parasite killing was initiated, at which 
point the drug induced affects have become irreversible, the PRR (the decrease in viable 
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parasite over 48 hours) and PCT (the time taken to clear 99.9% of a parasite population) 
were also similar to atovaquone. Compounds with similar killing profiles, it is suggested, 
have similar modes of action (Sanz et al., 2012). As atovaquone acts via the parasite 
mitochondria (Srivastava and Viaidya, 1999), mitochondrial depolarization in response to 
both compounds was evaluated.  Again, parasites responded similarly to emetine and 
atovaquone drug pressure, but both compounds where not as effective at inducing loss of 
mitochondrial membrane potential as the CCCP positive control. This may be attributable 
to the assaying time-course. A notable difference was that parasitaemia, as determined by 
SG staining, was slightly reduced in the emetine treated sample but not the atovaquone 
sample. As emetine has also been shown to bind to the cytosolic 80s ribosome, predicted 
to be a fast-acting drug target (Wong et al., 2014), it is likely that the mitochondrion is not 
the only target of emetine in the parasite. Indeed, a rather broad spectrum of biological 
activities has been reported in the literature (Akinboye and Bakare, 2011). Although the 
mitochondrial action of atovaquone has not been associated with parasite apoptosis, 
emetine has been linked to the induction of apoptosis phenotypes in both trypanosomes 
and cancer cells (Boon-Unge et al., 2007; Rosenkranz and Wink, 2008).  Despite the fact it 
is more difficult to define the mode of action of multiple-targeted drugs, the potential of 
such a compound to help circumvent resistance development is obviously advantageous 
for antimalarial therapy. 
Through drug interaction analysis with CalcuSyn, optimised for malaria in the current 
study using SG-FCM, the ED50 level interactions between emetine-dihydroartemsisin, 
emetine-chloroquine and emetine-atovaquone were classified as antagonism, antagonism 
and synergism respectively. Data from the ED75 and ED90 levels of inhibition were not 
considered reliable due to background interference and possible misidentification of live 
parasites differentially affected by an intrinsic drug mode of action, as discussed above. 
However, the synergistic interaction between the pharmacokinetically similar atovaquone 
and emetine compounds provides an exciting opportunity for antimalarial therapy.  If the 
combination is found to be efficacious in vivo, the other advantages of combination 
therapy, such as prolongation of use before resistance development and the potential for a 
reduction in the required emetine dose, will have beneficial implications for the toxicity 
profile of the drug.  
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7.3.1 Conclusions and future directions for the antimalarial development of emetine 
The preliminary indication of a synergistic interaction between atovaquone and emetine is 
presented here for a single drug ratio of (IC50: IC50 dose ratio ATQ: Eme= 1: 46) at the 
ED50 level of inhibition and would need to be clarified for other ratios. Given the 
potentially infinite number of ratios that could be tested in further in vitro investigations, 
this could be considered following additional in vivo pharmacokinetic data being made 
available about the compound, as was proposed above. 
Most importantly, to further progress the evaluation of emetine and its related analogues as 
a novel antimalarial class, the compound or its derivatives need to be defined as being safe 
antimalarial options. In terms of the common emesis issue, drug formulation and novel 
delivery systems may help avoid irritating side effects (Allen and Cullis, 2004). To 
alleviate the more serious, yet less common cardiotoxic adverse events, cardiotoxicity 
should be evaluated using modern techniques. Information about cardiotoxicity should be 
gathered for natural and synthetic emetine derivatives, in particular dehydroemetine, 
alongside antimalarial potency evaluation, to inform useful structural modifications of the 
compound. Advances in in vitro cardiotoxic assessment assays has meant that patch clamp 
techniques, to determine the electrophysiology of cells in response to drug treatment, can 
be used for single ion channel analysis (Kang, 2001). One important channel, encoded by 
the human ether a-go-go related gene (hERG), is a common attrition hurdle for a number 
cardiotoxic compounds and would therefore serve as a good starting point for cardiotoxic 
evaluation (Recanatini et al., 2005). Subsequently, more intensive in vitro investigations, 
such as the microelectrode array (MEA) which is considered the in vitro ECG equivalent 
could be used to evaluate whole-cell ion channel effects (Kang, 2001). Other in vitro tests 
use biomarkers to determine cardiac hypertrophy or cardiac damage (Dinh et al., 2011).  
The results of these evaluations might be used to select or engineer an optimised form of 
emetine. 
In parallel to drug development, the mode of action of the drug should be further 
investigated. In addition to further work on mitochondrial depolarization, other features of 
parasite apoptosis in response to emetine treatment might usefully be evaluated. Cryo-EM 
and structural modelling could be employed to confirm whether a binding site in the 
mitochondrial ribosome is an emetine target. Indeed, the mitochondrial toxicity in the 
parasite may be accompanied by cardiotoxicity in the mitochondria-dense heart muscle 
(Montaigne et al., 2012). Thus, selectivity for parasite mitochondria should be determined. 
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The resulting optimised emetine derivative should then be re-combined with atovaquone to 
evaluate whether the moiety responsible for synergy has been retained. Furthering that, 
other combinatory options should be explored. In order to predict improved in vitro to in 
vivo translation, and overcome mode-of-action interference with existing susceptibility 
assays the results of the current study strongly suggests that interaction evaluation should 
be based on lethal dose concentrations, evaluated after an extended recovery period, as has 
been discussed above. 
Given that the trajectory of artemisinin resistance is following the route of the previous 
antimalarial drug classes, and has already reached the Indian border (Tun et al., 2015), it is 
imperative that repositioned hit candidates are taken forward to provide the much needed 
fast-track option to antimalarial drug development.  The main successes of antimalarial 
chemotherapy has largely been reliant on natural products. Along with the two most 
effective drugs, quinine and artemisinin, the most recent compound to present a novel 
antimalarial drug target, atovaquone, is a synthetic version of the natural product lapichol 
(Flannery et al., 2013). In emetine, we have yet another compound of natural origin with 
potent antimalarial activity and the possibility of multiple parasite targets. The antimalarial 
development of the compound is further supported by its potential for derivatisation and 
the pharmacokinetically-matched synergistic combination with atovaquone. 
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Appendix I: SYBR Green staining of P. falciparum for fluorescence confocal microscopy.  
Shows three different methods used to stain and unsynchronised culture of P. Falciparum 
(a-c) ; The traditional gieimsa method (a) the traditional Giemsa method followed by SYBR 
Green 1 staining (Guy et al., 2007) (b)  and a novel FCM staining procedure.  An example of 
the image produced by the each respective method is shown.  Method (c) was most 
successful in reducing background fluorescence and was therefore selected for future 
experiments. 
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Appendix II: An example of Giemsa stained P. falciparum parasites (strain K1) following 
treatment with dihydroartemisinin (DHA). Images were taken for the control sample and 
each DHA dose used (from 1.25nM - 40nM DHA) to generate the dose response curve. 
Examples of both the 48 and 72h time points are included. 
48h                                                       72h 
Control 
 
 
 
 
 
1.25nM 
DHA 
 
 
 
 
 
 
 
2.5nM 
DHA 
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xxShows an example of the flow cytometer output obtained during the generation of dose 
48h                                                       72h 
5nM 
DHA 
 
 
 
 
 
 
 
10nM 
DHA 
 
 
 
 
 
 
 
 
20nM 
DHA 
 
 
 
 
 
 
 
 
 
 
40nM 
DHA 
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Appendix III: An example of the flow cytometer output obtained during the generation of 
dose response curves, for dihydroartemisinin against P. falciparum strain K1, using the 
SYBR Green-based Flow cytometer method.  Images show density plots of forward scatter 
(size) against side scatter (granularity) and dot plots of FITC (SG fluorescence) against 
forward scatter.  Tables show the statistical information recorded for each experimental 
condition. Data is shown for blood only (uninfected) and infected controls alongside each 
DHA dose used (1.25nM - 40nM DHA) for both the 48 and 72 h time points.  
48 h 
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Name % inhibition P. 
falciparum strain K1 
Triamcinolone 50.79 
Levallorphan 50.64 
Propranolol 50.30 
Butoconazole nitrate 50.21 
Manidipine 49.55 
Fluperlapine 49.26 
Naltriben methanesulfonate hydrate 48.81 
Dihydroergotamine mesylate 48.73 
Stanozolol 48.63 
Oxatomide 48.57 
Troglitazone 48.40 
Diphenhydramine·HCl 48.28 
Strychnine·HCl 47.83 
Cinanserin 47.73 
Alprenolol·HCl 47.57 
Topotecan·HCl 47.31 
Lapatinib ditosylate 47.24 
Flecainide acetate 47.13 
Gestrinone 46.35 
Buphenine·HCl 46.27 
Promethazine·HCl 46.02 
amrinone 45.95 
Bepridil·HCl 45.81 
(R)-(-)-Apomorphine·HCl 45.80 
Fluphenazine·2HCl 45.77 
Etoposide 45.24 
Clozapine 45.14 
Pentamidine 44.97 
Vardenafil 44.23 
Astemizole 43.48 
Sulbactam 43.44 
Tylosin 43.40 
Bupivacaine 43.16 
Oxibendazole 43.00 
Telenzepine·2HCl 42.91 
Trans-triprolidine·HCl 42.88 
Memantine·HCl 42.82 
Tosufloxacin 42.81 
Ifenprodil tartrate 42.43 
Spiperone·HCl 42.17 
Cimaterol 42.12 
Tamsulosin 41.97 
Mepyramine maleate 41.97 
Olanzapine 41.97 
Appendix IV: Percentage inhibition table for each compound from the ENZO library against 
P. falciparum strain K1 at a concentration of 2.5 µM. The SYBR Green-MicroPlate method 
was used to analyse parasite growth in response to drug treatment. Each estimate 
represents duplicate data. Background fluorescence from uninfected blood was deducted 
accordingly and % inhibition was calculated relative to untreated controls. The 56 most 
potent compounds are excluded from the table as they are shown in Chapter 4, Table 4.1. 
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Harmine 41.62 
Tenoxicam 41.53 
Ketotifen 41.06 
Amantadine·HCl 41.01 
Lidocaine·HCl·H2O 40.60 
Tioconazole 40.55 
(+)-Butaclamol·HCl 40.47 
Terazosin 40.38 
Auranofin 40.37 
Amoxapine 40.17 
Captopril 40.13 
Tolbutamide 40.08 
Dobutamine·HCl 39.93 
Amoxicillin 39.91 
Vidarabine 39.82 
Atazanavir 39.40 
Dipyridamole 39.37 
Mianserin·HCl 39.25 
Flufenamic acid 39.13 
Alfuzosin 38.89 
Acetylsalicylic Acid 38.42 
Canthaxanthin 38.06 
Chlorpromazine·HCl 37.67 
Procainamide·HCl 37.25 
Ramipril 36.94 
Pentoxifylline 36.75 
Cyproheptadine 36.74 
Citalopram 36.59 
Aripiprazole 36.55 
Tetracycline 36.46 
Spectinomycin·2HCl 36.37 
Pergolide mesylate 36.19 
Anagrelide 36.16 
Tramadol 35.82 
Rosiglitazone maleate 35.79 
Glipizide 35.67 
Succinylcholine 35.55 
Remoxipride 35.00 
Vecuronium 34.61 
Nalbuphine 34.59 
Phenytoin 34.38 
Delavirdine mesylate 34.18 
Phentolamine 34.14 
Clonidine·HCl 34.03 
Pilocarpine·HCl 33.82 
Quetiapine Fumarate 33.51 
Sparfloxacin 33.22 
Ketoconazole 33.16 
Nialamide 33.02 
Clothiapine 32.73 
Venlafaxine 32.69 
Primaquine 32.67 
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Lincomycin 32.58 
Loratadine 32.26 
Pinacidil 32.08 
Vitamin A acetate 32.07 
Levocabastine·HCl 32.01 
Dexamethasone 31.59 
Sotalol·HCl 31.31 
Naloxonazine 30.92 
Imipramine·HCl 30.81 
Tropicamide 30.79 
Linezolid 30.53 
Sulfadimethoxine 30.43 
(R)-(-)-Deprenyl·HCl 30.34 
Ethacrynic Acid 30.17 
Calcitriol 30.15 
Disodium Cromoglycate 29.76 
Tolmetin 29.28 
Bezafibrate 29.23 
Oxacillin 28.86 
Propranolol S(-) 28.71 
Domperidone 28.63 
Thalidomide 28.50 
Xylazine 28.18 
Guanabenz 28.18 
Tobramycin (free base) 28.09 
Leflunomide 27.95 
Pancuronium·2Br 27.92 
Enalaprilat 27.90 
Temozolomide 27.79 
Nelfinavir mesylate 27.61 
Donepezil·HCl 27.60 
Lacidipine 27.29 
Prazosin·HCl 27.22 
Propofol 27.00 
Metoclopramide 26.78 
Fosinopril 26.77 
Cefepime 26.67 
Pregnenolone 26.60 
Amfebutamone 26.50 
Zolmitriptan 26.16 
Lovastatin 26.03 
Iproniazid 25.92 
Clindamycin·HCl 25.82 
Amorolfine 25.82 
Acitretin 25.70 
Mecamylamine 25.63 
Levamisole 25.62 
Novobiocin·Na 25.41 
Pantothenic acid 25.40 
Isoniazid 25.23 
Lobeline 25.21 
Sildenafil 25.07 
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Amisulpride 24.89 
Nimesulide 24.82 
Oxiconazole 24.65 
Oxotremorine 24.46 
Physostigmine sulfate 24.45 
Naloxone 24.42 
Naltrindole·HCl 24.24 
Indomethacin 23.97 
Benzamil 23.91 
Docetaxil 23.83 
Tenatoprazole 23.80 
Entacapone 23.58 
Imipenem 23.45 
Lorglumide 23.43 
Latanoprost 23.24 
Prothionamide 23.16 
Cimetidine 23.12 
Didanosine 22.90 
Camptothecin 22.83 
Escitalopram 22.60 
Rimantadine 22.55 
Metoprolol 22.51 
Mifepristone 22.22 
Decamethonium 22.08 
Clopidogrel 22.06 
Clodronic acid 22.06 
Toremifene 21.95 
Abamectin 21.91 
Climbazole 21.89 
Aceclofenac 21.77 
Acipimox 21.72 
Methimazole 21.61 
Piribedil·2HCl 21.59 
Pindolol 21.01 
Carbamyl-beta-methylcholine 20.94 
Rebamipide 20.92 
Methylprednisolone 20.88 
Amlodipine 20.58 
Neomycin 20.56 
Carvedilol 20.54 
Tiotidine 20.49 
Clenbuterol 20.47 
Guanfacine·HCl 20.36 
Olmesartan 20.34 
Levetiracetam 19.88 
Dofetilide 19.83 
Fluvastatin 19.82 
Octreotide 19.80 
Clomiphene 19.54 
Dilazep 19.44 
Methyl salicylate 19.44 
Naftopidil·2HCl 19.30 
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Tropisetron 19.19 
3'-Azido-3'-deoxythymidine 19.17 
Sulfadoxine 19.16 
Oxfendazole 19.04 
Methysergide maleate 18.92 
Norfloxacin 18.91 
Thiamphenicol glycinate 18.79 
Esmolol 18.72 
Procarbazine 18.30 
Moroxydine·HCl 18.12 
Yohimbine·HCl 18.12 
Calcifediol 17.71 
Tolfenamic acid 17.49 
Ibudilast 17.48 
Nisoldipine 17.04 
Riluzole·HCl 16.85 
Roxatidine acetate·HCl 16.72 
Fenretinide 16.68 
Prednisone 16.57 
Norethindrone 16.37 
Acycloguanosine 16.35 
Picotamide 16.35 
Lomofungin 16.23 
Butenafine 16.20 
Diltiazem 16.20 
Tolcapone 15.83 
Salbutamol hemisulfate 15.73 
Naproxen 15.72 
Losartan potassium 15.69 
Nicergoline 15.57 
Candesartan 15.52 
Ticlopidine 15.40 
Felbamate 15.13 
Furafylline 15.11 
FAMOTIDINE 14.93 
Scopolamine 14.81 
Idazoxan·HCl 14.77 
Risperidone 14.75 
Nicorandil 14.68 
Atropine 14.62 
Aminophylline 14.53 
Lamotrigine 14.50 
Ouabain 14.33 
Azathioprine 14.32 
Gallamine 14.31 
Orphenadrine citrate 14.10 
Pencillin V 14.05 
HA1077 14.03 
Nateglinide 14.00 
Mycophenolate mofetil 13.79 
Naltrexone·HCl 13.68 
Mesulergine 13.64 
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Lofexidine·HCl 13.56 
Myclobutanil 13.53 
Piroxicam 13.48 
Nystatin 13.46 
Nadifloxacin 13.43 
Gemcitabine 13.28 
Lisinopril 13.20 
Mevastatin 13.05 
Olopatadine 12.97 
Etoricoxib 12.94 
Oxymetazoline·HCl 12.57 
Cabergoline 12.54 
Tibolone 12.53 
Pirenzepine·2HCl 12.46 
DL-Isoproterenol 12.40 
S(-)-Raclopride 12.34 
Ozagrel 12.11 
Granisetron 12.11 
Troleandomycin 12.10 
Raloxifene 12.06 
Amiloride 12.04 
2',3' - Dideoxycytidine 11.94 
Ipratropium·Br 11.77 
Chlorpheniramine 11.71 
Terbinafine 11.69 
Rilmenidine phosphate 11.62 
Bumetanide 11.58 
L-thyroxine 11.53 
Lomerizine 11.39 
Desloratadine 11.30 
Ranolazine·2HCl 11.29 
Progesterone 11.26 
(+)-Tubocuraraine chloride 11.25 
Streptomycin 11.22 
Dorzolamide·HCl 10.98 
Ampicillin 10.86 
4-Aminosalicylic acid 10.85 
Galanthamine 10.52 
Sibutramine 9.74 
Clinafloxacin 9.64 
Zonisamide 9.55 
Ranitidine·HCl 9.08 
Guaiacol 9.01 
Erlotinib 8.66 
Nedaplatin 8.48 
Aniracetam 8.01 
Ampiroxicam 7.94 
Molsidomine 7.92 
Sodium Phenylacetate 7.88 
Hydroxytacrine 7.77 
Norepinephrine-(+)-tartrate L (-) 7.33 
Pravadoline 7.25 
Appendix IV 
173 
 
Ciprofloxacin 7.22 
Quinapril 7.02 
Ibuprofen 6.73 
Dolasetron 6.72 
Sulfasalazine 6.66 
Piperacillin 6.64 
Tinidazole 6.60 
5-Aminosalicylic acid 6.59 
Verapamil 6.56 
Ginkgolide A 6.53 
Vatalanib 6.50 
Benzydamine 6.44 
Melatonin 6.41 
Praziquantel 6.37 
Anethole, trans- 6.34 
Bosentan 6.22 
Ambroxol 6.07 
Ibandronate 6.05 
Apramycin 5.96 
Chlormadinone Acetate 5.94 
(S)-Timolol maleate 5.55 
Lomustine 5.51 
Adapalene 5.45 
Levonorgestrel 5.34 
Nimodipine 5.15 
Phenylbutazone 5.13 
Ribavirin 5.03 
Nabumetone 4.99 
(S)-(-)-Sulpiride 4.64 
Carbamylcholine 4.36 
Carbidopa 4.12 
Metronidazole 4.05 
Trichloromethiazide 4.04 
DL-Aminoglutethimide 4.01 
Roxithromycin 3.92 
Vinpocetine 3.91 
Benserazide 3.87 
Acetylcholine 3.82 
Suramin 2.89 
Actarit 2.74 
Bicalutamide 2.71 
Dinoprost 2.19 
Docebenone 1.94 
Enoxacin 1.79 
Moxifloxacin·HCl 1.73 
Flumazenil 1.60 
Atracurium besylate 1.31 
Fenbendazole 1.12 
Clarithromycin 1.07 
Fumagillin 0.75 
Capsaicin 0.63 
Lomefloxacin 0.54 
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Diclofenac 0.44 
Sodium Phenylbutyrate 0.43 
Chlorambucil 0.33 
Cetirizine 2HCl 0.18 
Doxazosin -0.03 
Sarafloxacin -0.05 
Salmeterol xinafoate -0.21 
Debrisoquin -0.21 
Idebenone -0.44 
Flunarizine·2HCl -0.51 
Minocycline -0.57 
Diethylstilbestrol -0.62 
Procaterol·HCl -0.71 
Diflunisal -0.80 
Cyproterone Acetate -0.94 
Doxifluridine -1.00 
Exemestane -1.03 
Naphazoline -1.05 
Levofloxacin -1.06 
Paroxetine -1.18 
Dehydroepiandrosterone -1.44 
Zoledronic acid -1.47 
Amifostine -1.55 
Clofibrate -1.75 
Azithromycin -1.80 
Ethisterone -1.92 
Crotamiton -1.96 
Azaperone -2.02 
Famciclovir -2.33 
Meropenem -2.43 
Doxofylline -2.48 
Betaxolol·HCl -2.59 
Clofarabine -2.63 
Estriol -2.71 
Eprosartan mesylate -2.82 
Imatinib -2.85 
Neostigmine -2.86 
Enalapril -3.11 
L-(+)-Epinephrine tartrate -3.15 
Altretamine -3.18 
Estradiol -3.19 
Oltipraz -3.24 
Prednisolone -3.35 
Nifedipine -3.43 
Danazol -3.52 
Dextromethorphan -3.65 
Enrofloxacin -3.72 
Doxycycline -3.74 
Amprenavir -3.80 
Retinoic Acid -3.92 
Esomeprazole -3.95 
Albendazole -3.99 
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Cyclocytidine -4.06 
Etretinate -4.13 
Canrenone -4.59 
Allopurinol -4.79 
Clopamide -4.91 
Emtricitabine -4.93 
Scopolamine N-butyl -4.97 
Etidronate -5.01 
Meglumine -5.04 
Tamoxifen -5.12 
Alprostadil -5.19 
Tranylcypromine -5.24 
Corticosterone -5.33 
Secnidazole -5.47 
Oxaliplatin -5.56 
Trequinsin·HCl -5.64 
Omeprazole -5.68 
Rufloxacin -5.96 
Gefitinib -6.09 
Disulfiram -6.16 
Sumatriptan Succinate -6.59 
Aprepitant -6.66 
Simvastatin -6.67 
Niflumic acid -6.71 
Cytarabine -6.74 
Chloramphenicol -6.93 
Atenolol -7.06 
Cyclophosphamide -7.10 
Estrone -7.13 
Dacarbazine -7.34 
Racecadotril -7.56 
Siguazodan -7.56 
Alendronate -7.61 
Acemetacin -8.08 
Zaprinast -8.17 
Bleomycin -8.62 
Aztreonam -8.66 
Butyrylcholine -8.67 
Clobetasol Propionate -8.90 
Vinorelbine -9.16 
Efavirenz -9.19 
Gabapentin -9.47 
Nifekalant -9.67 
Buspirone -9.80 
Metformin -10.09 
Montelukast -10.38 
Tulobuterol -10.66 
Tizanidine·HCl -10.68 
Levodopa -12.01 
Rolipram -12.29 
Oseltamivir -12.58 
Taurocholic acid -12.99 
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Pamidronate·2Na·5H2O -13.04 
Ofloxacin -13.07 
Pioglitazone -13.28 
Tacrine -13.85 
Xamoterol hemifumarate -14.32 
Oxcarbazepine -14.51 
Capecitabine -14.52 
Vinblastine -14.92 
Goserelin -15.17 
Pazufloxacin -15.52 
Minoxidil -15.58 
Penciclovir -15.59 
17- Hydroxyprogesterone -15.66 
Ceftazidime -15.68 
Fenofibrate -16.65 
Megestrol Acetate -16.88 
Melengestrol Acetate -17.28 
Pantoprazole -17.50 
Meloxicam -17.86 
Alfacalcidol -18.10 
Ketoprofen -18.26 
Nefazodone -18.34 
Fentiazac -18.41 
Finasteride -18.56 
Vindesine sulfate -18.61 
Caffeine -18.75 
Pefloxacine mesylate dihydrate -18.81 
Phenylpropanolamine -19.16 
Felodipine -19.62 
Anastrozole -20.47 
Miconazole -20.62 
Fenoldopam·HCl -20.69 
Cerivastatin -21.34 
Fenbufen -21.42 
Cefoperazone acid -22.30 
Trifluoperazine·2HCl -22.72 
Dinoprostone -22.91 
Sulindac -23.00 
Cilastatin -23.47 
Carbadox -24.42 
Cilnidipine -24.58 
Nitrendipine -24.73 
Phenoxybenzamine·HCl -24.80 
Denbufylline -24.89 
Miltefosine -24.94 
Bifonazole -24.96 
Pranoprofen -25.50 
Fenoprofen -25.54 
Zardaverine -25.80 
Hydrocortisone 21-acetate -27.04 
(S)-(+)-Ketoprofen -27.07 
Misoprostol -27.20 
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Letrozole -28.15 
Vincristine sulfate -28.29 
Clindamycin palmitate·HCl -28.71 
Tranilast -29.27 
5-Fluorouracil -29.52 
Imiquimod -29.55 
Celecoxib -29.69 
Cefotaxime Acid -29.75 
Carbamazepine -29.80 
Ergothioneine -30.17 
Itopride -30.46 
Tranexamic acid -30.52 
Mefenamic acid -31.07 
RIFAMYCIN SV -31.28 
Milrinone -31.64 
Melphalan -31.97 
Pravastatin Lactone -32.80 
Hydrocortisone -32.81 
Argatroban -32.92 
Fluconazole -33.47 
Pranlukast -34.94 
Fluocinolone acetonide -35.37 
Pyrantel Pamoate -35.46 
Bexarotene -35.65 
Tolazamide -35.73 
Gentamycin -36.03 
Medroxyprogesterone 17-Acetate -36.34 
Flurbiprofen -36.50 
Mephenytoin -36.76 
Gemfibrozil -37.66 
Ifosfamide -38.02 
Gliclazide -38.48 
Methyldopa -39.09 
Anethole-trithione -39.84 
Itraconazole -39.87 
Furosemide -40.87 
Hexestrol -41.88 
Betamethasone -42.56 
Amitriptyline·HCl -43.36 
Idoxuridine -44.31 
Bromhexine -44.84 
Mebendazol -44.96 
Glimepiride -46.25 
Formestane -46.73 
Guaifenesin -47.19 
Indapamide -47.85 
Gatifloxacin -48.27 
Flutamide -48.38 
Fleroxacin -48.67 
Ftorafur -49.12 
Floxuridine -50.01 
Valproic acid -51.11 
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Flubendazole -51.21 
Bisacodyl -51.98 
Carboplatin -54.28 
Glyburide -55.75 
Ganciclovir -56.89 
Pramipexole -57.83 
Rofecoxib -58.53 
Diazoxide -60.78 
Rivastigmine -67.33 
Risedronic acid -68.01 
Bambuterol -69.90 
Zafirlukast -72.88 
Taxol -75.10 
Triptorelin -77.68 
Miglustat -77.71 
Fulvestrant -79.41 
Rocuronium bromide -83.32 
Ricobendazole -88.62 
Calcipotriene -99.29 
Zileuton -112.80 
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Appendix V: Tanimoto similary fingerprints for identified LOPAC and ENZO library hits 
with existing antimalarials. ENZO library compounds were grouped in accordance with their 
previously defined medical subject heading (MeSH) category and analysed for Tanimoto similarity 
with representatives of existing antimalarial classes. Individual compound CIDs were determined and 
inputted into PubChem structural clustering for 2D similarity determination. Compounds with a 
score > 0.85 were consider to be structural similar and therefore likely to have the same mode of 
action. Three LOPAC of the compounds were also included and aligned well the identified MeSH 
catagories. 
Angiotensin receptor antagonist 
 
Antiparasitic  
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Betabblockers
 
Histamine receptor antagonist 
 
Immunosuppressant
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Phosphodiesterase and other 
 
Serotoninareceptoraantagonist
 
Vasodilator 
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Appendix VI: Optimisation of the ondansetron dose response against P. falciparum, strain 
K1. Despite showing ~60 % inhibition during the preliminary screen using a single 2.5 µM dose point, 
Ondansetron (anti-emetic compound) failed to show a clear dose response pattern using the SG-
MicroPlate method with concentrations up to 2.5 µM (a). A new powder stock was purchased and 
the dose series was shifted up to 10 µM and subsequently 20 µM (b). Data was analysed using the 
more accurate SG-FCM method. A clear dose response pattern was not visible until a 2.5 µM- 80 µM 
dose series was employed (c).  
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Appendix VII: Preliminary screen of cephaeline compared with emetine against strain K1, 
P .falciparum. Parasites were incubated for 72 hours under conditions described previously and 
analysed using SG-FCM.  The emetine (Eme) 3-point dose response achieved the expected level of 
inhibition (previously determined IC50 achieved 49.3% inhibition). Cephaeline (Ceph) was shown to 
be more potent than emetine against the parasite. 
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Appendix VIII Preliminary investigation of the comparison between the cellular toxicity of 
emetine and cephaeline against the HepG2 cell line. A wide dose range was selected (across 
two plates-14 doses in total) and analysed after either 48 or 120 hours incubation using the MTT 
assay. Cephaeline was consistently more toxic than emetine at the lower dose range for both time 
points.  For the high dose range both compounds were inhibitory at the first dose used. For this 
reason, future replicates were based on the lower dose range to determine cephaeline and emetine 
IC 50 against HepG2. The positive control, cisplatin, was shown to be effective on each plate used.  
 
 
 
Low doses Cisplatin (µM) Emetine (nM) Cephaeline (nM) 
Dose 1 0.39 3.05 3.05 
Dose 2 0.78 6.10 6.10 
Dose 3 1.56 12.21 12.21 
Dose 4 3.13 24.41 24.41 
Dose 5 6.25 48.83 48.83 
Dose 6 12.5 97.66 97.66 
Dose 7 25 195.3 195.3 
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High doses Cisplatin (µM) Emetine (µM) Cephaeline (µM) 
Dose 1 0.39 0.39 0.39 
Dose 2 0.78 0.78 0.78 
Dose 3 1.56 1.56 1.56 
Dose 4 3.13 3.13 3.13 
Dose 5 6.25 6.25 6.25 
Dose 6 12.5 12.5 12.5 
Dose 7 25 25 25 
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Appendix IX: Fluoresence microscopy of JC-1 stained malaria parasites. Parasites were 
treated with either CCCP (positive inducer of loss of mitochondrial membrane potential) or 
DHA as described in chapter 5 (section 5.2.5). Untreated parasite served as controls. 
Following treatment parasite were stained with JC-1 and viewed under the red fluorescence 
filter using Nikon Eclipse TE2000-S fluorescence microscope. Live parasites, with intact 
mitochondria, were stained red in the control (a-c) and DHA (g-i) treated sample. Staining 
was not visible in parasites that had been exposed to CCCP and thus confirmed loss of 
mitochondrial membrane potential (d-f). 
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Appendix X: Optimisation of the atovaquone proguanil combination against P. falciparum 
strain K1. (a) Three point or two-point dose series were set up to check the activity of 
dihydroartemisinin (DHA), chloroquine (CQ), emetine (Eme), atovaquone (ATQ), and 
proguanil (PG) stock solutions against P. falciparum strain K1 (ring stage parasite, 72 hr 
incubation). For proguanil two stock solutions, stored at either 4oC or -20oC, were tested. 
SG-FCM analysis was employed as described previously.  IC50 estimates (GraphPad Prism) 
were consistent with those obtained previously although the ATQ IC50 was slightly higher 
than the preliminary experiment it was consistent with more recent data. 
 
 (b) Shows data from a flask experiment when the culture was diluted (trophozoite stage 
parasites, 48 hr incubation) and then compounds were subsequently added the culture 
separately (doses: ATQ 1.6 ng/ ml and PG 4.6 µg/ml). Analysed using the SG-FCM method 
the data showed that although ATQ failed to reduce parasite growth, the ATQ-PG 
combination show additional suppression when compared with the drug alone treatments.  
IC
50 
=241.1 nM 
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Appendix XI: Recovery of P. falciparum strain K1 parasite after exposure to atovaquone 
or proguanil, either alone or at a non-constant ratio combination.  Parasites were 
treated with a non-constant ratio combination of atovaquone and proguanil.  IC25, IC50 
and IC75 doses were selected (0.05, 0.2 and 0.8 ng/ml for atovaquone and 2.4, 4.6 and 9.2 
µg/ml for proguanil respectively). Each does of atovaquone was combined with every 
dose of proguanil (15 combinations).  Untreated control and drug alone treatments 
served as controls. After 72 hours of treatment each sample (triplicate) was washed 3 x in 
complete media and suspended at double the original volume so that the haematocrit 
was reduced from 2.5 to 1.25 %.  A 1: 10 limiting serial dilution was performed in a 96 
well plate (prepared with 200 µl of fresh blood in complete media) so that there were 8 
dilutions (A-H) for each sample.  After 7 days, spent media was discarded and replaced 
with 1% haematocrit blood in complete media. On day 20 parasite growth at each 
dilution was determined using the SG-FCM method. Each control and test combination 
was displayed separately and bar graphs indicate the % parasitaemia at each dilution. 
Triplicate data was shown separately to permit accurate determination of growth at each 
dilution in a presence or absence manner (differently coloured bars). Growth was 
observed in the control sample up to dilution C. The atovaquone alone samples followed 
a dose response pattern with growth present up to dilutions C, B and A for IC25, IC50 and 
IC75 doses respectively.  Although the proguanil parasitaemia followed a dose response 
pattern growth was detected in dilutions A and B for all doses. No growth was observed 
at any dilution for the any of the combination treatments. Axis breaks indicate where 
data was not collected due to the consistency of surrounding data. 
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